



EUROPEAN COMMISSION
Directorate-General for Research and Innovation
People
Director



AMENDMENT Reference No AMD-643638-42

Grant Agreement number: 643638 — ERA-NET: Aligning national/regional translational cancer research programmes and activities (TRANSCAN-2)

The parties agree to amend the Grant Agreement as follows ('**Amendment**')

1 . Addition of a new beneficiary

The following new beneficiaries are added:

- REGIONE TOSCANA (TuscReg) — as from 6 August 2019
- FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA (FRRB) — as from 27 June 2019
- FUNDACION CIENTIFICA DE LA ASOCIACIÓN ESPANOLA CONTRA EL CANCER (FCAECC) — as from 27 June 2019

This implies the **following changes** to the Grant Agreement:

- The new beneficiaries and the 'accession date' are added to the **Preamble**:

30. "**REGIONE TOSCANA (TuscReg)**, established in Palazzo Strozzi Sacratì - Piazza del Duomo 10, FIRENZE 50122, Italy, VAT number: IT01386030488, — as from 6 August 2019"

31. "**FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA (FRRB)**, established in PIAZZA CITTA DI LOMBARDIA 1, MILANO 20124, Italy, VAT number: IT97608860157, — as from 27 June 2019"

32. "**FUNDACION CIENTIFICA DE LA ASOCIACIÓN ESPANOLA CONTRA EL CANCER (FCAECC)**, established in AMADOR DE LOS RIOS, 5, MADRID 28010, Spain, VAT number: ESG28655033, — as from 27 June 2019"

2 . Addition of a linked third party

The following new linked third party is added:

- FONDAZIONE TOSCANA LIFE SCIENCES (TLS), affiliated or linked to TuscReg — as from 6 August 2019

This implies the **following changes** to the Grant Agreement:

- **Article 14** becomes applicable.

The new linked third party and the 'starting date of participation' are added to **Article 14.1**:

“FONDAZIONE TOSCANA LIFE SCIENCES (TLS), affiliated or linked to TuscReg — as from 6 August 2019”

The other options for linked third parties:

- are added (**Preamble, Articles 4.1, 5.2, 5.3.1, 5.3.3, 6.4, 17.2, 18.1.2, 20.3, 20.4, 20.6, 21.3.1, 41.2, 44.1, 44.1.1(b), 44.1.2, 44.1.2(b)(i), 44.1.3, 44.1.3(b)(i), 48.2, 50.2.2, 50.3.1, 50.3.3, 56.1, Annex 3a)** and
- become applicable (**Article 6.3, 50.3.1(n)**).

3. Change of Annex 1 (description of the action)

Annex 1 is changed and replaced by the Annex 1 attached to this Amendment.

4 . Changes of Annex 2 (estimated budget)

Annex 2 is changed and replaced by the Annex 2 attached to this Amendment.

All other provisions of the Grant Agreement and its Annexes remain unchanged.

This Amendment **enters into force** on the day of the last signature.

This Amendment **takes effect** on the date on which the amendment enters into force, except where a different date has been agreed by the parties (for one or more changes).

Please inform the other members of the consortium of the Amendment.

SIGNATURES

For the coordinator

For the Commission

Enclosures:

Annex 2
Annex 1



EUROPEAN COMMISSION
Directorate-General for Research and Innovation
Combating Diseases



ANNEX 1 (part A)

ERA-NET Cofund

NUMBER — 643638 — TRANSCAN-2

Table of Contents

1.1. The project summary.....	3
1.2. The list of beneficiaries.....	4
1.3. Workplan Tables - Detailed implementation.....	6
1.3.1. WT1 List of work packages.....	6
1.3.2. WT2 List of deliverables.....	7
1.3.3. WT3 Work package descriptions.....	11
Work package 1.....	11
Work package 2.....	16
Work package 3.....	23
Work package 4.....	26
Work package 5.....	30
Work package 6.....	34
Work package 7.....	37
Work package 8.....	41
Work package 9.....	45
Work package 10.....	50
1.3.4. WT4 List of milestones.....	51
1.3.5. WT5 Critical Implementation risks and mitigation actions.....	55
1.3.6. WT6 Summary of project effort contribution.....	56
1.3.7. WT7 Tentative schedule of project reviews.....	58

1.1. The project summary

Project Number ¹	643638	Project Acronym ²	TRANSCAN-2
One form per project			
General information			
Project title ³	ERA-NET: Aligning national/regional translational cancer research programmes and activities		
Starting date ⁴	The first day of the month after the signature by the Commission		
Duration in months ⁵	72		
Call (part) identifier ⁶	H2020-HCO-2014		
Topic	HCO-08-2014 ERA-NET: Aligning national/regional translational cancer research programmes and activities		
Fixed EC Keywords			
Free keywords	translational cancer research, coordination of national and regional programmes, TRANSCAN co-funded transnational calls		
Abstract ⁷			
<p>Cancer is a worldwide health burden and represents a major public health challenge in Europe. It is responsible for 25% of all deaths, being the second most common cause of death after cardio-vascular diseases and the main cause of mortality among people aged 45–64. Today, an estimated 9 million individuals in Europe live with cancer (Globocan 2008, http://globocan.iarc.fr/). Cancer became a chronic disease which contributed substantially to the growth of medical expenditures and constitutes a major socio-economic challenge for Europe as well as globally. A rapid and effective bidirectional transfer of relevant cancer research findings between bench and bedside would play a pivotal role in addressing top-priority needs at the EU level to reduce incidence and mortality of malignancies and to improve the quality of life of cancer patients.</p> <p>The proposed ERA-NET Cofund TRANSCAN-2, in continuity with the preceding and ongoing TRANSCAN ERA-NET, aims at linking translational cancer research funding programmes in 15 Member States, 3 Associated Countries, and a third country. By concentrating transnational resources, TRANSCAN-2 will provide a critical financial and scientific mass for tackling large-scale problems, relevant for improving translational cancer research globally. A co-funded joint transnational call (JTC) will be launched focusing on the topic “Intratumour heterogeneity in resistance to therapy and recurrence” followed by three additional JTCs that will be implemented in a frame of multinational translational cancer research programmes. In addition, strategies will be developed for the enlargement of the network, for improvement of coordination and for an efficient communication and dissemination of the results of the consortium as well as of the research projects funded through the JTCs. The monitoring of the projects funded through the JTCs and the critical assessment of the performance of TRANSCAN-2, based on key indicators, will be also realised.</p>			

1.2. List of Beneficiaries

Project Number ¹	643638	Project Acronym ²	TRANSCAN-2
-----------------------------	--------	------------------------------	------------

List of Beneficiaries

No	Name	Short name	Country	Project entry date ⁸	Project exit date
1	MINISTERO DELLA SALUTE	MoH	Italy		
2	FONDS ZUR FÖRDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG	FWF	Austria		
3	ISTITUTO SUPERIORE DI SANITA	ISS	Italy		
4	LATVIJAS ZINATNU AKADEMIJA	LAS	Latvia		25/06/2016
5	INSTITUT NATIONAL DU CANCER GIP	INCa	France		
6	BUNDESMINISTERIUM FUER BILDUNG UND FORSCHUNG	BMBF	Germany		
7	DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV	DLR	Germany		
8	FONDATION ARC POUR LA RECHERCHE SUR LE CANCER	ARC	France		
9	GENIKI GRAMMATIA EREVNAS KAI TECHNOLOGIAS	GSRT	Greece		
10	MINISTRY OF HEALTH	CSO-MOH	Israel		
11	ALLEANZA CONTRO IL CANCRO	ACC	Italy		
12	ZORGONDERZOEK NEDERLAND ZON	ZonMw	Netherlands		
13	STICHTING KONINGIN WILHELMINA FONDS VOOR DE NEDERLANDSE KANKERBESTRIJDING	DCS	Netherlands		
14	NORGES FORSKNINGSRAD	RCN	Norway		
15	FUNDACAO PARA A CIENCIA E A TECNOLOGIA	FCT	Portugal		
16	SLOVENSKA AKADEMIA VIED	SAS	Slovakia		
17	Ministrstvo za izobraževanje, znanost in sport	MIZS	Slovenia		
18	INSTITUTO DE SALUD CARLOS III	ISCIII	Spain		
19	TURKIYE BILIMSEL VE TEKNOLOJIK ARASTIRMA KURUMU	TUBITAK	Turkey		
20	NARODOWE CENTRUM BADAN I ROZWOJU	NCBR	Poland		
21	FONDS VOOR WETENSCHAPPELIJK ONDERZOEK-VLAANDEREN	FWO	Belgium		
22	Országos Onkologiai Intezet	OOI	Hungary		

1.2. List of Beneficiaries

No	Name	Short name	Country	Project entry date ⁸	Project exit date
23	Kreftforeningen	NCS	Norway		
24	FEDERAAL FONDS VOOR WETENSCHAPPELIJK ONDERZOEK	FNRS	Belgium		
25	MINISTERO DELL'ISTRUZIONE, DELL'UNIVERSITA' E DELLA RICERCA	MIUR	Italy		
26	SIHTASUTUS EESTI TEADUSAGENTUUR	ETAg	Estonia		
27	FUNDACION PARA EL FOMENTO EN ASTURIAS DE LA INVESTIGACION CIENTIFICA APLICADA Y TECNOLOGIA	FICYT	Spain		
28	MINISTRY OF SCIENCE AND TECHNOLOGY	MoST	Taiwan		
29	VALSTS IZGLITIBAS ATTISTIBAS AGENTURA	VIAA	Latvia	01/01/2015	
30	REGIONE TOSCANA	TuscReg	Italy	06/08/2019	
31	FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA	FRRB	Italy	27/06/2019	
32	FUNDACION CIENTIFICA DE LA ASOCIACIÓN ESPANOLA CONTRA EL CANCER	FCAECC	Spain	27/06/2019	

1.3. Workplan Tables - Detailed implementation

1.3.1. WT1 List of work packages

WP Number ⁹	WP Title	Lead beneficiary ¹⁰	Start month ¹²	End month ¹³
WP1	Management and coordination	1 - MoH	1	72
WP2	Preparation and implementation of the co-funded (first) call	1 - MoH	1	72
WP3	Follow-up and monitoring of projects resulting from the co-funded JTC 2014 and the TRANSCAN-2 JTCs	16 - SAS	10	72
WP4	Strategy: network and scientific research priorities	5 - INCa	1	72
WP5	Communication, dissemination and networking	17 - MIZS	1	72
WP6	Assessment and monitoring of TRANSCAN-2 performance	15 - FCT	1	72
WP7	Preparation and implementation of a second joint transnational call	1 - MoH	13	72
WP8	Preparation and implementation of a third joint transnational call	13 - DCS	25	72
WP9	Preparation and implementation of a fourth joint transnational call	11 - ACC	37	72
WP10	Ethics requirements	1 - MoH	1	72

1.3.2. WT2 list of deliverables

Deliverable Number¹⁴	Deliverable Title	WP number⁹	Lead beneficiary	Type¹⁵	Dissemination level¹⁶	Due Date (in months)¹⁷
D1.1	First Progress Report	WP1	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	24
D1.2	Second Progress Report	WP1	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	36
D1.3	Third Progress Report	WP1	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	48
D1.4	Report 1 on cumulative expenditure incurred - Article 20.5	WP1	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	12
D1.5	Report 2 on cumulative expenditure incurred - Article 20.5	WP1	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	24
D1.6	Report 3 on cumulative expenditure incurred - Article 20.5	WP1	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	36
D1.7	Report 4 on cumulative expenditure incurred - Article 20.5	WP1	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	48
D1.8	Report 5 on cumulative expenditure incurred - Article 20.5	WP1	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	60

Deliverable Number¹⁴	Deliverable Title	WP number⁹	Lead beneficiary	Type¹⁵	Dissemination level¹⁶	Due Date (in months)¹⁷
D1.9	Fourth Progress Report	WP1	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	60
D1.10	Report 6 on cumulative expenditure incurred - Article 20.5	WP1	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	72
D2.1	JTC 2014 co-funded call-related documents	WP2	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	2
D2.2	Information on evaluation results (ranking list of full proposals recommended for funding by the SEC; CSC selection list; observer's report on the evaluation procedure)	WP2	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	11
D2.3	Publishable information about projects to be funded (participants, abstract), in EC-defined format	WP2	1 - MoH	Report	Public	12
D2.4	Formal (signed) commitments on availability of funds for the selected projects (each contributing CSC partner)	WP2	1 - MoH	Report	Public	12
D2.5	Publishable information about funded projects (participants, overview of results), in EC-defined format	WP2	1 - MoH	Report	Public	71
D3.1	Template for monitoring funded research projects	WP3	16 - SAS	Report	Confidential, only for members of the consortium (including the Commission Services)	12

Deliverable Number¹⁴	Deliverable Title	WP number⁹	Lead beneficiary	Type¹⁵	Dissemination level¹⁶	Due Date (in months)¹⁷
D4.1	Reports on contacts with non-TRANSCAN-2 funding organizations, interactions with other European and world-wide cancer initiatives, and on scientific priority topics	WP4	3 - ISS	Report	Confidential, only for members of the consortium (including the Commission Services)	18
D5.1	Updated website	WP5	1 - MoH	Websites, patents filling, etc.	Public	3
D5.2	E-newsletters 1-10	WP5	10 - CSO-MOH	Websites, patents filling, etc.	Public	6
D5.3	Reports of the scientific symposia	WP5	17 - MIZS	Websites, patents filling, etc.	Public	16
D6.1	Survey to monitor partners' satisfaction with TRANSCAN-2 procedures and results	WP6	15 - FCT	Other	Confidential, only for members of the consortium (including the Commission Services)	6
D7.1	JTC 2015 call-related documents	WP7	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	13
D7.2	Information on JTC 2015 evaluation results	WP7	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	22
D7.3	Publishable information about projects to be funded under JTC 2015 (participants, abstracts)	WP7	1 - MoH	Report	Public	23
D7.4	Publishable information about JTC 2015 funded projects (participants, overview of results)	WP7	1 - MoH	Report	Public	71
D8.1	JTC 2016 call-related documents	WP8	13 - DCS	Report	Confidential, only for members of the consortium (including the	25

Deliverable Number¹⁴	Deliverable Title	WP number⁹	Lead beneficiary	Type¹⁵	Dissemination level¹⁶	Due Date (in months)¹⁷
					Commission Services)	
D8.2	Information on JTC 2016 evaluation results	WP8	13 - DCS	Report	Confidential, only for members of the consortium (including the Commission Services)	34
D8.3	Publishable information about projects to be funded under JTC 2016 (participants, abstracts)	WP8	13 - DCS	Report	Public	35
D8.4	Publishable information about JTC 2016 funded projects (participants, overview of results)	WP8	13 - DCS	Report	Public	71
D9.1	JTC 2017 call-related documents	WP9	11 - ACC	Report	Confidential, only for members of the consortium (including the Commission Services)	37
D9.2	Information on JTC 2017 evaluation results	WP9	11 - ACC	Report	Confidential, only for members of the consortium (including the Commission Services)	46
D9.3	Publishable information about projects to be funded under JTC 2017 (participants, abstracts)	WP9	11 - ACC	Report	Public	47
D9.4	Publishable information about JTC 2017 funded projects (participants, overview of results)	WP9	11 - ACC	Report	Public	71
D10.1	POPD - Requirement No. 1	WP10	1 - MoH	Ethics	Confidential, only for members of the consortium (including the Commission Services)	1
D10.2	POPD - Requirement No. 5	WP10	1 - MoH	Ethics	Confidential, only for members of the consortium (including the Commission Services)	12

1.3.3. WT3 Work package descriptions

Work package number ⁹	WP1	Lead beneficiary ¹⁰	1 - MoH
Work package title	Management and coordination		
Start month	1	End month	72

Objectives

The ultimate goal of WP1 is to ensure the proper technical and administrative management of the project as well as the efficient communication and flow of information within the TRANSCAN-2 network and of the network with the European Commission (EC). To this end, WP1 will be responsible for the efficient coordination of the project activities, by providing the necessary support to the governance body of the consortium, i.e. the Network Steering Committee (NSC), and to Call Steering Committees (CSCs) and Joint Call Secretariats (JTCs) as for the preparation and implementation of the Joint Transnational Calls (JTCs). WP1, under the responsibility of the coordinator, will ensure the implementation of the decisions taken by NSC, through the scientific-technical work carried out in the WPs and tasks. WP1 specifically aims at coordinating the activities among the other WPs and at monitoring the progress of the project activities, so as to guarantee the implementation of the work plan as agreed among the partners. In the context of its management role, WP1 will also organise the activities of the NSC and of the Scientific Advisory Board (SAB), including the meetings of these bodies.

Description of work and role of partners

WP1 - Management and coordination [Months: 1-72]

MoH

The functions of WP1 will be implemented through the Network Coordination Unit (NCU) including a secretariat, which acts according to the NSC decisions. The NCU will be composed of the TRANSCAN-2 coordinator, Dr. Giovanni Leonardi, and his deputy, Dr. Gaetano Guglielmi, as for the Italian Ministry of Health (MoH), and of personnel from the Istituto Superiore di Sanità (ISS), namely a project manager and two project assistants, supporting the day-to-day operational management. The NCU will be responsible for ensuring that the objectives of TRANSCAN-2 are achieved, that the timetable is maintained and milestones met, and for proposing to the NSC corrective actions if necessary. The NCU will have also the responsibilities of informing and reporting to the NSC, the SAB, and the EC. The NCU will organise or co-organise, together with the hosting partners, the NSC meetings as well as the joint meetings of the NSC and the SAB. As the coordination must ensure high quality and integrity in all its operations as well as compliance with the obligations of the EC contract, WP1 will define procedures, to be approved by the NSC, aimed to meet these requirements.

The WP1 activities will be structured into the tasks described below, each under the responsibility of a task leader.

Task 1.1: Management, coordination and monitoring of the work plan implementation (leader: MoH-ISS)

The activities of task 1.1 will support specific functions of the NSC and of the NCU, as described below. The task activities include:

- preparatory work for assisting the NSC in the implementation of the work plan;
- support and monitoring of the implementation of the work plan;
- the day-to-day scientific-technical management and administration of the project;
- the financial management, including financial reporting to the EC;
- the coordination and communication among WPs (via the respective WP leaders), of the WP leaders with the NCU and the NSC, of the NSC with the SAB;
- organisational support to the activities of and communication between the Call Steering Committees (CSCs) and Joint Call Secretariats (JTCs), as for the preparation and implementation of the Joint Transnational Calls (JTCs);
- interaction and communication with the EC, through regular reporting and by inviting EC representatives to the TRANSCAN-2 meetings.

Teleconferences will be held periodically and upon request, with WP leaders and among the NSC members to confer about the implementation of the TRANSCAN-2 work plan as well as on strategic issues. The WP leaders will report to the NSC, through the coordination unit, in the form of half-yearly written progress reports, and to the NSC and SAB on an annual basis (during the annual meetings) to evaluate the progress of the respective WP activities and to discuss and decide corrective actions, if needed. A first version of the Consortium Agreement will be finalised by the NCU soon after the start of the project and signature of the Grant Agreement. This version will be updated, if necessary, and submitted to the final approval by the NSC (at month 3). Regular meetings of the NSC will be organised approximately

every 6 months for a plenary discussion and evaluation of project achievements and for decision on corrective actions, if needed. Officers of the relevant EC Directorates (DGs) will be invited in every case.

Task 1.2: Installing the TRANSCAN-2 Scientific Advisory Board (SAB) (leaders: MoH-ISS; participant: ACC)

Members of the Scientific Advisory Board (SAB) will be nominated at the very beginning of the TRANSCAN-2 project, following a selection process that foresees: a) gathering suggestions of members from each partner; b) elaborating a list of possible SAB members; c) voting by the NSC members for the selection of SAB members taking into account categories, gender and geographical balance. The coordinator will contact and invite the selected experts to join the SAB of TRANSCAN-2. The SAB will comprise scientists with recognized expertise in different fields of translational cancer research, from the basic biomedical and clinical sciences, epidemiology, and public health; representatives of patients' organisations will be also included in the SAB. They will work in a personal capacity and on a honorary basis and, in performing the work, they will not represent any organisation. The specific mission of the SAB will be to advise the NSC on the definition of the topics of the joint transnational calls. The composition of the SAB, based on the scientific grounds, skills and experience, will ensure input with regard to networking basic and applied research and translation of results from research into medical and industrial applications. The SAB should first meet at month 5 of the project and then annually, and at least 3 months before the design of each one of the additional TRANSCAN-2 joint transnational calls. SAB members must not participate as applicants in calls in order to avoid a conflict of interest. The chair and vice chair of the SAB are elected among the participants by the SAB itself at its first meeting.

Participation per Partner

Partner number and short name¹⁰

1 - MoH

3 - ISS

11 - ACC

List of deliverables

Deliverable Number ¹⁴	Deliverable Title	Lead beneficiary	Type ¹⁵	Dissemination level ¹⁶	Due Date (in months) ¹⁷
D1.1	First Progress Report	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	24
D1.2	Second Progress Report	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	36
D1.3	Third Progress Report	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	48
D1.4	Report 1 on cumulative expenditure incurred - Article 20.5	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	12

List of deliverables

Deliverable Number¹⁴	Deliverable Title	Lead beneficiary	Type¹⁵	Dissemination level¹⁶	Due Date (in months)¹⁷
D1.5	Report 2 on cumulative expenditure incurred - Article 20.5	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	24
D1.6	Report 3 on cumulative expenditure incurred - Article 20.5	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	36
D1.7	Report 4 on cumulative expenditure incurred - Article 20.5	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	48
D1.8	Report 5 on cumulative expenditure incurred - Article 20.5	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	60
D1.9	Fourth Progress Report	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	60
D1.10	Report 6 on cumulative expenditure incurred - Article 20.5	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	72

Description of deliverables

D1.1: First Progress report, as established in the Grant Agreement, containing: an explanation of the work carried out by the beneficiaries; an overview of the progress towards the objectives of the action, and a summary for publication by the Commission [month 24]

D1.2: Second Progress report, as established in the Grant Agreement, containing: an explanation of the work carried out by the beneficiaries; an overview of the progress towards the objectives of the action, and a summary for publication by the Commission [month 36]

D1.3: Third Progress report, as established in the Grant Agreement, containing: an explanation of the work carried out by the beneficiaries; an overview of the progress towards the objectives of the action, and a summary for publication by the Commission [month 48]

D1.9: Fourth Progress report, as established in the Grant Agreement, containing: an explanation of the work carried out by the beneficiaries; an overview of the progress towards the objectives of the action, and a summary for publication by the Commission [month 60]

D1.1 : First Progress Report [24]

The deliverable D1.1 will consist in the progress report due at month 24, as established in the Grant Agreement, to provide: an explanation of the work carried out by the beneficiaries, an overview of the progress towards the objectives of the action, and a summary for publication by the Commission.

D1.2 : Second Progress Report [36]

The deliverable D1.1 will consist in the progress report due at month 36, as established in the Grant Agreement, to provide: an explanation of the work carried out by the beneficiaries, an overview of the progress towards the objectives of the action, and a summary for publication by the Commission.

D1.3 : Third Progress Report [48]

The deliverable D1.1 will consist in the progress report due at month 48, as established in the Grant Agreement, to provide: an explanation of the work carried out by the beneficiaries, an overview of the progress towards the objectives of the action, and a summary for publication by the Commission.

D1.4 : Report 1 on cumulative expenditure incurred - Article 20.5 [12]

Report on cumulative expenditure incurred in accordance with Article 20.5

D1.5 : Report 2 on cumulative expenditure incurred - Article 20.5 [24]

Report on cumulative expenditure incurred (Article 20.5)

D1.6 : Report 3 on cumulative expenditure incurred - Article 20.5 [36]

Report on cumulative expenditure incurred - Article 20.5

D1.7 : Report 4 on cumulative expenditure incurred - Article 20.5 [48]

Report on cumulative expenditure incurred - Article 20.5

D1.8 : Report 5 on cumulative expenditure incurred - Article 20.5 [60]

Report on cumulative expenditure incurred - Article 20.5

D1.9 : Fourth Progress Report [60]

Deliverable D1.9 will consist in a progress report due at month 60, as established in the Grant Agreement and will provide the following information: an explanation of the work carried out by the beneficiaries, an overview of the progress towards the objectives of the action and a publishable summary report.

D1.10 : Report 6 on cumulative expenditure incurred - Article 20.5 [72]

Report on cumulative expenditure incurred - Article 20.5

Schedule of relevant Milestones

Milestone number¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
MS1	Establishment of the SAB	1 - MoH	3	Report
MS2	Kick-off NSC meeting	1 - MoH	5	Meeting minutes
MS3	First Meeting of the NSC and SAB	1 - MoH	5	Meeting minutes
MS4	Second Meeting of the NSC	1 - MoH	10	Meeting minutes
MS5	Second Meeting of the NSC and SAB	1 - MoH	14	Meeting minutes
MS6	Third Meeting of the NSC	1 - MoH	17	Meeting minutes
MS7	Fourth Meeting of the NSC	1 - MoH	22	Meeting minutes
MS8	Third Meeting of the NSC and SAB	1 - MoH	29	Meeting minutes
MS9	Fifth Meeting of the NSC	1 - MoH	34	Meeting minutes
MS10	Fourth Meeting of the NSC and SAB	1 - MoH	38	Meeting minutes
MS11	Sixth Meeting of the NSC	1 - MoH	41	Meeting minutes

Schedule of relevant Milestones

Milestone number¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
MS12	Seventh Meeting of the NSC	1 - MoH	46	Meeting minutes
MS13	Eighth Meeting of the NSC	1 - MoH	50	Meeting minutes
MS14	Fifth Meeting of the NSC and SAB	1 - MoH	58	Meeting minutes
MS53	Ninth Meeting of the NSC	1 - MoH	64	Meeting minutes
MS54	Tenth Meeting of the NSC	1 - MoH	69	Meeting Minutes

Work package number ⁹	WP2	Lead beneficiary ¹⁰	1 - MoH
Work package title	Preparation and implementation of the co-funded (first) call		
Start month	1	End month	72

Objectives

WP2 aims to address the following tasks:

- the preparation and launch of a joint transnational call with EC co-funding
- the implementation of the co-funded call (including evaluation and proposal selection);
- the monitoring of the funded projects;
- the communication, exploitation and dissemination of the research results.

Description of work and role of partners

WP2 - Preparation and implementation of the co-funded (first) call [Months: 1-72]

MoH

Task 2.1: Management of the consortium of funding organisations participating in the co-funded call (leader: MoH-ISS)
The main objective of this task is to ensure that the participation of the funding organisations committing in the co-funded call, i.e. the JTC 2014, complies with the rules established by the European Commission for the ERA-NET Cofund. The task leader has ascertained that all programme managers involved in the co-funded call have been mandated by the national/regional authorities in charge and that the minimum conditions for participation, as set out by the European Commission in the “General Annex D. Types of action: specific provisions and funding rates” to the Horizon 2020 – Work Programme 2014-2015”, are respected. In addition, the task leader will ensure that i) the direct costs of providing financial support to third parties implementing transnational projects within the co-funded call will be paid in accordance with national funding rules; ii) the coordination costs for additional activities, as a unit cost per year, will be paid to those beneficiaries who will carry out activities that go beyond the co-funded call; and, iii) the Union contribution will not exceed 33% of partners' funding of trans-national projects and unit costs for additional activities, as established in the above mentioned General Annex D under the item Funding rate.

In order to meet these requirements, the task leader will propose a financial plan to all interested partners, which will be agreed upon in writing and annexed to the Consortium Agreement.

Finally, the task leader will support the preparation and implementation of the co-funded JTC 2014 by ensuring the necessary communication between the corresponding Call Steering Committee and Joint Call Secretariat and by contributing to the organisation of the evaluation meetings.

Task 2.2: Preparation and launch of a joint transnational call with EC co-funding (leader: INCa; co-leader: MoH-ISS)
The group of funding organisations participating in the EC co-funded call (see short name of participants in WP2) constitute the Call Steering Committee (CSC). The CSC is the ultimate decision-making body for all issues related to this call: preparation, launch, implementation (incl. evaluation), monitoring, and dissemination.

It is however the responsibility of the task 2.1 leader to organise any discussions within the CSC and to ask for decisions on all call-related issues. As a result of these decisions, all relevant call documents will be prepared (D2.1) and the joint transnational call will be launched on the TRANSCAN website (M2.1).

Subtask 2.2.1 Topic selection (leader: INCa; participants: CSC partners)

At their meeting in April 2013, the TRANSCAN Scientific Advisory Board suggested the priority topic “(intra- and inter-) tumour heterogeneity” to the NSC because of its very high impact on the entire field of translational cancer research. Indeed, tumour heterogeneity reflects a cancer's evolution, and gives information of the mutational, epigenetic, and exposome load over life, which in turn provides clues about prior exposures and prevention strategies. Likewise, tumour heterogeneity & microenvironment is critical for treatment response and resistance.

At the TRANSCAN strategy meeting of the participating funding organisations, the NSC decided to focus this topic on “Intratumour heterogeneity in resistance to therapy and recurrence” to maintain a reasonably high funding rate (10-25%) and to avoid that many worthwhile applications may not be brought forward to TRANSCAN-2.

Detailed discussions on the specific call topic are ongoing at the time of writing (March until start of April 2014), with further input from the Scientific Advisory Board of the first TRANSCAN project expected mid April; at the time of writing, specific aims included (i) studies on intratumour heterogeneity (including heterogeneity between the primary tumour and the metastatic sites) aiming at the development and validation of alternative sampling methods (liquid biopsy, imaging, etc.); (ii) studies on intratumour heterogeneity aiming at the development of new predictive biomarkers/assays and at the validation of the associated mechanisms of treatment resistance in order to guide therapeutic

intervention and identify new therapeutic targets; (iii) studies on intratumour heterogeneity aiming at the development of new personalised therapeutic strategies and at the identification of the best combination of treatments in order to counteract resistance to therapy and recurrence.

The final decisions on the call topic will be taken by the CSC, in close communication with the EC, and the call topic will be a critical element of the call text.

Subtask 2.2.2 Preparation of the joint transnational co-funded call (leader: INCa; participants: CSC partners)

The leader of subtask 2.1.2 will draft all documents (D2.1), send these drafts to all CSC partners asking for comments, if necessary organise teleconferences with all CSC partners to discuss and decide on major issues, and finalise all documents.

The most important document to be prepared is the formal call text (in English, for the central publication; in addition, if required, in national languages for national publications). Additional documents are relevant for different stakeholders, as described below.

The “call text” addresses potential applicants. It includes a description of the motivation for this call as well as the scientific call topic. It describes the application procedure (including planned deadlines), the evaluation procedure as well as other financial and legal issues concerning the call (including national regulations).

The “Memorandum of Understanding” (MoU) is relevant for the CSC partners. It summarizes the commitments necessary for the participation of each CSC partner at the co-funded call. In signing this MoU, each partner agrees to make every reasonable effort to fulfill the intended commitments of this partner, including financial commitments.

The document “Governance of the Call and Evaluation” addresses the CSC partners. It includes: a description of the different steps of the implementation of the call, especially on the two-stage submission and evaluation step, the final selection step, as well as the project monitoring (see task 2.3). It also includes a description of the rules underlying the co-funded call.

The document “Guidelines for applicants” is relevant for potential applicants. It includes information about administrative details of the application procedure as well as specific rules and regulations for the different national funding agencies (i.e. CSC partners). Adherence to these (national) rules and regulations are required in order to be eligible for funding (and to be forwarded to the evaluation process).

The “pre-proposal and full proposal templates” must be used by the potential applicants in order to provide all relevant information during submission for the subsequent evaluation process. Standardizing the proposals by requiring the use of these templates allows easy comparison of specific information for the members of the Scientific Evaluation Committee.

The “pre-proposal and full proposal evaluation templates” are provided for the SEC members. Using these templates allows easy comparison, for the SEC members as well as the CSC members, across the different evaluators for a given proposal. It also simplifies the compilation of an (pre-proposal, full proposal) “evaluation book” for both steps of evaluation, including all comments and corresponding scores for all proposals.

Subtask 2.2.3 Launch of the co-funded call (leader: MoH-ISS; participants: CSC partners)

The joint transnational co-funded call will be published “centrally”, i.e. on the TRANSCAN website (in English) (M2.1), and, if necessary (for some CSC partner organisations), via national publication routes (in national languages). The EC will be formally informed about the planned call at least 30 days prior to the launch of the call. The launch of the co-funded call will take place a minimum of 60 days prior to proposal submission. Information about this call will be communicated to potential applicants via the central TRANSCAN-2 website and also via established national communication channels such as websites, e-mailing lists, press announcements, newsletters, scientific meetings etc. If feasible, a call pre-announcement will be published even earlier in order to enhance the mobilization of the relevant scientific community.

Task 2.3: Implementation of the co-funded call (evaluation and proposal selection) (leader: MoH-ISS; participants: CSC partners)

This task aims to (i) establish the Joint Call Secretariat; (ii) establish an electronic submission and evaluation system; (iii) selection of an observer for the two-step evaluation process; (iv) eligibility check and evaluation of pre-proposals (= step 1 of evaluation); (v) evaluation of full proposals (= step 2 of evaluation); (vi) decision of a final ranking list of full proposals recommended by the Scientific Evaluation Committee; (vii) Call Steering Committee decision of a final selection list of full proposals to be funded.

The proposed evaluation and selection mechanisms of the co-funded call are based on well-established procedures in previous TRANSCAN (and other ERA-Net) joint transnational calls as well as on additional rules and regulations defined by the EC for this co-funded call.

The proposals will be evaluated based on the scoring system and the criteria (“excellence”, “impact” and “quality and efficiency of the implementation”) described in Annex H of the General Annexes of the Horizon 2020 Work Programme 2014-2015.

The JCS and the CSC will take all necessary steps to guarantee the confidentiality of all information obtained during the evaluation and selection procedures of the co-funded call.

The overall evaluation will be implemented in two subsequent steps, as described below.

Subtask 2.3.1: Establishment of the Joint Call Secretariat, the Scientific Evaluation Committee, and assistance to potential applicants by national contact points (leader: MoH-ISS; participants: CSC partners)

A Joint Call Secretariat (JCS) will be set up at MoH-ISS. The JCS is responsible for overall assistance to potential applicants regarding any questions related to the co-funded call, especially to details on writing and submission of the pre-proposal and full proposal. With respect to national rules and regulations, potential applicants will be directed to contact the national contact persons from the respective CSC partner organisation. These national contact points will provide (country-specific) detailed information on national eligibility criteria and financial regulations. Starting with the date of the launch of the call, advisory service from the JCS and the national contact points will be available via phone and e-mail throughout the entire call implementation period.

The JCS is responsible for the establishment of a Scientific Evaluation Committee (SEC). SEC candidates are internationally recognized scientists with excellent knowledge (scientific and/or technical, and/or clinical) on the topic of the co-funded call. The CSC partners propose the candidates for the SEC. The JCS compiles a list of the most-suited SEC candidates taking into account factors such as gender, basic vs. clinical expertise, expert from participating vs. non-participating country, experienced (i.e. member of previous SEC) vs. inexperienced. In addition, the JCS suggests some SEC candidates as the chair or vice-chair of the SEC. Of course, all candidates will be thoroughly checked against any potential conflict of interest by the JCS. The candidate list will be forwarded to the CSC for final approval.

Subtask 2.3.2: Establishment of an electronic submission and evaluation system (leader: MoH-ISS)

The JCS will be responsible for the setting-up of an electronic submission and evaluation system. The system will be adapted to the specific requirements of the co-funded call.

Subtask 2.3.3: Appointment of an observer for the two-step evaluation process (leader: INCa; participants: all CSC partners)

The JCS will organise the process leading to the appointment of an independent observer for the two-step evaluation process of the co-funded call. Nominations for adequate candidates will be asked for from all participating CSC partners, as well as from the EC. Candidates should have prior experience in accompanying similar evaluation processes and declare that they are independent and have no conflicts of interest.

The chosen observer will communicate with and be supported by the JCS. The observer will receive all relevant information prior to the two meetings of the SEC and participate at these evaluation meetings. After the end of the evaluation (SEC: ranking list, see D2.2) and selection (CSC: selection list, see D2.2) process, the observer will deliver a report on the evaluation process (D2.2) to the JCS, which will forward it to the EC.

Subtask 2.3.4: Submission of pre-and full proposals (leader: MoH-ISS)

As described, the JCS will establish an electronic submission (and evaluation) system; with keyword-protected access via the world-wide web (each potential applicant chooses her keyword for repeated access). Applicants must upload the pre- and full proposals, using the adequate templates, in PDF-format.

Subtask 2.3.5: Eligibility check and evaluation of pre-proposals (leader: FICYT; co-leader: ISCIII; participants: CSC partners)

The JCS will examine all submitted pre-proposals for compliance with the call's formal criteria, defined by the CSC in order to guarantee equal treatment to all applicants: date of submission; geometry of research consortium (numbers and countries of origin of research groups); presence of all relevant information in English (i.e. addressing all chapters of the pre-proposal template); adherence to text constraints (page lengths of each section, formatting).

The JCS will make the pre-proposals available to all CSC partners who will examine them for agreement with country-specific eligibility rules.

The pre-proposals that successfully pass both the formal as well as the eligibility examinations will subsequently be evaluated by the SEC (unsuccessful pre-proposals will be informed by the JCS for the reasons of rejection).

With the use of the electronic submission and evaluation system the JCS will make each pre-proposal available to at least two SEC members. Each reviewer will be asked to complete the pre-proposal evaluation form for each assigned pre-proposal on-line, providing scores and explanatory statements for each of the evaluation criteria.

In a first review meeting, the SEC will discuss all pre-proposals, and recommend those that shall be invited for full proposal submission. Approximately two to three times the number of proposals that can ultimately be funded (given the committed call budget and the average requested budget per proposal) should be recommended by the SEC for full proposal submission, with the exact number depending on where a clear drop in the quality of the proposals is perceived by the SEC. Formally, the CSC will take the final decision on which pre-proposals shall be selected for the second evaluation step.

The JCS will inform the coordinators of the successful pre-proposals to submit full proposals, again using the adequate proposal template and uploading the final proposal onto the electronic submission system. A deadline for full proposal submission will be chosen that allows at least 60 days for the preparation of the proposal.

For the unsuccessful pre-proposal, the respective SEC members will provide a summary evaluation statement (with the reasons for rejection) to the JCS. The JCS will include these evaluation statements when informing the coordinators of rejected pre-proposals (without disclosing the identity of the reviewers).

Subtask 2.3.6: Evaluation of full proposals and ranking list of proposals recommended by the SEC (leader: MoH-ISS; co-leader: ARC; participants: CSC partners)

The JCS will examine the submitted full proposals for compliance with the formal and eligibility criteria of the call; in addition, no substantial changes will be allowed with respect to the previously submitted (and evaluated) pre-proposal, unless that was specifically recommended by the SEC.

With the use of the electronic submission and evaluation system the JCS will make each full proposal available to the two SEC members who had reviewed the corresponding pre-proposal and to at least two external reviewers. Each reviewer will provide a completed full proposal evaluation form for each assigned pre-proposal on-line, providing scores and explanatory statements for each of the evaluation criteria (cf. Annex H of the General Annexes of the Horizon 2020 Work Programme 2014-2015: “excellence”, “impact”, “quality and efficiency of the implementation”). In order to allow for overall comparison of the quality of all full proposals, all SEC members will have on-line access to all full proposals (i.e. also those not assigned to them for evaluation).

In a second review meeting, the SEC will discuss all full proposals, mainly driven by the assigned reviewers, but also complemented by the other SEC members. The final result of this meeting is a recommendation on the ranking of the full proposals to be funded (with number 1 corresponding to the best proposal, 2 to the next best, and so on).

For all full proposals, the respective SEC members will provide summary evaluation statements to the JCS. After the decision of the CSC (see below), the JCS will include these evaluation statements when informing the coordinators of the full proposals recommended or not recommended for funding (without disclosing the identity of the reviewers).

Subtask 2.3.7: Call Steering Committee decision of a final selection list of full proposals to be funded (leader: MoH-ISS; participants: CSC partners)

Representatives from funding organisations contributing to the EC co-funded call (CSC members) will participate in both evaluation meetings. Following the second SEC meeting, the CSC will formally meet and report their observations of the evaluation process and the ranking list of full proposals recommended for funding by the SEC.

Based on previously agreed procedures (use of EC co-fund, use of national funds), in a consensus decision, the CSC will agree on a final selection list of full proposals to be funded (with EC and/or national funds). In doing so, the ranking list recommended by the SEC will be strictly followed, until the available combined EC and national budget is spent (D2.4).

A funding organisation from a certain country or region will fund the national or regional applicants, according to the national or regional administrative regulations (“virtual common pot model”). The EC co-fund will be used to fill funding gaps (resulting from the total spent of one or several national budgets) and/or topping-up of national funds, resulting in an increase of the number of proposals that can be funded. The JCS will prepare the final selection list, forwarding it to the WP1 leader for publication on the TRANSCAN-2 website (D2.3). The JCS will inform the coordinators of the full proposals about the final funding decision, so that the national negotiations can start.

Task 2.4: Monitoring of the funded projects (leader: SAS; participants: CSC partners)

Performing the work described in detail in WP3 below, the developments of the EC co-funded projects will be monitored by the WP3 leader, with yearly reports as well as with final reports on the entire 3-year period provided by the project coordinators. For each year, and for the entire the 3-year period, the WP3 leader will provide a summary analysis of these monitoring reports to all CSC members, describing the status of the progress, major achievements and, if existing, occurrence of problems. In the case of problems in the project execution, the CSC will discuss whether the corrective actions proposed by the project coordinators are acceptable or should take into account other modifications.

In addition to this centrally-organised monitoring established by TRANSCAN-2, most national funding organisations have in place their national monitoring and reporting system (usually also in yearly tranches as well as in a whole-duration, i.e. 3-year, tranche). Any relevant information on a part of the funded research consortium, as seen in such a national examination, will be reported to the WP3 leader who takes this information into account for preparing the summary analysis report.

Task 2.5: Communication, exploitation and dissemination of the research results (leader: MIZS; co-leader: CSO-MOH; participant: ISCIII)

Performing the work described in detail in WP5 below, the results of the EC co-funded research projects will be communicated and disseminated by the WP5 leaders (D2.5). The WP5 leaders are also responsible to make sure that these research results will be exploited in an appropriate manner, usually laid down in agreements of the research consortia. Of course, the respective national funding organisations involved in the funding of a research consortium will also make sure that the results will be exploited adequately. As described above in the context of monitoring (task 2.3), national funding organisations will provide any relevant knowledge to the WP5 leaders.

Partner number and short name ¹⁰
1 - MoH
2 - FWF
3 - ISS
5 - INCa
6 - BMBF
7 - DLR
8 - ARC
9 - GSRT
10 - CSO-MOH
11 - ACC
12 - ZonMw
13 - DCS
14 - RCN
15 - FCT
16 - SAS
17 - MIZS
18 - ISCIII
19 - TUBITAK
20 - NCBR
21 - FWO
23 - NCS
24 - FNRS
25 - MIUR
26 - ETAg
27 - FICYT
28 - MoST
29 - VIAA

List of deliverables

Deliverable Number ¹⁴	Deliverable Title	Lead beneficiary	Type ¹⁵	Dissemination level ¹⁶	Due Date (in months) ¹⁷
D2.1	JTC 2014 co-funded call-related documents	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	2

List of deliverables

Deliverable Number¹⁴	Deliverable Title	Lead beneficiary	Type¹⁵	Dissemination level¹⁶	Due Date (in months)¹⁷
D2.2	Information on evaluation results (ranking list of full proposals recommended for funding by the SEC; CSC selection list; observer's report on the evaluation procedure)	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	11
D2.3	Publishable information about projects to be funded (participants, abstract), in EC-defined format	1 - MoH	Report	Public	12
D2.4	Formal (signed) commitments on availability of funds for the selected projects (each contributing CSC partner)	1 - MoH	Report	Public	12
D2.5	Publishable information about funded projects (participants, overview of results), in EC-defined format	1 - MoH	Report	Public	71

Description of deliverables

The deliverable D2.1 (month 1) will comprise all the documents related to the JTC 2014 call (Call text, incl. country-specific information; Memorandum of Understanding, Governance of the Call and Evaluation, Guidelines for applicants, Pre-proposal and full proposal templates, Pre-proposal and full proposal evaluation templates) (Task 2.2).

The deliverable D2.2 (month 10) will provide the information on the results of the evaluation of the projects submitted under the JTC 2014 call (ranking list of full proposals recommended for funding by the SEC; CSC selection list; observer's report on the evaluation procedure) (Task 2.3).

The deliverable D2.3 (month 11) will provide the publishable information about the projects to be funded under JTC 2014 (i.e. participants, abstracts), in EC-defined format (Task 2.3).

The deliverable D2.4 (month 11) will consist of the formal commitments on availability of funds for the JTC 2014 selected projects, as signed by each contributing CSC partner (Task 2.3).

The deliverable D2.5 (month 71) will report on the publishable information about the projects funded under the JTC 2015 (i.e. participants, overview of results), in EC-defined format (Task 2.4 and Task 2.5).

D2.1 : JTC 2014 co-funded call-related documents [2]

The deliverable D2.1 (month 1) will comprise all the documents related to the JTC 2014 call (Call text, incl. country-specific information; Memorandum of Understanding, Governance of the Call and Evaluation, Guidelines for applicants, Pre-proposal and full proposal templates, Pre-proposal and full proposal evaluation templates) (Task 2.2).

D2.2 : Information on evaluation results (ranking list of full proposals recommended for funding by the SEC; CSC selection list; observer's report on the evaluation procedure) [11]

The deliverable D2.2 (month 10) will provide the information on the results of the evaluation of the projects submitted under the JTC 2014 call (ranking list of full proposals recommended for funding by the SEC; CSC selection list; observer's report on the evaluation procedure) (Task 2.3).

D2.3 : Publishable information about projects to be funded (participants, abstract), in EC-defined format [12]

The deliverable D2.3 (month 11) will provide the publishable information about the projects to be funded under JTC 2014 (i.e. participants, abstracts), in EC-defined format (Task 2.3).

D2.4 : Formal (signed) commitments on availability of funds for the selected projects (each contributing CSC partner) [12]

The deliverable D2.4 (month 11) will consist of the formal commitments on availability of funds for the JTC 2014 selected projects, as signed by each contributing CSC partner (Task 2.3).

D2.5 : Publishable information about funded projects (participants, overview of results), in EC-defined format [71]

The deliverable D2.5 (month 59) will report on the publishable information about the projects funded under the JTC 2015 (i.e. participants, overview of results), in EC-defined format (Task 2.4 and Task 2.5).

Schedule of relevant Milestones

Milestone number ¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
MS15	Launch of the JTC 2014 co-funded call on TRANSCAN website	1 - MoH	2	Publication on website
MS16	Establishment of the JTC 2014 Joint Call Secretariat	1 - MoH	3	Notification to JTC 2014 CSC
MS17	Eligibility check of JTC 2014 pre-proposals	1 - MoH	4	Report
MS18	First meeting of the JTC 2014 Scientific Evaluation Committee, pre-proposal evaluation	1 - MoH	6	Meeting minutes
MS19	Second meeting of the JTC 2014 Scientific Evaluation Committee, full proposal evaluation	1 - MoH	11	Meeting minutes
MS20	Selection list of the JTC 2014 projects to be funded by the CSC	1 - MoH	11	List of JTC 2014 projects to be funded

Work package number ⁹	WP3	Lead beneficiary ¹⁰	16 - SAS
Work package title	Follow-up and monitoring of projects resulting from the co-funded JTC 2014 and the TRANSCAN-2 JTCs		
Start month	10	End month	72

Objectives

WP3 has the following objectives:

- Monitoring the implementation and progress of the research projects funded within TRANSCAN-2 JTCs (WP7-9).
- Analyzing the monitored data to get feedback on the performance of the funded projects and how they comply with the scope of the TRANSCAN-2 JTCs (WP7-9).

Description of work and role of partners

WP3 - Follow-up and monitoring of projects resulting from the co-funded JTC 2014 and the TRANSCAN-2 JTCs [Months: 10-72]

SAS

Task 3.1: Preparation of a template for monitoring research projects (leader: SAS; participant: DCS, DLR)

The research projects funded within TRANSCAN-2 JTCs will be monitored using a structured template (D3.1), which will be distributed to the research project coordinators. This template will be developed from the one elaborated under the TRANSCAN project and will collect information which will enable the task leader to generate the following outputs:

- overview of the research project implementation and progress towards the project's objectives
- assessment of the research project coordinators' views on TRANSCAN-2 JTC procedures and call-related documents
- assessment of the evolution of the projects funded under TRANSCAN-2 JTCs regarding consortium effectiveness, scientific results, perceived advantages over other types of transnational projects

The content and the structure of the template will be elaborated in cooperation with all partners of the TRANSCAN-2 consortium, after consultation with the SAB.

One general template will be used for all JTCs (including the co-funded call) for long-term trend analysis. If necessary, the template can be adjusted for each JTC to meet specific demands of each JTC topic.

Task 3.2: Implementation and evaluation of the monitoring (leader: SAS; participants: CSC partners committing in the co-funded JTC 2014 and/or in the additional JTCs)

The task leader will distribute the reporting forms to the applicants and collect the completed reports. Then, it will distribute the reports to the CSC of JTCs, along with a brief analysis of the reports. The structure of the analysis will be discussed with all CSC partners. The analyses of the reports will serve as an additional source of information about the steps possibly required to be taken to enhance efficiency and impact of the JTCs. The results of the analyses will be included in the deliverables D2.5, D7.4, D8.4 and D9.4 pertaining to the publishable information about the projects funded under the JTC 2014 (WP2), JTC 2015 (WP7), JTC 2016 (WP8), and JTC 2017 (WP9). In these deliverables, the outcomes of the monitoring of the projects funded under the JTCs launched by the TRANSCAN project will be referred to, aiming at both a retrospective and prospective analysis of the results. The individual funding agencies will share information of the national assessment of the nationally required scientific and/or financial reports, especially if any changes of project funding occurred. TRANSCAN-2 will evaluate outputs of the monitoring. If necessary, adequate actions will be taken by Consortium on the basis of the reports.

Participation per Partner

Partner number and short name ¹⁰
1 - MoH
2 - FWF
3 - ISS
5 - INCa
6 - BMBF

Partner number and short name ¹⁰
7 - DLR
8 - ARC
10 - CSO-MOH
11 - ACC
12 - ZonMw
13 - DCS
14 - RCN
15 - FCT
16 - SAS
17 - MIZS
18 - ISCIII
19 - TUBITAK
20 - NCBR
21 - FWO
23 - NCS
24 - FNRS
25 - MIUR
26 - ETAg
27 - FICYT
28 - MoST
29 - VIAA
31 - FRRB
32 - FCAECC

List of deliverables

Deliverable Number ¹⁴	Deliverable Title	Lead beneficiary	Type ¹⁵	Dissemination level ¹⁶	Due Date (in months) ¹⁷
D3.1	Template for monitoring funded research projects	16 - SAS	Report	Confidential, only for members of the consortium (including the Commission Services)	12

Description of deliverables

The deliverable D3.1 will consist in the template approved by the TRANSCAN-2 consortium for monitoring the progress of the projects funded under the JTCs implemented during the action [month 12].

D3.1 : Template for monitoring funded research projects [12]

The deliverable D3.1 will consist in the template approved by the TRANSCAN-2 consortium for monitoring the progress of the projects funded under the JTCs implemented during the action [month 12].

Schedule of relevant Milestones

Milestone number¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
MS21	Agreement on the content and the structure of a template for monitoring	16 - SAS	12	Final template
MS22	Review of the analyses conducted in 2016	16 - SAS	24	Report
MS23	Review of the analyses conducted in 2017	16 - SAS	36	Report
MS24	Review of the analyses conducted in 2018	16 - SAS	48	Report
MS25	Review of the analyses conducted in 2019	16 - SAS	60	Report

Work package number ⁹	WP4	Lead beneficiary ¹⁰	5 - INCa
Work package title	Strategy: network and scientific research priorities		
Start month	1	End month	72

Objectives

The first aim of WP4 is to develop and update the strategy of the TRANSCAN-2 network regarding the following essential issues: enlarging the network of funding organisations; improving the success of certain partners in future JTCs; improving the decision-making processes; goal-directed interactions with relevant projects and stakeholders in EU and world-wide translational cancer research.

The second aim of WP4 is to develop, and continuously update, a strategy on identifying scientific priority topics in translational cancer research. This will be pursued by organising more frequent and systematic contacts with relevant scientific stakeholders (scientists, clinicians, major institutes, etc.) from as many partner countries as possible.

Description of work and role of partners

WP4 - Strategy: network and scientific research priorities [Months: 1-72]

INCa

WP4 comprises five tasks that will help to develop and implement specific strategies of fundamental importance for the future performance of TRANSCAN-2.

Task 4.1: Strategy on enlarging the network of funding organisations (leader: MoH-ISS; co-leader: ZonMw; participants: DCS, BMBF-DLR, RCN)

This task will identify potential major funding organisations not yet included in the TRANSCAN-2 consortium, both from the public and private (charity) sectors. The Network Steering Committee will decide which organisations should favourably be contacted. Funding organisations will receive various information materials and, in case of interest, will be invited to TRANSCAN-2 meetings.

The recruitment of additional partners will need to be limited to a certain degree, in order to keep the network manageable.

As a rule, new funding organisations should become a member of TRANSCAN-2. However, in specific cases TRANSCAN-2 will allow the participation in one of the planned joint transnational calls without being a formal TRANSCAN-2 partner.

Task 4.2: Strategy on improving partner's success in JTCs (leader: FCT; co-leader: VIAA; participants: OOI, RCN, TUBITAK)

The cancer research landscapes within the European Research Area are not equally developed in all countries participating in TRANSCAN-2. This means that for any given research topic, as chosen for a specific TRANSCAN-2 call, some countries have many more expert groups responding to that call than other countries. As a simple mathematical rule, with success rates in the magnitude of 10 to 15%, being successful in a highly competitive evaluation is very unlikely for expert groups from less-developed countries (for that research topic). As a consequence, proven by experiences from the first two TRANSCAN calls (on cancer biomarker validation; on primary and secondary cancer prevention), some TRANSCAN funding partners have committed national funds for joint calls for proposals, but because of the negative results of the evaluation (i.e. no research groups from their country were successful) none of these funds could be spend. This situation is very detrimental to a continuing, long-term commitment of these funding partners, since chances for future budgetary commitments will rather decline with each unsuccessful experience.

This task will explore possibilities for increasing the chances for success for these TRANSCAN-2 partners, either prior to (in the call preparation phase) or after the evaluation (subsequent integration, e.g. with training activities).

Of course, the implementation of any of these possible actions will have to be agreed upon by the respective Call Steering Committees of the future TRANSCAN-2 joint transnational calls.

Task 4.3: Strategy on improving the decision-making (leader: FCT; co-leader: ISCIII; participants: ACC, BMBF, FCT, INCa, MoH-ISS, OOI, RCN, VIAA)

The success of a complex network such as TRANSCAN-2, with its numerous public and private funding organisations from many different countries working on different national principles, depends on efficient decision-making processes. The general agreements on decision-making are laid down in this proposal as well as in the consortium agreement that will be worked after a (hopefully) successful evaluation of this proposal. Specific agreements on specific issues (e.g. how to check the eligibility of proposals) have proven to be imprecisely prepared, resulting in difficulties and loss of time during the implementation (e.g. of joint transnational calls).

Thus, in order to increase the overall efficiency and the satisfaction of the participating funding organisations with the performance of TRANSCAN-2 (see WP6), there is a clear need for more precise agreements on decision-making.

What is more, it is a consequence of the new EC funding instrument (“co-fund”) of ERA-Nets, that one element of this proposal will have to be very precisely defined and subject to a clear reporting to the EC (i.e. the EC co-funded joint transnational call) whereas the other elements (representing the “other activities”) will be clearly described, but are subject to a detailed monitoring of the work progress by the TRANSCAN-2 partners only. This means, that the TRANSCAN-2 consortium must increase the internal monitoring mechanisms, including precise decision-making processes that will positively influence the implementation of the different work packages.

This task will summarize the current situation of general and specific decision-making, feeding in the experiences (positive, negative) from the previous TRANSCAN period. Since the main outcomes of TRANSCAN-2, visible to the cancer researchers in Europe, are the joint transnational calls, one focus of this task will lie in improving the decision-making during the preparation and implementation phases of future JTCs (e.g. eligibility check; selection of the SEC; adherence to timetables).

Another focus will be to take into account, as much as possible, the different opinions of the TRANSCAN-2 partners in more general decision-making situations (e.g. defining the degree of decision-making of the leaders of work packages, tasks and subtasks – in relation to the ultimate decision-making body, i.e. the NSC).

Task 4.4: Strategy on interaction with relevant projects and stakeholders (leader: INCa; participants: FICYT, GSRT, MoH-ISS, OOI, RCN, BMBF-DLR, MIZS)

The purpose of this task is to ensure optimal coordination at global level with other European and international initiatives that may spur TRANSCAN-2 strategy on translational research. To this end, the initial task activity will be dedicated to the elaboration of a strategy for interaction with the relevant initiatives, taking into consideration the partners’ priorities and expectations.

Translational research should be seen as an integrative process where all aspects of the cancer research continuum from basic to clinical to outcome research and epidemiology, ultimately contribute to the transfer the most recent knowledge in medical practice and cancer control. As way of example, but not limited to, it is hence important to ensure that TRANSCAN-2 keeps track of the work being conducted under the Joint Action CANCON (European Guide on Quality Improvement in Comprehensive Cancer Control), funded by DG SANCO, and in particular its WP6 which tackle research integration into comprehensive cancer control networks. As this trend for organising translational research through integrated facilities is widely shared, some TRANSCAN-2 activities may help leverage the development process of the concept across Europe.

Likewise, H2020 work program in health addresses the many challenges of personalising health and care, creating real opportunities to support translational findings. Some areas are highly relevant to translational cancer research, like those dealing with the screening and prevention programs (PHC6-2014) or the development of personalised medicine pilots (PHC24-2014). TRANSCAN-2 coordination strategy would mean here to enhance convergence of TRANSCAN-2 actions with other European programs.

A special attention will be also paid to the interaction with the ESFRI Biological and Medical Sciences Research Infrastructures projects, in particular EATRIS, ECRIN and BBMRI, as well as with the Innovative Medicine Initiative (IMI). To have a global vision at the EU level, other already existing EU research and training initiatives promoted and/or supported by public or private organisations will be taken into consideration for the establishment of specific connections with TRANSCAN-2 activities. The interaction with other European initiatives contributes also to a better perception and visibility of the TRANSCAN-2 consortium in the scientific community and the relevant stakeholders in Europe.

Finally, it is important to liaise with international initiatives. Again as way of example, regular meetings of cancer research funders from across the world have been convened to discuss areas of common interest and potential for collaboration. The latest one organised by INCa and IARC in Paris in January 2014, gathered leaders in cancer research and policy from 23 economically diverse countries. The purpose of these meetings is to share cancer control issues, understand where commonalities exist and where there is potential to act in a globally coordinated way through partnership. It is important that TRANSCAN-2 is aware of the recommendations arising from such high level group and their schedule for implementation.

Task 4.5: Strategy on identifying scientific priority topics (leader: INCa; co-leader: FICYT; participants: ACC, DCS, GSRT, MoH-ISS, OOI, RCN, VAA, ETAg)

This task will continue and deepen the activities on scientific issues in translational cancer research, which have been started in the previous TRANSCAN project. The central question is how a consortium such as TRANSCAN-2 can best contribute to support European translational cancer research, and the underlying research-performers (e.g. more basic-oriented and more clinically-oriented researchers, expert centres and institutes for translational cancer research, young investigators). The activities that will be prepared and implemented in order to answer this question will include: ongoing contacts, of each TRANSCAN-2 partner, with their national scientific community; participation at scientific conferences and workshops; comparison with priority-setting at other major funding organisations (e.g. EC, NCI); site visits of

TRANSCAN-2 representatives at major European centers of expertise for translational cancer research). Additional input will be provided by task 5.1 (scientific TRANSCAN-2 symposia).

All information gained will be presented to and discussed among the NSC, accompanied and/or followed by thorough discussions with the Scientific Advisory Board. The ultimate result of these continuing activities is to keep the NSC informed about current developments in translational cancer research, and to identify scientific priority topics relevant to further this field of research. Of course, these topics will be candidate topics for future JTCs of TRANSCAN-2 (following the EC co-funded call, see WP2), to be chosen by the particular CSCs.

Participation per Partner

Partner number and short name ¹⁰
1 - MoH
3 - ISS
5 - INCa
6 - BMBF
7 - DLR
9 - GSRT
11 - ACC
12 - ZonMw
13 - DCS
14 - RCN
15 - FCT
17 - MIZS
18 - ISCIII
19 - TUBITAK
22 - OOI
27 - FICYT
29 - VIAA
30 - TuscReg
31 - FRRB
32 - FCAECC

List of deliverables

Deliverable Number ¹⁴	Deliverable Title	Lead beneficiary	Type ¹⁵	Dissemination level ¹⁶	Due Date (in months) ¹⁷
D4.1	Reports on contacts with non-TRANSCAN-2 funding organizations, interactions with other European and world-wide cancer initiatives,	3 - ISS	Report	Confidential, only for members of the consortium (including the Commission Services)	18

List of deliverables

Deliverable Number¹⁴	Deliverable Title	Lead beneficiary	Type¹⁵	Dissemination level¹⁶	Due Date (in months)¹⁷
	and on scientific priority topics				

Description of deliverables

The deliverable D4.1 will consist of periodic updated reports (months 18, 36, 60) on: i) the establishment and outcome of contacts of TRANSCAN-2 with funding organisations not comprised in the consortium (Task 4.1), as well as of the interactions with other European and world-wide cancer initiatives (Task 4.4); ii) the results of the process of identification of scientific priority topics (Task 4.5).

D4.1 : Reports on contacts with non-TRANSCAN-2 funding organizations, interactions with other European and world-wide cancer initiatives, and on scientific priority topics [18]

The deliverable D4.1 will consist of periodic updated reports (months 18, 36, 60) on: i) the establishment and outcome of contacts of TRANSCAN-2 with funding organisations not comprised in the consortium (Task 4.1), as well as of the interactions with other European and world-wide cancer initiatives (Task 4.4); ii) the results of the process of identification of scientific priority topics (Task 4.5).

Schedule of relevant Milestones

Milestone number¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
--------------------------------------	------------------------	-------------------------	-----------------------------	------------------------------

Work package number ⁹	WP5	Lead beneficiary ¹⁰	17 - MIZS
Work package title	Communication, dissemination and networking		
Start month	1	End month	72

Objectives

Increase awareness of TRANSCAN-2 and its impact through the communication of undertaken activities and dissemination of achieved results, both of the TRANSCAN-2 consortium and of the research projects funded through the Joint Transnational Calls (JTCs) launched by the preceding TRANSCAN project as well as by TRANSCAN-2. This will be achieved by broadening, deepening, strengthening and streamlining communication and dissemination towards different stakeholder groups.

Description of work and role of partners

WP5 - Communication, dissemination and networking [Months: 1-72]

MIZS

This Work Package will provide the basis for maximal communication and dissemination of the results attained by TRANSCAN-2 and the projects funded through the preceding TRANSCAN and TRANSCAN-2 JTCs using different outreach materials and activities. Key in this process will be providing support to other WPs (especially WP2 and 4) and integrating all of TRANSCAN-2's stakeholders as defined in the task dedicated to the communication strategy.

Task 5.1: Communication Strategy (leader: MIZS; participants: MoH, ISS, ACC, ISCIII, FICYT, VIAA)

The communication strategy (M5.1) will be a strategic document which will aim at ensuring the optimal ways of addressing the relevant stakeholder groups, namely the scientific community, other interested publics and the general public. As such, it will serve as the basis for all outreach and networking activities, providing support to the delivery of the results of individual WPs through different communication and dissemination means. It will define the communication activities and tools, devise the main messages to be conveyed to each identified stakeholder groups, identify a broad range of communication and dissemination channels and provide a comprehensive schedule of planned outreach activities and events.

Task 5.2: Internal and external communication (leader: MoH-ISS)

Internal communication with systematic exchange of information is essential for the performance of TRANSCAN-2. To this end, the website set up for the preceding TRANSCAN ERA-NET will be revamped (D5.1) so as to best serve the purposes of the task and WP. The TRANSCAN-2 website will continue to be the central repository of all the historical data of the project (databases, working documents, meeting reports, progress reports, etc.). The implementation of the TRANSCAN-2 activities will be facilitated by unrestricted circulation of information within the consortium on the website intranet, and accurate technical reports prior to and after each teleconferences and meetings. The website intranet will host all relevant documentation provided by the participants, such as meeting announcements, reports, minutes, and documents on new activities.

The public part of the website will be used for the communication of the TRANSCAN-2 activities, outcomes and perspectives, as agreed by the NSC. The public part of the TRANSCAN-2 website will be advertised and offered as a link on official websites of relevant regional/national/European institutions.

Task 5.3: Outreach materials and activities (leader: MIZS; participants: CSO-MOH, MoH-ISS, ISCIII, ACC)

Outreach materials and activities will guarantee a continuous information flow to all interested stakeholders regarding the impact of activities already performed under the preceding TRANSCAN project as well of those that will be implemented in the context of the proposed TRANSCAN-2, namely information on funded projects for general public and the scientific community (WP 2 and WP3), publication of scientific priority topics (WP4), as well as assessment and monitoring of the consortium's performance (WP6).

An e-newsletter will be published 2 times per year (D5.2) to report on the progress of TRANSCAN-2, providing information on the JTCs launched by TRANSCAN-2 and all other TRANSCAN-2 relevant activities giving insight into new developments. The newsletter will be circulated through the TRANSCAN-2 central mailing list (based on subscription) and partners' mailing lists, and will be published on the TRANSCAN-2 website as well as on the individual websites of the funding organisations partnering in TRANSCAN-2.

Information on TRANSCAN-2 will also be periodically disseminated via NETWATCH (<http://netwatch.jrc.ec.europa.eu>), the ERAWATCH platform (<http://erawatch.jrc.ec.europa.eu>) and CORDIS WIRE, under the responsibility of MoH-ISS, as the institutional couple in charge of coordinating TRANSCAN-2. To enhance the dissemination of results a link to social networks (Twitter, Facebook, LinkedIn or Google+) could be established.

Additional outreach materials, such as i) brochures providing information on TRANSCAN-2 as well as on the JTCs which will be launched under this project; and ii) a booklet describing the major achievements of TRANSCAN-2, could be elaborated. Furthermore, the participation of TRANSCAN-2's representatives in events such as the European Science and Technology Week, Researcher Nights, etc. shall be supported as much as possible.

Task 5.4: Scientific Symposia with targeted network activities (leader: CSO-MoH; participants: MIZS, INCa, MoH-ISS, ACC, FICYT, TUBITAK)

The coordinators of the projects funded under the JTCs launched by the preceding TRANSCAN project and by TRANSCAN-2, within the time limits foreseen for the latter project, will be given the opportunity to illustrate their results to a wide public, during scientific symposia which will be organised in years 2 (M5.2), 4 (M5.3) and 5 (M5.4). These events will gather, in addition to the above mentioned coordinators, the interested programme owners/managers and representatives of the national and international top-notch scientific community working in the field of cancer research. Thus, the scientific symposia will represent a true occasion for both the funding organisations partnering in TRANSCAN-2 and the researchers funded through the current TRANSCAN and TRANSCAN-2 JTCs to exchange information and to network with their peers to get a broader view of existing initiatives in Europe and beyond. Likewise, policy makers and programme owners/managers will increase their awareness of the outcomes and impact of the projects funded under the current TRANSCAN and TRANSCAN-2 JTCs. The results of the symposia will be disseminated through the activities foreseen in task 5.3 (D5.2 and D5.3) so as to render as visible as possible their impact in the field of translational cancer research.

A keynote lecture dedicated to a specific hot topic in the field of translational cancer research, followed by discussion with the audience, will take place at the beginning of each scientific symposium. Each keynote lecture will focus on a topic predefined in close collaboration with the SAB. This will provide an opportunity to increase the knowledge on cancer for the general public as well.

In conjunction with the scientific symposia, an additional session will take place:

Sub-task 5.4.1. Networking of Young scientists participating in the projects funded under the Joint Transnational Calls implemented by TRANSCAN and TRANSCAN-2

This sub-task is specifically designed as functional support to serve the young scientists participating in the research consortia funded through the TRANSCAN and TRANSCAN-2 JTCs. Networking activities will be organised for each symposium by opening a communication network to reach all young scientists (PhD students, postdocs, young Principal Investigators) participating in the above mentioned funded projects using email lists, social networks, newsletters and other means of communication.

Each networking meeting will be organised to bring together young scientists that are connected through the funded projects. The main aims are:

- to increase exchange of academic information,
- to facilitate technology transfer, and
- to provide information about mobility options for the young researchers.

Participation per Partner

Partner number and short name ¹⁰
1 - MoH
3 - ISS
5 - INCa
10 - CSO-MOH
11 - ACC
17 - MIZS
18 - ISCIII
19 - TUBITAK
27 - FICYT
29 - VIAA
30 - TuscReg

Partner number and short name ¹⁰
31 - FRRB
32 - FCAECC

List of deliverables

Deliverable Number ¹⁴	Deliverable Title	Lead beneficiary	Type ¹⁵	Dissemination level ¹⁶	Due Date (in months) ¹⁷
D5.1	Updated website	1 - MoH	Websites, patents filling, etc.	Public	3
D5.2	E-newsletters 1-10	10 - CSO-MOH	Websites, patents filling, etc.	Public	6
D5.3	Reports of the scientific symposia	17 - MIZS	Websites, patents filling, etc.	Public	16

Description of deliverables

The deliverable D5.1 (month 3) will report on the revamping of the TRANSCAN website aimed at best meeting the requirements of the TRANSCAN-2 communication strategy and disseminations activities and at supporting the achievement of the related objectives (Task 5.2).

The deliverable D5.2 will consist in ten newsletters planned to be published every six months during the TRANSCAN-2 action (months 6, 12, 18, 24, 30, 36, 42, 48, 54, 60) and three reports on the scientific symposia at month 16, 40 and 60 (Task 5.3).

The deliverable D5.3 will consist in periodic reports (months 16, 40, 60) of the outcome of the three scientific symposia planned to be held during the TRANSCAN-2 action at month 14, 38 and 58 (Task 5.4).

D5.1 : Updated website [3]

The deliverable D5.1 (month 3) will report on the revamping of the TRANSCAN website aimed at best meeting the requirements of the TRANSCAN-2 communication strategy and disseminations activities and at supporting the achievement of the related objectives (Task 5.2).

D5.2 : E-newsletters 1-10 [6]

The deliverable D5.2 will consist in periodic reports of the content of the ten newsletters planned to be published every six months during the TRANSCAN-2 action (months 6, 12, 18, 24, 30, 36, 42, 48, 54, 60) (Task 5.3).

D5.3 : Reports of the scientific symposia [16]

The deliverable D5.3 will consist in periodic reports (months 16, 40, 60) of the outcome of the three scientific symposia planned to be held during the TRANSCAN-2 action at month 14, 38 and 58 (Task 5.4).

Schedule of relevant Milestones

Milestone number ¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
MS26	Communication strategy	17 - MIZS	3	Report
MS27	First Scientific Symposium	17 - MIZS	14	Report

Schedule of relevant Milestones

Milestone number¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
MS28	Second Scientific Symposium	17 - MIZS	38	Report
MS29	Third Scientific Symposium	17 - MIZS	58	Report

Work package number ⁹	WP6	Lead beneficiary ¹⁰	15 - FCT
Work package title	Assessment and monitoring of TRANSCAN-2 performance		
Start month	1	End month	72

Objectives

As the ERA-NET Cofund instrument is new in the European Research Area cooperation scheme, WP6 will monitor and assess the work and results of the consortium, not only to allow for timely corrections in procedures or in the path to desired outcomes, but also to identify best practices in the new ERA-NET Cofund instrument. The objectives of this WP, which will be achieved through the 3 tasks detailed below, are:

- To identify indicators to assess the results of the Joint Transnational Calls, and of their contribution to the European cancer research landscape;
 - Taking advantage of lessons learned in the current TRANSCAN project, to monitor and evaluate the internal procedures of TRANSCAN-2, taking into account the level of satisfaction of the partners within the consortium;
 - To identify best practices among the new ERA-NET Cofund consortia and compare them with TRANSCAN-2 own procedure, as a way to tackle the challenge of being among the first using the new Horizon 2020 funding instrument.
- As most of the partners involved in TRANSCAN-2 have a medium- to long-term perspective on their cancer research funding strategy, the continuous monitoring and assessment of the cooperation between funding agencies becomes of paramount importance, so that the cooperation can be fruitful and long-lasting.

Description of work and role of partners

WP6 - Assessment and monitoring of TRANSCAN-2 performance [Months: 1-72]

FCT

Task 6.1: Assessing TRANSCAN-2 Joint Transnational Calls results (leader: FCT; participants: MoH, ISS, ACC, MIUR)

Among the main expected outcomes of TRANSCAN-2 are the Joint Transnational Calls, the first, co-funded one, and also the other ones to be launched by the consortium in subsequent years. As such, assessing the results of these calls will be a valuable instrument not only to gauge the success of TRANSCAN-2 as a consortium, but also to estimate its contribution towards the development of cancer research in the ERA. The indicators to be defined in this task, regarding the call results, will then be fed into the periodic reports created in task 3.3. This task 6.1 will be strongly articulated with the WPs related to the implementation of Joint Transnational Calls.

Task 6.2: Monitoring partners' satisfaction with TRANSCAN-2 procedures and results (leader: FCT; participant: TUBITAK)

Cooperation among funding agencies is one the main objectives of the ERA-NET instrument since its creation, and there have been several success cases throughout the years. Even though there is already some experience and common ground threaded in TRANSCAN, it is important to create internal assessment mechanisms to evaluate how TRANSCAN-2 is being able to cope with each partners' expectations. This assessment will create the possibility to identify areas or procedures that are not satisfactory to some or to all of the partners, and bring them to the attention of the whole consortium so that the issue can be addressed. The data will be gathered through surveys sent to all partners involved in TRANSCAN-2, after the results of each Joint Transnational Call are made public, and a report made to the NSC up to 3 months after. This task will be articulated with the work from WP3 (Monitoring of research projects), as the results from the funded projects themselves can influence TRANSCAN-2 strategic decisions and results.

Task 6.3: Mapping ERA-NET Cofund procedures and comparison of TRANSCAN-2 with other ERA-NET Cofund projects (leader: FCT; participants: MoH, ISS, ACC)

TRANSCAN-2 will be among the first of the ERA-NET Cofund to be approved. Even though the ERA-NET scheme was well established, and the pool of knowledge gathered by several funding agencies allowed for a clear identification of best practices, the ERA-NET Cofund instrument brings new challenges to the consortia as not all internal procedures are directly transferable from the previous scheme. Nevertheless, using the experience gathered during FP7, and also taking advantage of the links with other ERA-NET Cofund consortia, in this task there will be a mapping of new procedures created by the different ERA-NET Cofund approved. This mapping will be based in the Consortium Agreements to be signed, but also in the actual experience of the funding agencies involved, with which there are several links and communication channels. Depending on the results of the analysis of the Consortium Agreements, there might be the need to develop a survey to be sent to funding agencies involved in other ERA-NET Cofund, to further clarify the

internal procedures. The data gathered will then be compared with the one available from TRANSCAN-2 itself, also taking into account the results of Task 6.2.

Participation per Partner

Partner number and short name ¹⁰
1 - MoH
3 - ISS
11 - ACC
15 - FCT
19 - TUBITAK
25 - MIUR

List of deliverables

Deliverable Number ¹⁴	Deliverable Title	Lead beneficiary	Type ¹⁵	Dissemination level ¹⁶	Due Date (in months) ¹⁷
D6.1	Survey to monitor partners' satisfaction with TRANSCAN-2 procedures and results	15 - FCT	Other	Confidential, only for members of the consortium (including the Commission Services)	6

Description of deliverables

The deliverable D6.1 (month 6) will describe the design and format of the surveys to be implemented during the TRANSCAN-2 action to monitor partners' satisfaction with TRANSCAN-2 procedures and results (Task 6.2), after publication of the results of each JTC (i.e. at month 13, 23 and 34 and 46).

D6.1 : Survey to monitor partners' satisfaction with TRANSCAN-2 procedures and results [6]

The deliverable D6.1 (month 6) will describe the design and format of the surveys to be implemented during the TRANSCAN-2 action to monitor partners' satisfaction with TRANSCAN-2 procedures and results (Task 6.2), after publication of the results of each JTC (i.e. at month 9, 21 and 33).

Schedule of relevant Milestones

Milestone number ¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
MS30	List of monitoring indicators for TRANSCAN-2 call results	15 - FCT	6	List of monitoring indicators
MS31	Implementation of the survey to monitor partners' satisfaction after the first call	15 - FCT	10	Report
MS32	Implementation of the survey to monitor partners'	15 - FCT	21	Report

Schedule of relevant Milestones

Milestone number¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
	satisfaction after the second call			
MS33	Implementation of the survey to monitor partners' satisfaction after the third call	15 - FCT	33	Report
MS34	Implementation of the survey to monitor partners' satisfaction after the fourth call	15 - FCT	45	Report

Work package number ⁹	WP7	Lead beneficiary ¹⁰	1 - MoH
Work package title	Preparation and implementation of a second joint transnational call		
Start month	13	End month	72

Objectives

WP7 aims to address the following tasks:

- the preparation and launch of a second joint transnational call (JTC 2015)
- the implementation of the call (including evaluation and proposal selection);
- the monitoring of the funded projects;
- the communication, exploitation and dissemination of the research results.

Description of work and role of partners

WP7 - Preparation and implementation of a second joint transnational call [Months: 13-72]

MoH

Task 7.1: Preparation and launch of the joint transnational call JTC 2015 (leaders: MoH-ISS)

The CSC will be the ultimate decision-making body for all issues related to this call: preparation, launch, implementation (incl. evaluation), monitoring and dissemination. As a result of these decisions, all relevant call documents will be prepared (D7.1) and the joint transnational call will be launched on the TRANSCAN-2 website.

The activities planned in this task will be implemented through the following subtasks.

Subtask 7.1.1 Topic selection (participants: CSC partners)

The first step in the preparation of the JTC 2015 will be the selection of the topic of the call, as the end-result of a process involving the TRANSCAN-2 Scientific Advisory Board, who will convey its recommendations, as well as the scientific community working in the field of cancer research, as foreseen under the WP4 task 4.5 "Strategy on identifying scientific priority topics". Based on all these contributions, the final decisions on the JTC 2015 topic will be taken by the CSC.

Subtask 7.1.2 Preparation of the JTC 2015 (leaders: MoH-ISS; participants: CSC partners)

The subtask leader will draft all call-related documents, send these drafts to all CSC partners asking for comments, if necessary organise teleconferences with all CSC partners to discuss and decide on major issues, and finalise all documents.

The most important documents to be prepared are those already indicated in WP2, and, therefore, they will not be repeated in this description, although they will represent deliverables of this WP.

Subtask 7.1.3 Launch of the JTC 2015 (leaders: MoH-ISS; participants: CSC partners)

The JTC 2015 will be published "centrally", i.e. on the TRANSCAN-2 website (in English), and, if necessary (for some CSC partner organisations), via national publication routes (in national languages). The launch of the JTC 2015 will take place a minimum of 60 days prior to proposal submission. Information about this call will be communicated to potential applicants via the central TRANSCAN-2 website and also via established national communication channels such as websites, e-mailing lists, press announcements, newsletters, scientific meetings etc. If feasible, a call pre-announcement will be published even earlier in order to enhance the mobilization of the relevant scientific community.

Task 7.2: Implementation of the JTC 2015 (evaluation and proposal selection) (leaders: MoH-ISS; participants: CSC partners)

This task aims to (i) establish the Joint Call Secretariat; (ii) establish an electronic submission and evaluation system; (iii) implement the eligibility check and evaluation of pre-proposals (= step 1 of evaluation); (iv) evaluation of full proposals (= step 2 of evaluation); (v) take a decision of a final ranking list of full proposals recommended by the Scientific Evaluation Committee (SEC); (vi) reach a decision of the Call Steering Committee on a final selection list of full proposals to be funded.

The proposed evaluation and selection mechanisms of the call will be based on well-established procedures applied in previous TRANSCAN (and other ERA-NETs) JTCs, and on the criteria of scientific excellence, impact and quality and efficiency of the implementation.

The JCS and the CSC will take all necessary steps to guarantee the confidentiality of all information obtained during the evaluation and selection procedures of the JTC 2015.

Subtask 7.2.1: Establishment of the Joint Call Secretariat, the Scientific Evaluation Committee, and assistance to potential applicants by national contact points (leaders: MoH-ISS; participants: CSC partners)

A Joint Call Secretariat (JCS) will be set up at MoH-ISS. The responsibilities of the JCS will be the same as those detailed in WP2, subtask 2.3.1.

Subtask 7.2.2: Establishment of an electronic submission and evaluation system (leaders: MoH-ISS)

The JCS will be responsible for the setting-up of an electronic submission and evaluation system, with keyword-protected access via the world-wide web. The system will be adapted to the specific requirements of the JTC 2015.

Subtask 7.2.3: Eligibility check and evaluation of pre-proposals (leaders: MoH-ISS; participants: CSC partners)

The procedures for the eligibility check and the responsibilities of the JCS will be the same as those detailed in WP2, subtask 2.3.5.

Subtask 7.2.4: Evaluation of full proposals and ranking list of proposals recommended by the SEC (leaders: MoH-ISS; participants: CSC partners)

The JCS will examine the submitted full proposals for compliance with the formal and eligibility criteria of the call; in addition, no substantial changes will be allowed with respect to the previously submitted (and evaluated) pre-proposal, unless that was specifically recommended by the SEC.

With the use of the electronic submission and evaluation system the JCS will make each full proposal available to the two SEC members who had reviewed the corresponding pre-proposal and to at least two external reviewers. Each reviewer will provide a completed full proposal evaluation form for each assigned pre-proposal on-line, providing scores and explanatory statements for each of the evaluation criteria. In order to allow for overall comparison of the quality of all full proposals, all SEC members will have on-line access to all full proposals (i.e. also those not assigned to them for evaluation).

In a second review meeting, the SEC will discuss all full proposals, mainly driven by the assigned reviewers, but also complemented by the other SEC members. The final result of this meeting is a recommendation on the ranking of the full proposals to be funded (D7.2).

For all full proposals, the respective SEC members will provide summary evaluation statements to the JCS. After the decision of the CSC (see below), the JCS will include these evaluation statements when informing the coordinators of the full proposals recommended or not recommended for funding (without disclosing the identity of the reviewers).

Subtask 7.2.5: Call Steering Committee decision of a final selection list of full proposals to be funded (leader: MoH-ISS; participants: CSC partners)

CSC representatives will participate in both evaluation meetings. Following the second SEC meeting, the CSC will formally meet and report their observations of the evaluation process and the ranking list of full proposals recommended for funding by the SEC.

Based on previously agreed procedures, in a consensus decision, the CSC will agree on a final selection list of full proposals to be funded (D7.2). In doing so, the ranking list recommended by the SEC will be strictly followed, within the available national/regional budget.

A funding organisation from a certain country or region will fund the national or regional applicants, according to the national administrative regulations ("virtual common pot model"). The JCS will prepare the final selection list, forwarding it to the WP1 leader for publication on the TRANSCAN-2 website (D7.3). The JCS will inform the coordinators of the full proposals about the final funding decision, so that the national negotiations can start.

Task 7.3: Monitoring of the funded projects (leader: SAS; participants: CSC partners)

The developments of the funded projects will be monitored by the WP3 and task 7.4 leaders, as described in WP3.

Task 7.4: Communication, exploitation and dissemination of the research results (leader: MIZS; co-leader: CSO-MOH; participant: ISCIII)

The results of the funded research projects will be communicated and disseminated by the WP5 leaders, as described in WP5 (D7.4).

Participation per Partner

Partner number and short name ¹⁰
1 - MoH
2 - FWF
3 - ISS
5 - INCa
6 - BMBF
7 - DLR
8 - ARC

Partner number and short name ¹⁰
10 - CSO-MOH
13 - DCS
14 - RCN
15 - FCT
16 - SAS
17 - MIZS
18 - ISCH
21 - FWO
23 - NCS
24 - FNRS
25 - MIUR
27 - FICYT
29 - VIAA

List of deliverables

Deliverable Number ¹⁴	Deliverable Title	Lead beneficiary	Type ¹⁵	Dissemination level ¹⁶	Due Date (in months) ¹⁷
D7.1	JTC 2015 call-related documents	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	13
D7.2	Information on JTC 2015 evaluation results	1 - MoH	Report	Confidential, only for members of the consortium (including the Commission Services)	22
D7.3	Publishable information about projects to be funded under JTC 2015 (participants, abstracts)	1 - MoH	Report	Public	23
D7.4	Publishable information about JTC 2015 funded projects (participants, overview of results)	1 - MoH	Report	Public	71

Description of deliverables

The deliverable D7.1 (month 13) will comprise all the documents related to the JTC 2015 call (Call text, incl. country-specific information; Memorandum of Understanding, Governance of the Call and Evaluation, Guidelines for applicants, Pre-proposal and full proposal templates, Pre-proposal and full proposal evaluation templates) (Task 7.1).

The deliverable D7.2 (month 22) will provide the information on the results of the evaluation of the projects submitted under the JTC 2015 call (ranking list of full proposals recommended for funding by the SEC; CSC selection list) (Task 7.2).

The deliverable D7.3 (month 23) will provide the publishable information about the projects to be funded under JTC 2015 (i.e. participants, abstracts) (Task 7.2).

The deliverable D7.4 (month 71) will report on the publishable information about the projects funded under the JTC 2015 (i.e. participants, overview of results) (Task 7.3 and Task 7.4).

D7.1 : JTC 2015 call-related documents [13]

The deliverable D7.1 (month 13) will comprise all the documents related to the JTC 2015 call (Call text, incl. country-specific information; Memorandum of Understanding, Governance of the Call and Evaluation, Guidelines for applicants, Pre-proposal and full proposal templates, Pre-proposal and full proposal evaluation templates) (Task 7.1).

D7.2 : Information on JTC 2015 evaluation results [22]

The deliverable D7.2 (month 22) will provide the information on the results of the evaluation of the projects submitted under the JTC 2015 call (ranking list of full proposals recommended for funding by the SEC; CSC selection list) (Task 7.2).

D7.3 : Publishable information about projects to be funded under JTC 2015 (participants, abstracts) [23]

The deliverable D7.3 (month 23) will provide the publishable information about the projects to be funded under JTC 2015 (i.e. participants, abstracts) (Task 7.2).

D7.4 : Publishable information about JTC 2015 funded projects (participants, overview of results) [71]

The deliverable D7.4 (month 71) will report on the publishable information about the projects funded under the JTC 2015 (i.e. participants, overview of results) (Task 7.3 and Task 7.4).

Schedule of relevant Milestones

Milestone number ¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
MS35	Establishment of the JTC 2015 Joint Call Secretariat	1 - MoH	13	Notification to JTC 2015 CSC
MS36	Eligibility check of JTC 2015 pre-proposals	1 - MoH	15	Report
MS37	First meeting of the JTC 2015 Scientific Evaluation Committee, pre-proposal evaluation	1 - MoH	17	Meeting minutes
MS38	Second meeting of the JTC 2015 Scientific Evaluation Committee, full proposal evaluation	1 - MoH	22	Meeting minutes
MS39	Selection list of the JTC 2015 projects to be funded by the CSC	1 - MoH	22	Report
MS40	Commitment on availability of funds for the JTC 2015 selected projects (each contributing CSC partner)	1 - MoH	23	Report

Work package number ⁹	WP8	Lead beneficiary ¹⁰	13 - DCS
Work package title	Preparation and implementation of a third joint transnational call		
Start month	25	End month	72

Objectives

WP8 aims to address the following tasks:

- the preparation and launch of a third joint transnational call (JTC 2016)
- the implementation of the call (including evaluation and proposal selection);
- the monitoring of the funded projects;
- the communication, exploitation and dissemination of the research results.

Description of work and role of partners

WP8 - Preparation and implementation of a third joint transnational call [Months: 25-72]

DCS

Task 8.1: Preparation and launch of the joint transnational call JTC 2016 (leader: DCS)

The CSC will be the ultimate decision-making body for all issues related to this call: preparation, launch, implementation (incl. evaluation), monitoring and dissemination. As a result of these decisions, all relevant call documents will be prepared (D8.1) and the joint transnational call will be launched on the TRANSCAN-2 website.

The activities planned in this task will be implemented through the following subtasks.

Subtask 8.1.1 Topic selection (participants: CSC partners)

The first step in the preparation of the JTC 2016 will be the selection of the topic of the call, as the end-result of a process involving the TRANSCAN-2 Scientific Advisory Board, who will convey its recommendations, as well as the scientific community working in the field of cancer research, as foreseen under the WP4 task 4.5 “Strategy on identifying scientific priority topics”. Based on all these contributions, the final decisions on the JTC 2016 topic will be taken by the CSC.

Subtask 8.1.2 Preparation of the JTC 2016 (leader: DCS; participants: CSC partners)

The subtask leader will draft all call-related documents, send these drafts to all CSC partners asking for comments, if necessary organise teleconferences with all CSC partners to discuss and decide on major issues, and finalise all documents.

The most important documents to be prepared are those already indicated in WP2, and, therefore, they will not be repeated in this description, although they will represent deliverables of this WP.

Subtask 8.1.3 Launch of the JTC 2016 (leader: DCS; participants: CSC partners)

The JTC 2016 will be published “centrally”, i.e. on the TRANSCAN-2 website (in English), and, if necessary (for some CSC partner organisations), via national publication routes (in national languages). The launch of the JTC 2016 will take place a minimum of 60 days prior to proposal submission. Information about this call will be communicated to potential applicants via the central TRANSCAN-2 website and also via established national communication channels such as websites, e-mailing lists, press announcements, newsletters, scientific meetings etc. If feasible, a call pre-announcement will be published even earlier in order to enhance the mobilization of the relevant scientific community.

Task 8.2: Implementation of the JTC 2016 (evaluation and proposal selection) (leader: DCS; participants: CSC partners)

This task aims to (i) establish the Joint Call Secretariat; (ii) establish an electronic submission and evaluation system; (iii) implement the eligibility check and evaluation of pre-proposals (= step 1 of evaluation); (iv) evaluation of full proposals (= step 2 of evaluation); (v) take a decision of a final ranking list of full proposals recommended by the Scientific Evaluation Committee (SEC); (vi) reach a decision of the Call Steering Committee on a final selection list of full proposals to be funded.

The proposed evaluation and selection mechanisms of the call will be based on well-established procedures applied in previous TRANSCAN (and other ERA-NETs) JTCs, and on the criteria of scientific excellence, impact and quality and efficiency of the implementation.

The JCS and the CSC will take all necessary steps to guarantee the confidentiality of all information obtained during the evaluation and selection procedures of the JTC 2016.

Subtask 8.2.1: Establishment of the Joint Call Secretariat, the Scientific Evaluation Committee, and assistance to potential applicants by national contact points (leader: DCS; participants: CSC partners)

A Joint Call Secretariat (JCS) will be set up at DCS. The responsibilities of the JCS will be the same as those detailed in WP2, subtask 2.3.1.

Subtask 8.2.2: Establishment of an electronic submission and evaluation system (leader: DCS)

The JCS will be responsible for the setting-up of an electronic submission and evaluation system (D8.1), with keyword-protected access via the world-wide web. The system will be adapted to the specific requirements of the JTC 2016.

Subtask 8.2.3: Eligibility check and evaluation of pre-proposals (leader: DCS; participants: CSC partners)

The procedures for the eligibility check and the responsibilities of the JCS will be the same as those detailed in WP2, subtask 2.3.5.

Subtask 8.2.4: Evaluation of full proposals and ranking list of proposals recommended by the SEC (leader: DCS; participants: CSC partners)

The JCS will examine the submitted full proposals for compliance with the formal and eligibility criteria of the call; in addition, no substantial changes will be allowed with respect to the previously submitted (and evaluated) pre-proposal, unless that was specifically recommended by the SEC.

With the use of the electronic submission and evaluation system the JCS will make each full proposal available to the two SEC members who had reviewed the corresponding pre-proposal and to at least two external reviewers. Each reviewer will provide a completed full proposal evaluation form for each assigned pre-proposal on-line, providing scores and explanatory statements for each of the evaluation criteria. In order to allow for overall comparison of the quality of all full proposals, all SEC members will have on-line access to all full proposals (i.e. also those not assigned to them for evaluation).

In a second review meeting, the SEC will discuss all full proposals, mainly driven by the assigned reviewers, but also complemented by the other SEC members. The final result of this meeting is a recommendation on the ranking of the full proposals to be funded (D8.2).

For all full proposals, the respective SEC members will provide summary evaluation statements to the JCS. After the decision of the CSC (see below), the JCS will include these evaluation statements when informing the coordinators of the full proposals recommended or not recommended for funding (without disclosing the identity of the reviewers).

Subtask 8.2.5: Call Steering Committee decision of a final selection list of full proposals to be funded (leader: DCS; participants: CSC partners)

CSC representatives will participate in both evaluation meetings. Following the second SEC meeting, the CSC will formally meet and report their observations of the evaluation process and the ranking list of full proposals recommended for funding by the SEC.

Based on previously agreed procedures, in a consensus decision, the CSC will agree on a final selection list of full proposals to be funded (D8.2). In doing so, the ranking list recommended by the SEC will be strictly followed, within the available national/regional budget.

A funding organisation from a certain country or region will fund the national or regional applicants, according to the national administrative regulations ("virtual common pot model"). The JCS will prepare the final selection list, forwarding it to the WP1 leader for publication on the TRANSCAN-2 website (D8.3). The JCS will inform the coordinators of the full proposals about the final funding decision, so that the national negotiations can start.

Task 8.3: Monitoring of the funded projects (leader: SAS; participants: CSC partners)

The developments of the funded projects will be monitored by the WP3 and task 8.4 leader, as described in WP3.

Task 8.4: Communication, exploitation and dissemination of the research results (leader: MIZS; co-leader: CSO-MOH; participant: ISCIII)

The results of the funded research projects will be communicated and disseminated by the WP5 leaders, as described in WP5 (D8.4).

Participation per Partner

Partner number and short name¹⁰

1 - MoH

2 - FWF

3 - ISS

5 - INCa

6 - BMBF

7 - DLR

8 - ARC

10 - CSO-MOH

Partner number and short name ¹⁰
13 - DCS
14 - RCN
15 - FCT
16 - SAS
17 - MIZS
18 - ISCIII
19 - TUBITAK
21 - FWO
23 - NCS
24 - FNRS
25 - MIUR
27 - FICYT
29 - VIAA
31 - FRRB
32 - FCAECC

List of deliverables

Deliverable Number ¹⁴	Deliverable Title	Lead beneficiary	Type ¹⁵	Dissemination level ¹⁶	Due Date (in months) ¹⁷
D8.1	JTC 2016 call-related documents	13 - DCS	Report	Confidential, only for members of the consortium (including the Commission Services)	25
D8.2	Information on JTC 2016 evaluation results	13 - DCS	Report	Confidential, only for members of the consortium (including the Commission Services)	34
D8.3	Publishable information about projects to be funded under JTC 2016 (participants, abstracts)	13 - DCS	Report	Public	35
D8.4	Publishable information about JTC 2016 funded projects (participants, overview of results)	13 - DCS	Report	Public	71

Description of deliverables

The deliverable D8.1 (month 25) will comprise all the documents related to the JTC 2016 call (Call text, incl. country-specific information; Memorandum of Understanding, Governance of the Call and Evaluation, Guidelines for applicants, Pre-proposal and full proposal templates, Pre-proposal and full proposal evaluation templates) (Task 8.1).

The deliverable D8.2 (month 34) will provide the information on the results of the evaluation of the projects submitted under the JTC 2016 call (ranking list of full proposals recommended for funding by the SEC; CSC selection list) (Task 8.2).

The deliverable D8.3 (month 35) will provide the publishable information about the projects to be funded under JTC 2016 (i.e. participants, abstracts) (Task 8.2).

The deliverable D8.4 (month 71) will report on the publishable information about the projects funded under the JTC 2016 (i.e. participants, overview of results) (Task 8.3 and Task 8.4).

D8.1 : JTC 2016 call-related documents [25]

The deliverable D8.1 (month 25) will comprise all the documents related to the JTC 2016 call (Call text, incl. country-specific information; Memorandum of Understanding, Governance of the Call and Evaluation, Guidelines for applicants, Pre-proposal and full proposal templates, Pre-proposal and full proposal evaluation templates) (Task 8.1).

D8.2 : Information on JTC 2016 evaluation results [34]

The deliverable D8.2 (month 34) will provide the information on the results of the evaluation of the projects submitted under the JTC 2016 call (ranking list of full proposals recommended for funding by the SEC; CSC selection list) (Task 8.2).

D8.3 : Publishable information about projects to be funded under JTC 2016 (participants, abstracts) [35]

The deliverable D8.3 (month 35) will provide the publishable information about the projects to be funded under JTC 2016 (i.e. participants, abstracts) (Task 8.2).

D8.4 : Publishable information about JTC 2016 funded projects (participants, overview of results) [71]

The deliverable D8.4 (month 59) will report on the publishable information about the projects funded under the JTC 2016 (i.e. participants, overview of results) (Task 8.3 and Task 8.4).

Schedule of relevant Milestones

Milestone number ¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
MS41	Establishment of the JTC 2016 Joint Call Secretariat	13 - DCS	25	Notification to JTC 2016 CSC
MS42	Eligibility check of JTC 2016 pre-proposals	13 - DCS	27	Report
MS43	First meeting of the JTC 2016 Scientific Evaluation Committee, pre-proposal evaluation	13 - DCS	29	Meeting minutes
MS44	Second meeting of the JTC 2016 Scientific Evaluation Committee, full proposal evaluation	13 - DCS	34	Meeting minutes
MS45	Selection list of the JTC 2016 projects to be funded by the CSC	13 - DCS	34	Report
MS46	Commitment on availability of funds for the JTC 2016 selected projects (each contributing CSC partner)	13 - DCS	35	Report

Work package number ⁹	WP9	Lead beneficiary ¹⁰	11 - ACC
Work package title	Preparation and implementation of a fourth joint transnational call		
Start month	37	End month	72

Objectives

WP9 aims to address the following tasks:

- the preparation and launch of a fourth joint transnational call (JTC 2017)
- the implementation of the call (including evaluation and proposal selection);
- the monitoring of the funded projects;
- the communication, exploitation and dissemination of the research results.

Description of work and role of partners

WP9 - Preparation and implementation of a fourth joint transnational call [Months: 37-72]

ACC

Task 9.1: Preparation and launch of the joint transnational call JTC 2017 (leader: ACC; co-leader: FCT; participant: VIAA)

The CSC will be the ultimate decision-making body for all issues related to this call: preparation, launch, implementation (incl. evaluation), monitoring and dissemination. As a result of these decisions, all relevant call documents will be prepared (D9.1) and the joint transnational call will be launched on the TRANSCAN-2 website.

The activities planned in this task will be implemented through the following subtasks.

Subtask 9.1.1 Topic selection (leader: FCT; co-leader: FICYT; participants: CSC partners)

The first step in the preparation of the JTC 2017 will be the selection of the topic of the call, as the end-result of a process involving the TRANSCAN-2 Scientific Advisory Board, who will convey its recommendations, as well as the scientific community working in the field of cancer research, as foreseen under the WP4 task 4.5 “Strategy on identifying scientific priority topics”. Based on all these contributions, the final decisions on the JTC 2017 topic will be taken by the CSC.

Subtask 9.1.2 Preparation of the JTC 2017 (leader: ACC; co-leader: ARC; participants: CSC partners)

The subtask leader will draft all call-related documents, send these drafts to all CSC partners asking for comments, if necessary organise teleconferences with all CSC partners to discuss and decide on major issues, and finalise all documents.

The most important documents to be prepared are those already indicated in WP2, and, therefore, they will not be repeated in this description, although they will represent deliverables of this WP.

Subtask 9.1.3 Launch of the JTC 2017 (leader: ACC; co-leader: FICYT; participants: CSC partners)

The JTC 2017 will be published “centrally”, i.e. on the TRANSCAN-2 website (in English), and, if necessary (for some CSC partner organisations), via national publication routes (in national languages). The launch of the JTC 2017 will take place a minimum of 60 days prior to proposal submission. Information about this call will be communicated to potential applicants via the central TRANSCAN-2 website and also via established national communication channels such as websites, e-mailing lists, press announcements, newsletters, scientific meetings etc. If feasible, a call pre-announcement will be published even earlier in order to enhance the mobilization of the relevant scientific community.

Task 9.2: Implementation of the JTC 2017 (evaluation and proposal selection) (leader: ACC; co-leader: FICYT; participants: CSC partners)

This task aims to (i) establish the Joint Call Secretariat; (ii) establish an electronic submission and evaluation system; (iii) implement the eligibility check and evaluation of pre-proposals (= step 1 of evaluation); (iv) evaluation of full proposals (= step 2 of evaluation); (v) take a decision of a final ranking list of full proposals recommended by the Scientific Evaluation Committee (SEC); (vi) reach a decision of the Call Steering Committee on a final selection list of full proposals to be funded.

The proposed evaluation and selection mechanisms of the call will be based on well-established procedures applied in previous TRANSCAN (and other ERA-NETs) JTCs, and on the criteria of scientific excellence, impact and quality and efficiency of the implementation.

The JCS and the CSC will take all necessary steps to guarantee the confidentiality of all information obtained during the evaluation and selection procedures of the JTC 2017.

Subtask 9.2.1: Establishment of the Joint Call Secretariat, the Scientific Evaluation Committee, and assistance to potential applicants by national contact points (leader: ACC; co-leader: ISCIII; participants: CSC partners)

A Joint Call Secretariat (JCS) will be set up at ACC (Italy). The responsibilities of the JCS will be the same as those detailed in WP2, subtask 2.3.1.

Subtask 9.2.2: Establishment of an electronic submission and evaluation system (leader: MoH-ISS; co-leader: ACC)

The JCS will be responsible for the setting-up of an electronic submission and evaluation system (D9.1), with keyword-protected access via the world-wide web. The system will be adapted to the specific requirements of the JTC 2017.

Subtask 9.2.3: Eligibility check and evaluation of pre-proposals (leader: ACC; co-leader: VIAA; participants: CSC partners)

The procedures for the eligibility check and the responsibilities of the JCS will be the same as those detailed in WP2, subtask 2.3.5.

Subtask 9.2.4: Evaluation of full proposals and ranking list of proposals recommended by the SEC (leader: ACC; participants: CSC partners)

The JCS will examine the submitted full proposals for compliance with the formal and eligibility criteria of the call; in addition, no substantial changes will be allowed with respect to the previously submitted (and evaluated) pre-proposal, unless that was specifically recommended by the SEC.

With the use of the electronic submission and evaluation system the JCS will make each full proposal available to the two SEC members who had reviewed the corresponding pre-proposal and to at least two external reviewers. Each reviewer will provide a completed full proposal evaluation form for each assigned pre-proposal on-line, providing scores and explanatory statements for each of the evaluation criteria. In order to allow for overall comparison of the quality of all full proposals, all SEC members will have on-line access to all full proposals (i.e. also those not assigned to them for evaluation).

In a second review meeting, the SEC will discuss all full proposals, mainly driven by the assigned reviewers, but also complemented by the other SEC members. The final result of this meeting is a recommendation on the ranking of the full proposals to be funded (D9.2).

For all full proposals, the respective SEC members will provide summary evaluation statements to the JCS. After the decision of the CSC (see below), the JCS will include these evaluation statements when informing the coordinators of the full proposals recommended or not recommended for funding (without disclosing the identity of the reviewers).

Subtask 9.2.5: Call Steering Committee decision of a final selection list of full proposals to be funded (leader: ACC; participants: CSC partners)

CSC representatives will participate in both evaluation meetings. Following the second SEC meeting, the CSC will formally meet and report their observations of the evaluation process and the ranking list of full proposals recommended for funding by the SEC.

Based on previously agreed procedures, in a consensus decision, the CSC will agree on a final selection list of full proposals to be funded (D9.2). In doing so, the ranking list recommended by the SEC will be strictly followed, within the available national/regional budget.

A funding organisation from a certain country or region will fund the national or regional applicants, according to the national administrative regulations ("virtual common pot model"). The JCS will prepare the final selection list, forwarding it to the WP1 leader for publication on the TRANSCAN-2 website (D9.3). The JCS will inform the coordinators of the full proposals about the final funding decision, so that the national negotiations can start.

Task 9.3: Monitoring of the funded projects (leader: SAS; participants: CSC partners)

The developments of the funded projects will be monitored by the WP3 and task 9.4 leader, as described in WP3.

Task 9.4: Communication, exploitation and dissemination of the research results (leader: MIZS; co-leader: CSO-MOH; participant: ISCIII)

The results of the funded research projects will be communicated and disseminated by the WP5 leaders, as described in WP5 (D9.4).

Participation per Partner

Partner number and short name¹⁰

1 - MoH

2 - FWF

3 - ISS

5 - INCa

6 - BMBF

Partner number and short name ¹⁰
7 - DLR
8 - ARC
10 - CSO-MOH
11 - ACC
13 - DCS
14 - RCN
15 - FCT
16 - SAS
17 - MIZS
18 - ISCIII
19 - TUBITAK
21 - FWO
23 - NCS
24 - FNRS
25 - MIUR
26 - ETAg
27 - FICYT
29 - VIAA
31 - FRRB
32 - FCAECC

List of deliverables

Deliverable Number ¹⁴	Deliverable Title	Lead beneficiary	Type ¹⁵	Dissemination level ¹⁶	Due Date (in months) ¹⁷
D9.1	JTC 2017 call-related documents	11 - ACC	Report	Confidential, only for members of the consortium (including the Commission Services)	37
D9.2	Information on JTC 2017 evaluation results	11 - ACC	Report	Confidential, only for members of the consortium (including the Commission Services)	46
D9.3	Publishable information about projects to be funded under JTC 2017 (participants, abstracts)	11 - ACC	Report	Public	47

List of deliverables

Deliverable Number¹⁴	Deliverable Title	Lead beneficiary	Type¹⁵	Dissemination level¹⁶	Due Date (in months)¹⁷
D9.4	Publishable information about JTC 2017 funded projects (participants, overview of results)	11 - ACC	Report	Public	71

Description of deliverables

The deliverable D9.1 (month 37) will comprise all the documents related to the JTC 2017 call (Call text, incl. country-specific information; Memorandum of Understanding, Governance of the Call and Evaluation, Guidelines for applicants, Pre-proposal and full proposal templates, Pre-proposal and full proposal evaluation templates) (Task 9.1).

The deliverable D9.2 (month 46) will provide the information on the results of the evaluation of the projects submitted under the JTC 2017 call (ranking list of full proposals recommended for funding by the SEC; CSC selection list) (Task 9.1).

The deliverable D9.3 (month 47) will provide the publishable information about the projects to be funded under JTC 2017 (i.e. participants, abstracts) (Task 9.2).

The deliverable D9.4 (month 71) will report on the publishable information about the projects funded under the JTC 2017 (i.e. participants, overview of results) (Task 9.3 and Task 9.4).

D9.1 : JTC 2017 call-related documents [37]

The deliverable D9.1 (month 37) will comprise all the documents related to the JTC 2017 call (Call text, incl. country-specific information; Memorandum of Understanding, Governance of the Call and Evaluation, Guidelines for applicants, Pre-proposal and full proposal templates, Pre-proposal and full proposal evaluation templates) (Task 9.1).

D9.2 : Information on JTC 2017 evaluation results [46]

The deliverable D9.2 (month 46) will provide the information on the results of the evaluation of the projects submitted under the JTC 2017 call (ranking list of full proposals recommended for funding by the SEC; CSC selection list) (Task 9.1).

D9.3 : Publishable information about projects to be funded under JTC 2017 (participants, abstracts) [47]

The deliverable D9.3 (month 47) will provide the publishable information about the projects to be funded under JTC 2017 (i.e. participants, abstracts) (Task 9.2).

D9.4 : Publishable information about JTC 2017 funded projects (participants, overview of results) [71]

The deliverable D9.4 (month 71) will report on the publishable information about the projects funded under the JTC 2017 (i.e. participants, overview of results) (Task 9.3 and Task 9.4).

Schedule of relevant Milestones

Milestone number¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
MS47	Establishment of the JTC 2017 Joint Call Secretariat	11 - ACC	37	Notification to JTC 2017 CSC
MS48	Eligibility check of JTC 2017 pre-proposals	11 - ACC	39	Report
MS49	First meeting of the JTC 2017 Scientific Evaluation Committee, pre-proposal evaluation	11 - ACC	41	Meeting minutes

Schedule of relevant Milestones

Milestone number¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
MS50	Second meeting of the JTC 2017 Scientific Evaluation Committee, full proposal evaluation	11 - ACC	46	Meeting minutes
MS51	Selection list of the JTC 2017 projects to be funded by the CSC	11 - ACC	46	Report
MS52	Commitment on availability of funds for the JTC 2017 selected projects (each contributing CSC partner)	11 - ACC	47	Report

Work package number ⁹	WP10	Lead beneficiary ¹⁰	1 - MoH
Work package title	Ethics requirements		
Start month	1	End month	72

Objectives

The objective is to ensure compliance with the 'ethics requirements' set out in this work package.

Description of work and role of partners

WP10 - Ethics requirements [Months: 1-72]

MoH

This work package sets out the 'ethics requirements' that the project must comply with.

List of deliverables

Deliverable Number ¹⁴	Deliverable Title	Lead beneficiary	Type ¹⁵	Dissemination level ¹⁶	Due Date (in months) ¹⁷
D10.1	POPD - Requirement No. 1	1 - MoH	Ethics	Confidential, only for members of the consortium (including the Commission Services)	1
D10.2	POPD - Requirement No. 5	1 - MoH	Ethics	Confidential, only for members of the consortium (including the Commission Services)	12

Description of deliverables

The 'ethics requirements' that the project must comply with are included as deliverables in this work package.

D10.1 : POPD - Requirement No. 1 [1]

Detailed information must be provided on the procedures that will be implemented for data collection, storage, protection, retention and destruction and confirmation that they comply with national and EU legislation. The applicant must explicitly confirm that the existing data are publicly available.

D10.2 : POPD - Requirement No. 5 [12]

A mission creep risk mitigation procedure must be devised in order to make sure data are collected on a need to know basis.

Schedule of relevant Milestones

Milestone number ¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
---------------------------------------	------------------------	-------------------------	-----------------------------	------------------------------

1.3.4. WT4 List of milestones

Milestone number¹⁸	Milestone title	WP number⁹	Lead beneficiary	Due Date (in months)¹⁷	Means of verification
MS1	Establishment of the SAB	WP1	1 - MoH	3	Report
MS2	Kick-off NSC meeting	WP1	1 - MoH	5	Meeting minutes
MS3	First Meeting of the NSC and SAB	WP1	1 - MoH	5	Meeting minutes
MS4	Second Meeting of the NSC	WP1	1 - MoH	10	Meeting minutes
MS5	Second Meeting of the NSC and SAB	WP1	1 - MoH	14	Meeting minutes
MS6	Third Meeting of the NSC	WP1	1 - MoH	17	Meeting minutes
MS7	Fourth Meeting of the NSC	WP1	1 - MoH	22	Meeting minutes
MS8	Third Meeting of the NSC and SAB	WP1	1 - MoH	29	Meeting minutes
MS9	Fifth Meeting of the NSC	WP1	1 - MoH	34	Meeting minutes
MS10	Fourth Meeting of the NSC and SAB	WP1	1 - MoH	38	Meeting minutes
MS11	Sixth Meeting of the NSC	WP1	1 - MoH	41	Meeting minutes
MS12	Seventh Meeting of the NSC	WP1	1 - MoH	46	Meeting minutes
MS13	Eighth Meeting of the NSC	WP1	1 - MoH	50	Meeting minutes
MS14	Fifth Meeting of the NSC and SAB	WP1	1 - MoH	58	Meeting minutes
MS15	Launch of the JTC 2014 co-funded call on TRANSCAN website	WP2	1 - MoH	2	Publication on website
MS16	Establishment of the JTC 2014 Joint Call Secretariat	WP2	1 - MoH	3	Notification to JTC 2014 CSC
MS17	Eligibility check of JTC 2014 pre-proposals	WP2	1 - MoH	4	Report
MS18	First meeting of the JTC 2014 Scientific Evaluation Committee, pre-proposal evaluation	WP2	1 - MoH	6	Meeting minutes
MS19	Second meeting of the JTC 2014 Scientific	WP2	1 - MoH	11	Meeting minutes

Milestone number¹⁸	Milestone title	WP number⁹	Lead beneficiary	Due Date (in months)¹⁷	Means of verification
	Evaluation Committee, full proposal evaluation				
MS20	Selection list of the JTC 2014 projects to be funded by the CSC	WP2	1 - MoH	11	List of JTC 2014 projects to be funded
MS21	Agreement on the content and the structure of a template for monitoring	WP3	16 - SAS	12	Final template
MS22	Review of the analyses conducted in 2016	WP3	16 - SAS	24	Report
MS23	Review of the analyses conducted in 2017	WP3	16 - SAS	36	Report
MS24	Review of the analyses conducted in 2018	WP3	16 - SAS	48	Report
MS25	Review of the analyses conducted in 2019	WP3	16 - SAS	60	Report
MS26	Communication strategy	WP5	17 - MIZS	3	Report
MS27	First Scientific Symposium	WP5	17 - MIZS	14	Report
MS28	Second Scientific Symposium	WP5	17 - MIZS	38	Report
MS29	Third Scientific Symposium	WP5	17 - MIZS	58	Report
MS30	List of monitoring indicators for TRANSCAN-2 call results	WP6	15 - FCT	6	List of monitoring indicators
MS31	Implementation of the survey to monitor partners' satisfaction after the first call	WP6	15 - FCT	10	Report
MS32	Implementation of the survey to monitor partners' satisfaction after the second call	WP6	15 - FCT	21	Report
MS33	Implementation of the survey to monitor partners' satisfaction after the third call	WP6	15 - FCT	33	Report
MS34	Implementation of the survey to monitor partners' satisfaction after the fourth call	WP6	15 - FCT	45	Report

Milestone number¹⁸	Milestone title	WP number⁹	Lead beneficiary	Due Date (in months)¹⁷	Means of verification
MS35	Establishment of the JTC 2015 Joint Call Secretariat	WP7	1 - MoH	13	Notification to JTC 2015 CSC
MS36	Eligibility check of JTC 2015 pre-proposals	WP7	1 - MoH	15	Report
MS37	First meeting of the JTC 2015 Scientific Evaluation Committee, pre-proposal evaluation	WP7	1 - MoH	17	Meeting minutes
MS38	Second meeting of the JTC 2015 Scientific Evaluation Committee, full proposal evaluation	WP7	1 - MoH	22	Meeting minutes
MS39	Selection list of the JTC 2015 projects to be funded by the CSC	WP7	1 - MoH	22	Report
MS40	Commitment on availability of funds for the JTC 2015 selected projects (each contributing CSC partner)	WP7	1 - MoH	23	Report
MS41	Establishment of the JTC 2016 Joint Call Secretariat	WP8	13 - DCS	25	Notification to JTC 2016 CSC
MS42	Eligibility check of JTC 2016 pre-proposals	WP8	13 - DCS	27	Report
MS43	First meeting of the JTC 2016 Scientific Evaluation Committee, pre-proposal evaluation	WP8	13 - DCS	29	Meeting minutes
MS44	Second meeting of the JTC 2016 Scientific Evaluation Committee, full proposal evaluation	WP8	13 - DCS	34	Meeting minutes
MS45	Selection list of the JTC 2016 projects to be funded by the CSC	WP8	13 - DCS	34	Report
MS46	Commitment on availability of funds for the JTC 2016 selected projects (each contributing CSC partner)	WP8	13 - DCS	35	Report

Milestone number¹⁸	Milestone title	WP number⁹	Lead beneficiary	Due Date (in months)¹⁷	Means of verification
MS47	Establishment of the JTC 2017 Joint Call Secretariat	WP9	11 - ACC	37	Notification to JTC 2017 CSC
MS48	Eligibility check of JTC 2017 pre-proposals	WP9	11 - ACC	39	Report
MS49	First meeting of the JTC 2017 Scientific Evaluation Committee, pre-proposal evaluation	WP9	11 - ACC	41	Meeting minutes
MS50	Second meeting of the JTC 2017 Scientific Evaluation Committee, full proposal evaluation	WP9	11 - ACC	46	Meeting minutes
MS51	Selection list of the JTC 2017 projects to be funded by the CSC	WP9	11 - ACC	46	Report
MS52	Commitment on availability of funds for the JTC 2017 selected projects (each contributing CSC partner)	WP9	11 - ACC	47	Report
MS53	Ninth Meeting of the NSC	WP1	1 - MoH	64	Meeting minutes
MS54	Tenth Meeting of the NSC	WP1	1 - MoH	69	Meeting Minutes

1.3.5. WT5 Critical Implementation risks and mitigation actions

Risk number	Description of risk	WP Number	Proposed risk-mitigation measures
1	Withdrawal of a partner organisation	WP1, WP2, WP3, WP4, WP5, WP6, WP7, WP8, WP9	<ul style="list-style-type: none"> • Strong initial commitment from all partners • In case of loss of leadership of WP or task: substitution by another partner
2	“Matching problem”: national financial bottlenecks for funding joint research consortia	WP2, WP7, WP8, WP9	<ul style="list-style-type: none"> • Strong initial commitment from all partners • Earmarked national budgets are flexible, i.e. increase of national budget in case of numerous successful research groups from that country • Negotiation with successful applicants about level of funding • EC co-funded call: use of EC funds for filling gaps in national funding capabilities
3	Delay or failure of a partner to deliver work as agreed	WP1, WP2, WP3, WP4, WP5, WP6, WP7, WP8, WP9	<ul style="list-style-type: none"> • Experienced NCU will detect problem early on (close monitoring of work progress) and propose new deadlines; if that fails: • Redistribution of work to other partners after discussion and decision by the NSC

1.3.6. WT6 Summary of project effort contribution

	WP1	WP2	WP3	WP4	WP5	WP6	WP7	WP8	WP9	WP10
1 - MoH	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
2 - FWF		✓	✓				✓	✓	✓	
3 - ISS	✓	✓	✓	✓	✓	✓	✓	✓	✓	
4 - LAS										
5 - INCa		✓	✓	✓	✓		✓	✓	✓	
6 - BMBF		✓	✓	✓			✓	✓	✓	
7 - DLR		✓	✓	✓			✓	✓	✓	
8 - ARC		✓	✓				✓	✓	✓	
9 - GSRT		✓		✓						
10 - CSO-MOH		✓	✓		✓		✓	✓	✓	
11 - ACC	✓	✓	✓	✓	✓	✓			✓	
12 - ZonMw		✓	✓	✓						
13 - DCS		✓	✓	✓			✓	✓	✓	
14 - RCN		✓	✓	✓			✓	✓	✓	
15 - FCT		✓	✓	✓		✓	✓	✓	✓	
16 - SAS		✓	✓				✓	✓	✓	
17 - MIZS		✓	✓	✓	✓		✓	✓	✓	
18 - ISCIII		✓	✓	✓	✓		✓	✓	✓	
19 - TUBITAK		✓	✓	✓	✓	✓		✓	✓	
20 - NCBR		✓	✓							

	WP1	WP2	WP3	WP4	WP5	WP6	WP7	WP8	WP9	WP10
21 - FWO		✓	✓				✓	✓	✓	
22 - OOI				✓						
23 - NCS		✓	✓				✓	✓	✓	
24 - FNRS		✓	✓				✓	✓	✓	
25 - MIUR		✓	✓			✓	✓	✓	✓	
26 - ETAg		✓	✓						✓	
27 - FICYT		✓	✓	✓	✓		✓	✓	✓	
28 - MoST		✓	✓							
29 - VIAA		✓	✓	✓	✓		✓	✓	✓	
30 - TuscReg				✓	✓					
TLS				✓	✓					
31 - FRRB			✓	✓	✓			✓	✓	
32 - FCAECC			✓	✓	✓			✓	✓	

1.3.7. WT7 Tentative schedule of project reviews

No project reviews indicated

1. Project number

The project number has been assigned by the Commission as the unique identifier for your project. It cannot be changed. The project number **should appear on each page of the grant agreement preparation documents (part A and part B)** to prevent errors during its handling.

2. Project acronym

Use the project acronym as given in the submitted proposal. It can generally not be changed. The same acronym **should appear on each page of the grant agreement preparation documents (part A and part B)** to prevent errors during its handling.

3. Project title

Use the title (preferably no longer than 200 characters) as indicated in the submitted proposal. Minor corrections are possible if agreed during the preparation of the grant agreement.

4. Starting date

Unless a specific (fixed) starting date is duly justified and agreed upon during the preparation of the Grant Agreement, the project will start on the first day of the month following the entry into force of the Grant Agreement (NB : entry into force = signature by the Commission). Please note that if a fixed starting date is used, you will be required to provide a written justification.

5. Duration

Insert the duration of the project in full months.

6. Call (part) identifier

The Call (part) identifier is the reference number given in the call or part of the call you were addressing, as indicated in the publication of the call in the Official Journal of the European Union. You have to use the identifier given by the Commission in the letter inviting to prepare the grant agreement.

7. Abstract

8. Project Entry Month

The month at which the participant joined the consortium, month 1 marking the start date of the project, and all other start dates being relative to this start date.

9. Work Package number

Work package number: WP1, WP2, WP3, ..., WPn

10. Lead beneficiary

This must be one of the beneficiaries in the grant (not a third party) - Number of the beneficiary leading the work in this work package

11. Person-months per work package

The total number of person-months allocated to each work package.

12. Start month

Relative start date for the work in the specific work packages, month 1 marking the start date of the project, and all other start dates being relative to this start date.

13. End month

Relative end date, month 1 marking the start date of the project, and all end dates being relative to this start date.

14. Deliverable number

Deliverable numbers: D1 - Dn

15. Type

Please indicate the type of the deliverable using one of the following codes:

R	Document, report
DEM	Demonstrator, pilot, prototype
DEC	Websites, patent filings, videos, etc.
OTHER	
ETHICS	Ethics requirement
ORDP	Open Research Data Pilot
DATA	data sets, microdata, etc.

16. Dissemination level

Please indicate the dissemination level using one of the following codes:

- PU Public
- CO Confidential, only for members of the consortium (including the Commission Services)
- EU-RES Classified Information: RESTREINT UE (Commission Decision 2005/444/EC)
- EU-CON Classified Information: CONFIDENTIEL UE (Commission Decision 2005/444/EC)
- EU-SEC Classified Information: SECRET UE (Commission Decision 2005/444/EC)

17. Delivery date for Deliverable

Month in which the deliverables will be available, month 1 marking the start date of the project, and all delivery dates being relative to this start date.

18. Milestone number

Milestone number: MS1, MS2, ..., MSn

19. Review number

Review number: RV1, RV2, ..., RVn

20. Installation Number

Number progressively the installations of a same infrastructure. An installation is a part of an infrastructure that could be used independently from the rest.

21. Installation country

Code of the country where the installation is located or IO if the access provider (the beneficiary or linked third party) is an international organization, an ERIC or a similar legal entity.

22. Type of access

- VA if virtual access,
- TA-uc if trans-national access with access costs declared on the basis of unit cost,
- TA-ac if trans-national access with access costs declared as actual costs, and
- TA-cb if trans-national access with access costs declared as a combination of actual costs and costs on the basis of unit cost.

23. Access costs

Cost of the access provided under the project. For virtual access fill only the second column. For trans-national access fill one of the two columns or both according to the way access costs are declared. Trans-national access costs on the basis of unit cost will result from the unit cost by the quantity of access to be provided.



Horizon 2020

ERA-NET: Aligning national/regional
Translational cancer research programmes and activities

TRANSCAN-2

Part B

Table of Contents

1. Excellence	14
1.1. Objectives	14
1.2. Relation to the work programme	15
1.3. Concept and approach	15
1.4. Ambition	17
2. Impact	17
2.1. Expected impacts	17
2.2. Measures to maximise impact	19
a. Dissemination and exploitation of results	19
b. Communication activities	20
3. Implementation	20
3.1. Work Plan	20
3.2. Management structure and procedures	24
3.2.1. Network Steering Committee (NSC)	24
3.2.2. Network Coordination Unit (NCU)	25
3.2.3. Scientific Advisory Board (SAB)	25
3.2.4. Call Steering Committee (CSC)	25
3.3. Consortium as a whole	26
3.4. Resources to be committed	27
Table 3.3: Summary of national/regional call contributions	27
Table 3.4: Summary of Work package participation and number of years with coordination costs	29
4. Members of the Consortium	30
4.1. Participants	30
4.2. Third parties involved	99
4.3. Financial support to third parties	99
5. Ethics and security	100
5.1. Ethics	100
5.2. Security	100

History of changes

Proposal	DoA	Part A/Part B	Date of change
WP1 - Task 1.2: Installing the TRANSCAN-2 Scientific Advisory Board (SAB) “[...] The SAB will comprise scientists with recognized expertise in different fields of translational cancer research, from the basic biomedical and clinical sciences, epidemiology, and public health. [...]”	Change: “[...] The SAB will comprise scientists with recognized expertise in different fields of translational cancer research, from the basic biomedical and clinical sciences, epidemiology, and public health; representatives of patients’ organisations will be also included in the SAB. [...]”	Part A (1.3.3)	29/09/2014
WP4 - Task 4.4: Strategy on interaction with relevant projects and stakeholders. “The purpose of this task is to ensure optimal coordination at global level with other European and international initiatives that may spur TRANSCAN-2 strategy on translational research. [...]”	Change: “The purpose of this task is to ensure optimal coordination at global level with other European and international initiatives that may spur TRANSCAN-2 strategy on translational research. To this end, the initial task activity will be dedicated to the elaboration of a strategy for interaction with the relevant initiatives, taking into consideration the partners’ priorities and expectations. [...]”	Part A (1.3.3)	29/09/2014
Section 3.2.3 <i>Scientific Advisory Board (SAB)</i> : “[...] The SAB will be constituted of at least 10 and up to 15 recognised experts not belonging to the TRANSCAN-2 consortium, and will serve the main function of providing independent information as well as assessment and advice on the TRANSCAN-2 activities.[...]”	Change: Section 2.3.2.3 <i>Scientific Advisory Board (SAB)</i> : “[...] The SAB will be constituted of at least 10 and up to 15 recognised experts, including representatives of patients’ organisations , not belonging to the TRANSCAN-2 consortium, and will serve the main function of providing independent information as well as assessment and advice on the TRANSCAN-2 activities. [...]”	Part B (2.3.2.3)	29/09/2014
WP1 – Deliverables: D1.1, D1.2, D1.3, D1.4	Change: Reduction from four to three deliverables only, i.e., D1.1, D1.2 and D1.3 corresponding to the progress reports due at	Part A (1.3.3)	29/09/2014

	month 24, 36 and 48, respectively.		
WP2 – Deliverables: D2.1 – D2.13	Change: Reduction to five (5) deliverables only (D2.1-D2.5) comprising all documents pertaining to the cofunded call to be delivered to the European Commission, based on the instructions provided in the Grant Agreement.	Part A (1.3.3)	29/09/2014
WP3 - Deliverables: D3.1 – D3.9	Change: D3.2-D3.5 and D3.6-D3.9 have been deleted as the related information will be provided in the appropriate progress report and in the final report. The former deliverables D3.2-D3.9 will become documents internal to the TRANSCAN-2 consortium to be provided by the WP3 leader to the TRANSCAN-2 Network Steering Committee (NSC). These documents and the respective delivery dates will be listed in an appendix to the TRANSCAN-2 Consortium Agreement.	Part A (1.3.3)	29/09/2014
WP4 - Deliverables: D4.1 – D4.25	Change: the former deliverables D4.1-D4.25 have been condensed into the actual D4.1-D4-3 and the respective delivery dates have been adjusted.	Part A (1.3.3)	29/09/2014
WP5 - Deliverables: D5.1 – D5.15	Change: the former deliverable D5.1 (Communication strategy) has been converted into the milestone M5.1.	Part A (1.3.3)	29/09/2014
WP6 – Deliverables: D6.1 – D6.7	Change: the former deliverables D6.3-D6.6 have been deleted as the related information will be included in the appropriate progress report; the D6.7 has been deleted as the respective content will be comprised in the final report. The D6.3-D6.7 will become documents internal to the TRANSCAN-2 consortium to be provided by the WP6 leader to the TRANSCAN-2 NSC. These documents and the respective delivery dates will be listed in an appendix to the TRANSCAN-2 Consortium Agreement.	Part A (1.3.3)	29/09/2014
WP7 – Deliverables: D7.1 – D7.12	Change: the deliverables have been grouped so as to render them coherent with the deliverables included under WP2.	Part A (1.3.3)	29/09/2014
WP8- Deliverables: D8.1 – D8.12	Change: the deliverables have been grouped so as to render them coherent with the deliverables included under WP2.	Part A (1.3.3)	29/09/2014
WP9 – Deliverables: D9.1 – D9.12	Change: the deliverables have been grouped so as to render them coherent with the deliverables included under WP2.	Part A (1.3.3)	29/09/2014
Section 3.1: Gantt chart	Change: the Gantt chart has been revised according to the changes in the deliverables	Part B (2.3.1)	29/09/2014

	and milestones and respective delivery dates.		
WP3 – Task 3.2 results (1 st revision of the DoA)	Change: the contribution of the Task 3.2 results to the deliverables D2.5/D7.4/D8.4/D9.4 [Publishable information about JTC 2014/2015/2016/2017 funded projects (participants, overview of results), in EC-defined format] has been clarified under the task description as follows: “The results of the analyses will be included in the deliverables D2.5, D7.4, D8.4 and D9.4 pertaining to the publishable information about the projects funded under the JTC 2014 (WP2), JTC 2015 (WP7), JTC 2016 (WP8), and JTC 2017 (WP9)”.	Part A (1.3.3)	16/10/2014
WP4 – Deliverables: D4.1, D4.2 and D4.3 (1 st revision of the DoA)	Change: Reduction to one repetitive deliverable with several due dates, i.e., D4.1: Reports on contacts with non-TRANSCAN-2 funding organizations, interactions with other European and world-wide cancer initiatives, and on scientific priority topics.	Part A (1.3.3)	16/10/2014
WP5 – Deliverables: D5.2, D5.3, D.5.5-D5.8 and D5.10-D5.13 (biannual e-newsletters) (1 st revision of the DoA)	Change: Reduction to one repetitive deliverable with several due dates.	Part A (1.3.3)	16/10/2014
WP5 – Deliverables: D5.4, D5.9, D5.14 (reports of the annual scientific symposia) (1 st revision of the DoA)	Change: Reduction to one repetitive deliverable with several due dates.	Part A (1.3.3)	16/10/2014
WP6 – Deliverable D6.1 List of monitoring indicators for TRANSCAN-2 call results (1 st revision of the DoA)	Change: The D6.1 has been changed into milestone MS30.	Part A (1.3.3)	16/10/2014
WP7 (1 st revision of the DoA)	Change: Addition of milestone MS40: Commitment on availability of funds for the JTC 2015 selected projects (each contributing CSC partner).	Part A (1.3.3)	16/10/2014
WP8 (1 st revision of the DoA)	Change: Addition of milestone MS46: Commitment on availability of funds for the JTC 2015 selected projects (each contributing CSC partner).	Part A (1.3.3)	16/10/2014
WP9 (1 st revision of the DoA)	Change: Addition of the milestone MS52: Commitment on availability of funds for the JTC 2015 selected projects (each contributing	Part A (1.3.3)	16/10/2014

	CSC partner).		
WP9 description (1 st revision of the DoA)	Change: “WP9 aims to address the following tasks: the preparation and launch of a fourth joint transnational call (JTC 2017)”	Part A (1.3.3)	16/10/2014
EC request (1 st revision of DoA): to include project updates from the 3 TRANSCAN calls into TRANSCAN2 to show the continuity.	<p>Changes: <u>Section 1.1 Objectives</u> "[...] It is worth noting that in the current TRANSCAN project a similar monitoring of the projects funded under the three implemented JTCs has been undertaken. Given that the projects funded under said JTCs will be completed after the end of the TRANSCAN project, their monitoring will necessarily be continued under the TRANSCAN-2 action. Therefore, the analyses of the respective monitoring results will be comprised in the analyses of the monitoring of the projects funded under the TRANSCAN-2 JTCs. [...]"</p> <p><u>Task 3.2 description:</u> "[...] The results of the analyses will be included in the deliverables D2.5, D7.4, D8.4 and D9.4 pertaining to the publishable information about the projects funded under the JTC 2014 (WP2), JTC 2015 (WP7), JTC 2016 (WP8), and JTC 2017 (WP9). In these deliverables, the outcomes of the monitoring of the projects funded under the JTCs launched by the TRANSCAN project will be referred to, aiming at both a retrospective and prospective analysis of the results. [...]"</p>	Part B (1.1)	16/10/2014
EC request (1 st revision of DoA): to add websites for each partner and, if possible, to provide a link to national funding rules in Section 4.	Change: the requested information has been included in the revised Section 4.	Part B (4.1)	16/10/2014
EC request (1 st revision of DoA): After approval by the EC (dated 29/10/2014) relating to the replacement of original beneficiary 28 (NRPB) with the Ministry of Science and Technology (MoST) of Taiwan, the substitution of organizations was made. The reason was the fact that NRPB does not have its own legal personality and it depends on the Ministry	Change: The description of the current partner 28 corresponds to the Ministry of Science and Technology (MoST) of Taiwan and its description has been included in Section 4.	Part B (4.1)	16/10/2014

of Ministry of Science and Technology (MoST).			
EC request (1 st revision of DoA): to provide a more detailed description, in line with the H2020 provisions and wording, concerning third parties for FICYT.	Change: the revised description of FICYT excluding third parties has been integrated.	Part B (4.1)	16/10/2014
EC request (1 st revision of DoA): to clarify the exact involvement, in accordance with the H2020 provisions, of third parties for ISCIII.	Change: the revised description for ISCIII has been integrated.	Part B (4.1)	16/10/2014
Beneficiaries participating in the co-funded call	Change: GSRT (Greece) participation in the co-funded call with a committed budget of EUR 500,000 was communicated to the coordination on Tuesday, 23 September 2014. The information has been included in the final version of the DoA, in the WP2 description, in section 4.1. Participants, and in section 3.4. Resources to be committed.	Part A (1.3.3) Part B (3.4; 4.1)	14/11/2014
WP2, WP4, WP9 leadership	<p>Change: due to a decision communicated by beneficiary 7 (DLR) on Thursday, 6 November 2014 of withdrawing from the leadership of WP2, WP4 and WP9, changes in assignment of responsibilities (at the level of WP, task and subtask) were made, as indicated below.</p> <p>WP2: leader MoH-ISS. <u>Task 2.2:</u> leader INCa, co-leader MoH-ISS <u>Subtask 2.2.2:</u> leader INCa <u>Subtask 2.2.3:</u> leader MoH-ISS <u>Task 2.3:</u> leader MoH-ISS <u>Subtask 2.3.1:</u> leader MoH-ISS <u>Subtask 2.3.2:</u> leader MoH-ISS <u>Subtask 2.3.3:</u> leader INCa <u>Subtask 2.3.4:</u> leader MoH-ISS <u>Subtask 2.3.5:</u> leader FICYT, co-leader ISCIII <u>Subtask 2.3.6:</u> leader MoH-ISS, co-leader ARC <u>Subtask 2.3.7:</u> leader MoH-ISS</p> <p>WP4: leader INCa. <u>Task 4.1:</u> leader MoH-ISS, co-leader ZonMw <u>Task 4.2:</u> leader FCT, co-leader LAS <u>Task 4.3:</u> leader FCT, co-leader ISCIII <u>Task 4.5:</u> leader INCa, co-leader FICYT</p> <p>WP9: leader ACC.</p>	Part A (1.3.3) Part B (3.4; 4.1)	14/11/2014

	<u>Task 9.1:</u> leader ACC, co-leader FCT <u>Subtask 9.1.1:</u> leader FCT, co-leader FICYT <u>Subtask 9.1.2:</u> leader ACC, co-leader ARC <u>Subtask 9.1.3:</u> leader ACC, co-leader FICYT <u>Task 9.2:</u> leader ACC, co-leader FICYT <u>Subtask 9.2.1:</u> leader ACC, co-leader ISCIII <u>Subtask 9.2.2:</u> leader MoH-ISS, co-leader ACC <u>Subtask 9.2.3:</u> leader ACC, co-leader LAS <u>Subtask 9.2.4:</u> leader ACC <u>Subtask 9.2.5:</u> leader ACC		
EC request (2 nd revision of DoA): As previously referred to in the EC Legal Officer's e-mails dated 15/10/2014 and 07/10/2014, no reference at all to a third party under Article 11 or 12 should be included in the DoA. For that reason, a further revision of the description of beneficiary 18 (ISCIII) was requested by the EC (via e-mail, dated, 5/11/2014).	Change: As the participant did not envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement), beneficiary modified its description accordingly and the following text was deleted. “ISCIII's participation in this action will be carried out by the Research and Innovation Activities Assistance Office (OAIN) and which is part of the Deputy Director's Office for International Research Programmes and Institutional Relations (SGPIIRI). The Foundation for International Cooperation, Health and Social Affairs (FCSAI) will be involved as a third party. FCSAI has authorisation to administer the activities carried by OAIN.” The new beneficiary's description was approved by the EC Legal Officer via e-mail (dated, 6/11/2014).	Part B (4.1)	14/11/2014
EC request (2 nd revision of DoA): The EC Legal Officer (via e-mail, dated, 5/11/2014). requested further revision of the description of beneficiary 28 (MoST) because it still made reference to in-kind contribution (personnel). The solution proposed was to avoid any reference about NRPB in the tables about the third parties; in particular, to "third party" providing resources.	Change: In order to avoid any reference about NRPB in the tables about the third parties, as recommended, the following portions of text were deleted: 1) “Short profile of staff member(s) who will be undertaking the work Dr. Shan-Chi Ku, PhD, Manager, Office of International Collaboration, National Research Program for Biopharmaceuticals (NRPB). Elena Hung, Program Manager of NCP office, National Applied Research Laboratories, NARLabs, Taiwan” 2) “As for TRANSCAN-2, the MoST	Part B (4.1)	14/11/2014

	<p>encourages our National Research Program on Biopharmaceuticals (NRPB) to assist with technical aspects of the TRANSCAN project.</p> <p>"National Research Program for Biopharmaceuticals (NRPB)", a 6-year program was launched in 2011, to integrate and consolidate the existing domestic biomedical infrastructures, accelerate the commercialization of innovative technologies, and strengthen the domestic biomedical industry. The Program focuses on the R&D of new drugs/new reagents/new therapeutic strategies/new medical devices in a product-oriented approach, aims at developing a fully-integrated biopharmaceutical pipeline, and streamlines the operating system of preclinical testing and early clinical trials. By bringing "value identification" to "value creation", we hope to fulfill the vision of turning scientific concept into products. Our ultimate goal is to develop new therapeutics for disease prevention, diagnosis and treatment.</p> <p>The NRPB composed of 6 major parts, i.e. Research Group, Preclinical Development Group, Clinical Group, Resource Center, Industrial Bridging & International Collaboration (IBIC) Group, and Ethical, Legal and Social Issues (ELSI) Group.</p> <p>Website: http://nrpb.sinica.edu.tw/en/intro/background"</p> <p>The new beneficiary's description was approved by the EC Legal Officer via e-mail (dated, 6/11/2014).</p>		
<p>EC request: Compulsory amendment –initiated by the EC on 18 December 2015- to become in compliance with Article 20.5 of the GA which establishes the obligation to inform the Commission, by the end of each year, of the cumulative expenditure incurred by the beneficiaries during the lifespan of the action. In view of the above, new Deliverables were</p>	<p>Change: Addition of new deliverables: D1.4 : Report 1 on cumulative expenditure incurred - Article 20.5 [12] D1.5 : Report 2 on cumulative expenditure incurred - Article 20.5 [24] D1.6 : Report 3 on cumulative expenditure incurred - Article 20.5 [36] D1.7 : Report 4 on cumulative expenditure incurred - Article 20.5 [48] D1.8 : Report 5 on cumulative expenditure incurred - Article 20.5 [60]</p>	<p>Part A (1.3.2 & 1.3.3)</p>	<p>12/01/2016</p>

added: D1.4, D1.5, D1.6, D1.7 & D1.8			
Consortium request (3 rd revision of DoA): Change of beneficiary because of partial take- over. The rights and obligations under GA 643638 were transferred from Beneficiary 4 (LAS) to new Beneficiary 29 (VIAA).	Change: Based on a notification of 22 January 2015 by Beneficiary 4 (LAS), the coordinator was informed of the partial take- over by <i>Valsts izglītības attīstības aģentūra</i> (VIAA) of LAS's rights and obligations, starting from 1 January 2015. Changes in assignment of responsibilities (at the level of WP and task) were made to reflect the take- over, as indicated below WP2 <u>Task 2.2</u> <u>Task 2.3</u> <u>Task 2.4</u> WP3 Task 3.2 WP4. <u>Task 4.2:</u> leader FCT, co-leader VIAA <u>Task 4.3</u> <u>Task 4.5</u> WP5 Task 5.1 WP7 Task 7.1 Task 7.2 Task 7.3 WP8 Task 8.1 Task 8.2 Task 8.3 WP9 <u>Task 9.1</u> <u>Task 9.2</u> Task 9.3 3.5. Resources to be committed Table 3.3: Summary of national/regional call contributions LAS contribution was cancelled and VIAA was added including LAS's previous figures. Table 3.4: Summary of Work package participation and number of years with coordination costs	Part A (1.3.3; 1.3.6) Part B (3.4; 4.1)	6/06/2016

	<p>LAS's was replaced with VIAA in all WPs. The total number of years for declaring coordination costs (as unit costs) remained unchanged.</p> <p>4 Members of the consortium</p> <p>4.1 Participants</p> <ul style="list-style-type: none"> • Under description of Beneficiary 4 (LAS), text explaining the reason for LAS termination was added. • Description of new Beneficiary 29 (VIAA) was added to section 4.1. 		
<p>Consortium request (4th revision of DoA): Change of the action's duration from current sixty months to seventy two months. This change is necessary to achieve the full implementation of the action which requires more time than initially anticipated.</p>	<p>Changes in deadlines (at the level of WP) were made to reflect the change of the action's duration, as indicated below</p> <p>WP1: Change of end month from 60 to 72. Addition of new deliverables: D1.9: Fourth Progress Report [M60] D1.10: Report 6 on cumulative expenditure incurred - Article 20.5 [M72] Addition of new milestones: MS53: Ninth Meeting of the NSC [M64] MS54: Tenth Meeting of the NSC [M68]</p> <p>WP2 Change of end month from 60 to 72.</p> <p>WP3 Change of end month from 60 to 72.</p> <p>WP4 Change of end month from 60 to 72.</p> <p>WP5 Change of end month from 60 to 72.</p> <p>WP6 Change of end month from 60 to 72.</p> <p>WP7 Change of end month from 60 to 72.</p> <p>Changes in due date of: D7.4: Publishable information about JTC 2015 funded projects (participants, overview of results) from [M59] to [M71]</p> <p>WP8 Change of end month from 60 to 72.</p> <p>Changes in due date of: D8.4: Publishable information about JTC 2016 funded projects (participants, overview of results) from [M59] to [M71]</p> <p>WP9 Change of end month from 60 to 72.</p> <p>Changes in due date of: D9.4: Publishable information about JTC 2016 funded projects (participants, overview</p>	<p>Part A (1.3.1, 1.3.2, 1.3.3 & 1.3.4)</p>	<p>11/12/2018</p>

	<p>of results) from [M59] to [M71]</p> <p>WP10 Change of end month from 60 to 72.</p> <p>Section 3. Implementation Subsection 3.1 Work Plan Update of “Figure 2: Gantt chart of TRANSCAN-2 activities” to reflect the change of the action’s duration from 60 months to 72 months.</p>	Part B (3.1)	11/12/2018
<p>Consortium request (5th revision of DoA): Addition of new beneficiaries and addition to one third party linked to beneficiary 30.</p>	<p>Change: List of beneficiaries was modified to add TuscReg, FRRB and FCAECC</p> <p>Change: List of beneficiaries was modified to add TLS as linked third party to TuscReg</p> <p>Change: Changes were made to reflect addition of new beneficiaries, as indicated below: 1.3.3. WT3 Work package descriptions WP3 <u>Participation per Partner (FRRB and FCAECC were added)</u></p> <p>WP4 <u>Participation per Partner was modified by adding TuscReg and its linked third party (TLS), FRRB and FCAECC</u></p> <p>WP5 <u>Participation per Partner was modified by adding TuscReg and its linked third party (TLS), FRRB and FCAECC</u></p> <p>WP8 <u>Participation per Partner (FRRB and FCAECC were added)</u></p> <p>WP8 <u>Participation per Partner (FRRB and FCAECC were added)</u></p> <p>Change: Changes were made to reflect addition of new beneficiaries and new linked third party in: 1.3.6. WT6 Summary of project effort contribution: <u>TuscReg and its linked third party (TLS), FRRB and FCAECC</u></p> <p>Change: Number of participants has increased to 32.</p>	<p>Part A (1.2)</p> <p>Part A (1.3.3.)</p> <p>Part A (1.3.6.)</p> <p>Part B (3.3)</p>	5/11/2019

	<p>Change: In section 3.4 -Resources to be committed, Tables 3.3 and 3.4 were modified to include new beneficiaries and linked third party.</p> <p>Table 3.3: Summary of national/regional call contributions <u>TuscReg and its LTP (TLS), FRRB and FCAECC</u> were added.</p> <p>Table 3.4: Summary of Work package participation and number of years with coordination costs</p> <p>The table was adjusted by decreasing the participation of beneficiaries 22 (OOI) and 23 (NCS) in two unit costs each one. Then, they were reallocated to FRRB, FCAECC and TuscReg and TLS.</p> <p>The total number of years for declaring coordination costs (as unit costs) remained unchanged.</p>	Part B (3.4)	
	<p>4 Members of the consortium</p> <p>4.1 Participants</p> <p>Description of new Beneficiary 30 (TuscReg) was added to section 4.1.</p> <p>Description of new Beneficiary 31 (FRRB) was added to section 4.1.</p> <p>Description of new Beneficiary 32 (FCAECC) was added to section 4.1.</p>	Part B (4.1)	
	<p>4.2. Third parties involved</p> <p>Description of TLS (third party linked to TuscReg) and its contribution was added to section 4.2.</p>	Part B (4.2)	

List of acronyms

BBMRI	Biobanking and BioMolecular Research Infrastructure
CanCon	Joint Action “European Guide on Quality Improvement in Comprehensive Cancer Control”
CORDIS Wire	Community Research and Development Information Service
CSC	Call Steering Committee
D1.2	Deliverable number 2 in Work Package 1
EATRIS	European Advanced Translational Research Infrastructure in Medicine
EC	European Commission
ECRIN	European Clinical Research Infrastructures Network
ERA	European Research Area
E-Rare	ERA-NET on Research Programmes for Rare Diseases
ERAWATCH	Platform on Research and Innovation policies and systems
ESFRI	European Strategy Forum on Research Infrastructures
EU	European Union
FP	Framework Programme
HDHL	Joint Programming Initiative A Healthy Diet for a Healthy Life
IMI	Innovative Medicines Initiative
IPR	Intellectual Property Rights
JCS	Joint Call Secretariat
JPI	Joint Programming Initiative
JPND	EU Joint Programme – Neurodegenerative Disease Research
JTC	Joint Transnational Call
M2.1	Milestone number 1 of Work Package 2
MoU	Memorandum of Understanding
NCU	Network Coordination Unit
NETWATCH	Platform on transnational R&D programme collaboration
NEURON	Network for European funding for Neuroscience Research
NSC	Network Steering Committee
SAB	Scientific Advisory Board
SEC	Scientific Evaluation Committee
WP	Work Package
WPL	Work Package Leader

1. Excellence

1.1. Objectives

The objectives of the proposed ERA-NET TRANSCAN-2 meet those expressed in the EU Framework Programme for Research and Innovation Horizon 2020 Societal Challenge 1 Health, Demographic Change and Wellbeing Work Programme 2014-2015, with specific reference to the call under Health Co-ordination activities HCO 8 – 2014: ERA-NET: Aligning national/regional translational cancer research programmes and activities.

The objectives of TRANSCAN-2 will be achieved through the implementation of interconnected activities, structured into nine work packages (WP) (see section 3. Implementation), and can be summarized as follows.

The main objectives of WP2 are the preparation, launch and implementation of a joint transnational call with (JTC) co-funding from the European Commission (EC), including the evaluation and selection of the proposals as well as the monitoring of the funded projects and the communication, exploitation and dissemination of the research results (deliverables D2.1-D2.5 and milestones M2.1-M2.6).

The objectives of WP3 will be: i) the monitoring of the progress of the research projects funded within the co-funded JTC and the additional JTCs planned for the proposed ERA-NET TRANSCAN-2; ii) analyzing the results of the monitoring to assess the performance of the funded projects with respect to the scope of the above mentioned JTCs (deliverables D3.1 and milestones M3.1-M3.5). It is worth noting that in the current TRANSCAN project a similar monitoring of the projects funded under the three implemented JTCs has been undertaken. Given that the projects funded under said JTCs will be completed after the end of the TRANSCAN project, their monitoring will necessarily be continued under the TRANSCAN-2 action. Therefore, the analyses of the respective monitoring results will be comprised in the analyses of the monitoring of the projects funded under the TRANSCAN-2 JTCs.

The WP4 has the following dual aims. Firstly, to develop and update a strategy of the TRANSCAN-2 network with the purpose of i) enlarging the network of funding organisations; ii) promoting the participation of all partners in future JTCs; iii) improving the decision-making processes; iv) promoting goal-directed interactions with relevant projects and stakeholders in the EU and world-wide translational cancer research. Secondly, to develop and update a strategy on identifying scientific priority topics in translational cancer research, through a systematic exchange with the relevant scientific community, comprising both laboratory and clinical investigators (deliverable D4.1).

The main objective of WP5 is to establish an effective communication, dissemination and networking strategy so as to increase awareness of both TRANSCAN and TRANSCAN-2 and of their impact, in terms of results of these projects and of the research projects funded through the JTCs launched under their umbrella (deliverables D5.2- and milestones M5.1-M5.4).

The WP6 will aim to monitor and assess the performance of the TRANSCAN-2 consortium, in continuity with an activity already implemented in the current TRANSCAN project, and that appears of particular relevance, considering that the ERA-NET Cofund instrument is new in the European Research Area cooperation scheme. The WP6 will therefore contribute to identify not only timely corrections in procedures or in the path to desired outcomes, but also best practices in the new ERA-NET Cofund instrument. Importantly, given that the majority of the partners in TRANSCAN-2 have a medium- to long-term perspective on their cancer research funding strategy, monitoring and assessment of the cooperation between those funding organisations will certainly contribute to promoting a fruitful cooperation long-term (deliverables D6.1 and milestones M6.1-M6.5).

The objectives of WP7, WP8 and WP9 will be the preparation and implementation of three additional JTCs, to be launched in the year 2015, 2016 and 2017, respectively, given the commitment already expressed by the partners indicated in said WPs to fund the three JTCs (deliverables D7.1-D7.4 and milestones M7.1-M7.6, as for WP7; deliverables D8.1-D8.4 and milestones M8.1-M8.6, as for WP8; deliverables D9.1-D9.4 and milestones M9.1-M9.6, as for WP9).

Finally, the ultimate goal of WP1 is to ensure the proper technical and administrative management of the project as a whole as well as the management of the consortium of funding organisations participating in the co-funded JTC and additional JTCs. To this end, the WP1 will guarantee the efficient communication and flow of information within the TRANSCAN-2 network and with the EC (deliverables D1.1, D1.2, D1.3 and milestones M1.1-M1.14).

1.2. Relation to the work programme

This proposal relates to the topic of the Horizon 2020 Health, Demographic Change and Wellbeing work programme 2014-2015 identified as HCO 8 – 2014: ERA-NET: Aligning national/regional translational cancer research programmes and activities.

The specific challenge of this topic, as set out in the work programme, is to realise an effective cooperation at transnational level avoiding the duplication of efforts, by ensuring the availability of critical mass, by efficiently using available resources, by exchanging knowledge, by producing more significant results of higher quality and impact, and sharing data and infrastructures.

This challenge has been already addressed by the current TRANSCAN ERA-NET on Translational Cancer Research, started in January 2011. In fact, during its lifetime, the TRANSCAN project has brought together 29 funding organisations distributed over 20 European countries, including four major charities (CR-UK, the French ARC Foundation, the Dutch Cancer Society, and the Norwegian Cancer Society). Thanks to this remarkably large consortium, the TRANSCAN project has been able to implement three joint calls dedicated to high priority topics, i.e. i) validation of biomarkers for personalised cancer medicine; ii) translational research on primary and secondary prevention of cancer; and iii) translational research on tertiary prevention in cancer patients. The total budget committed to the funding of the research projects granted through these joint calls has been of approximately 33M Euro. The research projects awarded under the first two joint calls (the third one is currently under evaluation) have seen the involvement of over 100 research groups distributed over 23 European countries.

In continuity with the current TRANSCAN ERA-NET, the proposed TRANSCAN-2 project will build upon this potential, so as to optimise the use of available resources. Of note, the TRANSCAN network has recently been joined also by a third-country funding organisation, the Ministry of Science and Technology of Taiwan (MoST).

The planned co-funded call focused on “Intratumour heterogeneity in resistance to therapy and recurrence” (see WP2) is certainly embedded in the pathway already designed by TRANSCAN and will further contribute to the coordination of national and regional programmes for research in the area of translational cancer research. The top-priority areas where TRANSCAN-2 could bring an added value, through the funding of research projects under the additional joint calls planned in the project, will be selected through the development and updating of a specific strategy, as described in WP4, based on systematic exchanges with relevant scientific stakeholders.

The strategy planned in TRANSCAN-2 (see WP4) for enlarging the network, for improving the success of funding organisations in financing research groups in the respective countries, and for establishing goal-oriented interactions with other initiatives and stakeholders in EU and world-wide, will promote an effective transnational cooperation in the field of translational cancer research.

The proposed project will contribute to the sharing of knowledge and results of the project’s activities as well as of the research projects funded under the JTCs, through a specific communication and dissemination plan directed towards the scientific community and all stakeholders interested in cancer research (see WP5).

The impact of TRANSCAN-2 on national and transnational programmes as well as the leverage effect on European research and competitiveness will be assessed through the monitoring of the results of the projects resulting from the co-funded JTC 2014 and the JTCs launched by TRANSCAN and TRANSCAN-2 (see WP3). These monitoring and assessment activities will be closely linked to the evaluation of the performance of TRANSCAN-2, under the new ERA-NET Cofund instrument, through the development of specific key indicators (see WP6).

1.3. Concept and approach

TRANSCAN-2 is an experienced and internationally recognized consortium. The network has established and executed a successful model of preparing and implementing joint transnational calls, including fair and transparent evaluation procedures. This highly valuable experience is of great added value for the European and international community, both of which would benefit extensively from a productive continuation of the TRANSCAN-2 partners, supplemented by the considerable contribution of the European Commission. The envisioned second phase of TRANSCAN will further increase the efficiency of planning, implementing and monitoring of joint transnational calls, increasing their impact through the co-funding from the EC.

The main activities of the TRANSCAN-2 project are shown in two sections. Section I incorporates activities related the co-funded call (Work Package 2), and section II includes all other(additional) activities (Work Packages 1, 3-9).

Section I: Activities on the co-funded call including the related consortium management

The co-funded call will be organised in 2014 (JTC 2014) and will result in funding the most excellent transnational research projects for translational cancer research (Work Package 2). At the time of writing, this co-funded call will focus on the topic of “Intratumour Heterogeneity”. This call will combine budget contributions from the participating European and Associated member states, the European Commission and additional international research funders (Taiwan) in order to maximize the impact of funding transnational cancer research projects. 25 funding partners from 19 countries have committed financial contributions to fund research projects for more than 17 Mio €. The European Commission has expressed its intention to co-fund this call with approximately 5 Mio €.

Careful monitoring and assessment of the co-funded projects will be also performed within Work Package 2. The considerable experience gathered during the first phase of TRANSCAN will be used in order to optimize this monitoring process and to ensure the most effective use of the dedicated funds.

Dissemination activities directly related to the research results of the co-funded call will be also carried out by Work Package 2, and supported by the Work Package 5, which disseminates TRANSCAN-2 results of the other activities as well.

Section II: Additional activities

In addition to the co-funded call TRANSCAN-2 plans to perform various ambitious activities during the 5 years of the project.

Work Packages 7-9 include the preparation and implementation of additional three joint transnational calls. Based on already existing preliminary commitments and on the solid basis of previous experience in running transnational calls, this ambitious goal should be successfully achieved.

The coordination activities outside the co-funded call are included in Work Package 1. They include the management and monitoring of the work plan’s implementation and the establishment of the Scientific Advisory Board. It is the ultimate responsibility of the network coordination unit to guarantee the smooth operation of the consortium as a whole.

Work Package 3 is responsible for the follow-up and monitoring of the research projects of the three additional (nonco-funded) joint transnational calls.

The very large size of the TRANSCAN-2 consortium as well as the potential perspectives of this collaborative project, demand a strategic approach on different relevant issues (Work Package 4). This encompasses a strategy on expanding the network, on improving the funding partner’s success in the joint transnational calls, on lean and efficient decision-making procedures, on continuing and new interactions with relevant stakeholders in cancer research (e.g. ESFRI: EATRIS, ECRIN etc.; CanCon: DG SANCO-funded action on cancer control; IMI). An eminent field of activity is the development and continuous updating of a strategy that identifies the most important scientific topics, to be implemented within the joint transnational calls.

As mentioned before, Work Package 5 addresses the communication, dissemination and networking activities (beyond the co-funded call, into which it also inputs). The visibility of the funded research projects as well as of the large community of TRANSCAN-2 will be ensured through the various activities of this work package: definition and implementation of an internal and external communication strategy, creating outreach materials and performing outreach activities, organising scientific symposia with funded researchers and other excellent experts, with a focus on young investigators.

For a collaborative project the size of TRANSCAN-2 it is very relevant to assess and monitor the network’s performance, which is achieved by Work Package 6.

In summary, TRANSCAN-2 will foster excellent collaborative cancer research throughout Europe and therefore decreases fragmentation, helps to avoid duplications of efforts, and therefore improves the competitiveness and efficiency of European cancer research.

Gender issues

As already implemented in the procedures underlying the first phase of TRANSCAN, gender balance in TRANSCAN-2 will be a principle, namely in the constitution of the Scientific Advisory Board and of the

Scientific Evaluation Committees. Furthermore, gender will be one of the indicators for the assessment of the funded projects in the co-funded call and the three non-co-funded calls.

1.4. Ambition

Due to the complexity of the underlying scientific challenges in translational cancer research, a coordinated approach between European funding organisations is required in order to accelerate the translation of basic research findings into clinical practice. In the last five years, TRANSCAN has shown that an efficient coordination of this network with so many partners (25 partners from 19 countries) is not only feasible, but highly successful. During the first phase, additional 4 partners have joined the network (ARC, DCS, NCS, MoST), three of which are private charities (ARC, DCS, NCS). For TRANSCAN-2, another 3 partners have decided to join (ETAg, FICYT, FNRS). Next to the interest in this important research field, this interest from ever more funding organisations demonstrates the success of this ERA-NET. Nevertheless, it is the ambition of TRANSCAN-2 to recruit even more funding partners, for instance from the Scandinavian countries, and stay the most influential and largest cancer research funding consortium in Europe.

2. Impact

2.1. Expected impacts

The ultimate goal and expected outcome of TRANSCAN-2 is to strongly contribute to the building of a more effective European Research Area by facilitating and coordinating regional and national European cancer research funding programmes between European Member States and Associated Countries, including the European Commission (for the co-funded joint transnational call).

In the fight against cancer, the strengthening of translational cancer research is a high-priority and urgently needed in order to achieve the integration of basic, epidemiological, preclinical and clinical cancer research with the implementation and evaluation of interventions in prevention, diagnosis, prognosis, treatment and care. At a European level, this integrative process requires better coordination and combination of limited resources among Member States. With improved use of European funding resources, the unique strengths that Europe offers - namely excellent basic cancer research leading to outstanding scientific discoveries - could more readily be converted into medical inventions, including innovative medicinal products and services capable of boosting European healthcare and competitiveness in the medical sector.

TRANSCAN-2 brings together an exceptional consortium of major European funding organisations that has grown in the last years, with a common aim and commitment to accelerate the translation of scientific discoveries into clinical applications and to increase the quality of cancer research. All TRANSCAN-2 partners are key actors in their national research funding systems. They introduce considerable expertise and funding volumes into the TRANSCAN-2 consortium. Under Horizon 2020, the European Commission will contribute to TRANSCAN-2 by co-funding the first joint transnational call, thus increasing the capacity of funding excellent translational cancer research consortia and contributing to the overall impact of TRANSCAN-2.

The current prevailing economic and fiscal tensions in Europe will force new international modes of cooperation in cost-intensive fields of research like translational cancer research. TRANSCAN-2 is thus expected to become even more integrated into the existing research funding landscape and augment it by providing opportunities for transnational networking of small- to medium-sized research consortia and focusing joint activities on areas of demand. Moreover, it will substantially contribute to a common European vision of translational cancer research and hence to an improved European Research Area.

TRANSCAN-2 will coordinate and focus the available resources of its partners on strategic areas of mutual importance for one joint transnational call including the support from the European Commission. This will create a more efficient funding support for translational cancer research in Europe, both on a national level, as well as on a European level. The TRANSCAN-2 joint calls will contribute to the exchange of funding priorities both between funding partners, the European Commission, as well as other funding initiatives such as the Innovative Medicine Initiative (IMI), and the ESFRI research infrastructures in the biomedical sciences. As a result, a more efficient linking of the top scientists in this fast-moving field will increase the impact of these European research activities in a highly competitive situation worldwide.

TRANSCAN-2 will create added value for the construction of the European Research Area by developing strategic synergies also on a higher organisational level by establishing or further developing strong links with relevant international or European-funded collaborations and consortia, such as for instance the ESFRI Research Infrastructures projects in the biomedical sciences (e.g. EATRIS, ECRIN and BBMRI).

TRANSCAN-2 aims at the partnering and networking of 28 funding organisations from 19 countries, which in part have only recently become EU Member States (e.g. Slovenia, Slovakia, Latvia, Estonia, Romania, Hungary), and will also integrate Israel, Norway and Turkey as associated countries. Thus, TRANSCAN-2 has an integrative character for countries with different status within the EU, fully involves them in its work, reinforces their research capabilities, and provides opportunities for transnational benchmarking processes for efficient operational procedures underlying complex research programmes. As known to most TRANSCAN-2 partners from previous experience (in the first phase of TRANSCAN; in other ERA-NETs or Joint Programming Initiatives), working together on this level for a substantial period of time will shape policy-making processes taking place on the national level during this time, and will aid the development of mutual consensus in many areas relevant to the topic of TRANSCAN-2. Information exchange on existing national funding programmes and best practices will provide the prerequisites for coordinated multilateral activities, with particular regard to those areas of translational research that could most benefit from transnational coordination and collaboration. A platform will be provided to exchange information about the funded translational cancer research programmes and projects, to identify gaps, strengths and weaknesses. Based on this knowledge, synergies will be developed to fill the gaps and avoid overlapping in funding strategies, and to implement joint funding, ultimately leading to a strategic plan for national and European activities.

The thorough analysis and feedback on the implementation and results of the joint transnational calls will strongly contribute to the evolution of robust and high-quality administrative and managerial procedures for collaboration on a high professional level. The monitoring of the activities and developments of the project will contribute to improving the performance of the collaborative network and the alignment of the expectations and priorities of the TRANSCAN-2 partners with the project activities and achievements. This will in turn form a relationship between the participating funding organisations that will build a very solid platform for future cooperation, through the development of mutual understanding and trust among the partner organisations.

Breaking the barriers to multi-disciplinary collaboration and team building is key in translational cancer research. Laboratory and clinical researchers and the various operational staff should effectively work together to accelerate the translation of scientific discoveries into clinical medicine and to more rapidly fuel research directions with observational or clinical findings.

TRANSCAN-2 will contribute to the structuring of human resources in translational cancer research by supporting capacity building and training activities of multi-disciplinary research teams. In the planned joint transnational calls, specific support will be devoted to achieve this goal. This will promise cross-border synergies in the structuring of human resources, ensuring better exploitation of intellectual potential in pre-clinical and clinical translational cancer research.

The TRANSCAN-2 activities supporting capacity building, will positively impact both the quality of translational cancer research and the efficiency of the translational research process. Training of professionals with knowledge of all phases of a successful translational research process and of the best modalities for implementing those phases, is expected to result in a more rapid and efficient translational process. In addition, the promotion of programmes through which these new professionals are embedded in translational research teams, will contribute to the establishment of translational cancer research infrastructures gathering the different expertise and competences, including health care professionals, needed for the accomplishment of an “optimally” designed translational research process. In the long run, the capacity building activities are expected to accelerate the translation of scientific discoveries into novel and more effective and selective interventions in prevention, diagnosis and therapy, as well as their evaluation in the clinical setting. This in turn will more rapidly generate new research hypotheses, responding to the urgent need of fueling the “bedside-to-bench” direction of translational cancer research.

TRANSCAN-2 will have a strong positive impact on the setting up of a sustainable European network for the funding of translational cancer research by promoting integration and efficient use of resources concerning research policies.

The co-financing of translational research projects will allow the support of larger research projects and access to a larger pool of resources (biomedical resources, but also human resources) not readily available in one country. The contribution of the European Commission is very valuable because these funds can be used to

“fill the gaps” in funding capabilities of the national funding organisations contributing to the first joint transnational call, thus allowing the funding of even more of the excellent research consortia.

Furthermore, transnational collaborations have shown to be of utmost important in certain fields (like translational research) because of the complexity of the issues to be addressed. All organisations and funding agencies involved in cancer control and cancer research recognise that the development of anti-cancer interventions is a global effort and therefore it is in the interest of all to promote scientific collaboration in order to conduct high quality research.

The launching of joint transnational calls through a network of funding bodies at the European level, will allow the financial management of multinational translational cancer research projects based on the “variable geometry” principle. In this way, TRANSCAN-2 will respond to the actual need in European cancer research for integrating basic, epidemiological, preclinical and clinical research with the implementation and evaluation of interventions in prevention, diagnosis, prognosis, treatment and care. In fact, the joint transnational calls will promote not only scientific excellence, but also the achievement of the critical mass that is an absolute requirement for conducting long-term research on new preventive, diagnostic and therapeutic tools and interventions, with a comprehensive approach and a subject/patient-oriented attitude. Reaching this critical mass, in terms of scientific, intellectual, technical and financial resources, as well as of patient recruitment and coordination capacity, will greatly improve the communication between funding bodies and scientists, as well as exploit the unique strengths that Europe offers in terms of scientific quality, cancer registries, infrastructures and clinical research. The funding of multinational translational cancer research projects will also strengthen the coordination of academic clinical trials, i.e. independent clinical research. At the same time, it will release the potential for scientific discoveries and inventions to be transferred into innovative products and services capable of boosting competitiveness. Thus, TRANSCAN-2 will have a positive impact in increasing the attractiveness of Europe for the biomedical and biotechnology industry focused on the development of anti-cancer interventions. This effect will be reinforced by the interaction with IMI, the pan-European public and private sector collaboration attempting to promote the discovery and development of more selective and effective medicines, including cancer therapies.

The TRANSCAN network has been successfully set up in the last years. Work processes have evolved by critical discussions and have become more and more efficient. The network has grown due to the inclusion of new funding partners from both the public and private sector. Most importantly, through the early successes of TRANSCAN the partners have developed a very solid basis for trust building. On this basis of common understanding, the network is now working on the principle of consensus decisions in order to address the potential need to act in a flexible way in challenging situations.

Because some problems have been encountered in the build-up phase of TRANSCAN (2011 until now), and all of them have been successfully solved, we do not see any major barriers that will (negatively) influence the impact of TRANSCAN-2. Of course, some risk factors prevail, and these, and possible countermeasures, are described in section 3.2.

2.2. Measures to maximise impact

a. Dissemination and exploitation of results

TRANSCAN-2’s goals go beyond the implementation of joint transnational calls for proposals to promote cancer research, assuming the ambition to foster the creation of a European alignment on translational cancer research that can take advantage of the critical mass, the efficient use of resources and sharing of data and infrastructures that only transnational cooperation can provide. Thus, a strong communication and dissemination work package (WP5) was devised, aiming not only at strengthening the networks of collaboration between researchers, but also widening them by expanding them to other stakeholder groups, such as policy-makers, and the general public.

A communication strategy (M5.1) will serve as the basis of all outreach and networking activities, including support to WP2 and WP4 in the promotion of the calls for proposals and on identifying scientific priority topics. It will define the communication activities and tools, and devise the main messages to be conveyed to each identified stakeholder groups.

In order to promote the strengthening of a European Research Area network on Cancer Research, TRANSCAN-2 will organise scientific symposia, describe in Task 5.4, aimed primarily at the coordinators of the projects funded under the JTCs launched by the preceding TRANSCAN project and by TRANSCAN-2.

These symposia will raise scientific and public awareness on the funded projects, as researchers will be given the opportunity to show their results not only to fellow scientists, but also to the media and the general public. Also, these symposia will create the setting for stakeholders and policy makers to know the cancer research that is being developed in Europe, and take the opportunity to influence and be influenced by current research trends. As these symposia will include researchers from Europe and beyond, even from Taiwan, they will contribute to the notion of a transnational added value in cancer research, and foster the creation of new consortia and possibly of new lines of research in cancer. The results of these symposia will be disseminated through the activities foreseen in Task 5.3 so as to render as visible as possible their impact in the field of translational cancer research.

The exploitation of results from multilateral research projects initiated by joint transnational calls will require regulations concerning Intellectual Property Rights (IPR). The lessons learned and best practices developed by previous ERA-NETs and other multinational research collaborations will be transferred to TRANSCAN-2, and benchmarked templates to foster the protection of IPR within consortium agreements will be available to applicants.

b. Communication activities

The public TRANSCAN-2 website will be based on the current TRANSCAN, and will be a major tool for information sharing and dissemination of TRANSCAN-2 results. The website will be used for internal and external communication, as defined in Task 5.2, not only promoting and supporting the ongoing TRANSCAN-2 activities, but also serving as a central repository of all the historical data of the calls for proposals, funded projects and progress reports since the beginning of TRANSCAN. The public part of the website will be used for the communication of TRANSCAN-2 activities, outcomes and perspectives, and will be promoted on official websites of relevant regional/national/European institutions.

Additional outreach materials will be used to guarantee a continuous flow of information to all interested stakeholders regarding the impact of activities performed and projects funded. Information on the TRANSCAN-2 consortium's performance, on the funded projects and its results will be disseminated among the scientific community, the stakeholders and policy-makers, and the general public. This will be achieved through brochures providing information on TRANSCAN-2 as well as on the JTCs which will be launched under this project, and, if adequate, a booklet describing the major achievements of TRANSCAN-2.

Information on TRANSCAN-2 will also be periodically disseminated via NETWATCH, the ERAWATCH platform and CORDIS WIRE. Also, an e-newsletter will be published to report on the progress of TRANSCAN-2, providing information on the JTCs launched and all other TRANSCAN-2 relevant activities giving insight into new developments. The newsletter will be circulated through the TRANSCAN-2 central mailing list (based on subscription) and partners' mailing lists, and will be published on the TRANSCAN-2 website as well as on the individual websites of the funding organisations partnering in TRANSCAN-2.

As a way to reach new audiences and diversify the network of actors directly or indirectly involved in TRANSCAN-2, the participation of TRANSCAN-2 representatives in events such as the European Science and Technology Week, Researcher Nights, and similar events shall be supported as much as possible.

3. Implementation

3.1. Work Plan

The project is divided into nine work packages (WPs), each of which is structured into specific tasks (see the tables of Section 3.1).

The work plan foresees the implementation of the following interconnected activities:

- Design and implementation of the joint transnational call with EC co-funding (WP2);
- Development and update strategies for TRANSCAN-2 network functioning and for identification of scientific priority topics in translational cancer research (WP4);
- Design and implementation of three additional joint transnational calls (WP7, WP8 and WP9);

- Monitoring research projects funded within TRANSCAN-2 JTCs, including the co-funded JTC 2014 (WP3), communication and dissemination of their achieved results (WP5), as well as communication and dissemination of the TRANSCAN-2 consortium activities (WP5);
- Monitoring and assessment of the cooperation between funding agencies in the TRANSCAN-2 consortium in order to improve procedures and to identify best practices in the new ERA-NET Cofund instrument (WP6).

The integrated implementation of all above activities will be guaranteed by the management and network coordination (WP1). This strategy and structure of the work plan will lead to the achievements of the TRANSCAN-2 objectives, as explained in the following paragraphs.

TRANSCAN-2 aims at enlarging the network and improving the success of partners in future JTCs (WP4). In the past, the TRANSCAN network successfully recruited new funding organisations, including charities, allowing a significant increase in the budget allocated to research projects. Based on this positive experience, during TRANSCAN-2, the consortium aims to pursue its enlargement. Furthermore, TRANSCAN-2 will continue and improve its efforts to interact with relevant projects and stakeholders in EU and world-wide translational cancer research.

TRANSCAN-2 aims at integrating basic, epidemiological, and (pre-)clinical translational cancer research, in the context of the knowledge on the significance and impact of interventions in the area of cancer prevention, diagnosis, prognosis, treatment and care. One area identified by TRANSCAN for which the above mentioned integration is particularly instrumental is the role of intratumour heterogeneity in resistance to therapy and disease recurrence. The first TRANSCAN-2 JTC (co-funded by the EC) will focus on this area.

Furthermore, TRANSCAN-2 will continue to support European translational cancer research by identifying scientific priority topics in the field of translational cancer research (WP4). To achieve this goal, several types of activities will be undergone by the consortium: ongoing contacts of TRANSCAN-2 partners with their national scientific community; participation at scientific conferences and workshops; comparison with priority-setting at other major funding organisations; site visits of TRANSCAN-2 representatives at major European centers of expertise. Additional input will be provided by WP5, through the organisation of scientific TRANSCAN-2 symposia. All the gathered information will be presented to and discussed among the NSC, accompanied and/or followed by thorough discussions with the Scientific Advisory Board. These discussions will allow identifying candidate high priority topics for future JTCs of TRANSCAN-2 within the definition of translational cancer research adopted by the consortium.

In addition, the TRANSCAN-2 work plan will ensure the efficient implementation of the JTCs. JTC 2014 will be prepared, implemented and evaluated in compliance with the rules established by the European Commission for the ERA-NET Cofund (WP2). The Call Steering Committee (CSC) is the ultimate decision-making body for all issues related to calls: preparation, launch, implementation (incl. evaluation), monitoring, and dissemination. It is composed of funding organisations participating in the EC co-funded call.

The TRANSCAN consortium has already proven its capacity in organising and managing JTCs. Within WP7, WP8 and WP9, central call secretariats will be installed and maintained for each JTC. The secretariats will be located at MoH-ISS (Italy) for JTC 2015; at DCS (The Netherlands) for JTC 2016; and, at ACC (Italy) for JTC 2017. The call secretariats will be responsible for implementing the individual calls on behalf of the participating partners and monitoring the operational procedures applied for each call, thus ensuring feedback on their effectiveness and successive improvements of the procedures underlying the implementation of the JTCs.

TRANSCAN-2 JTCs will use an adequate electronic proposal submission and evaluation system.. Experience gained in the launch and implementation of the JTCs will be exploited in the subsequent calls.

The envisaged TRANSCAN-2 work plan will also ensure the efficient dissemination of the TRANSCAN-2 project results (WP5). The TRANSCAN-2 management and coordination unit will develop dedicated tools for the efficient and timely dissemination of project results among laboratory and clinical researchers, regulatory authorities, health professionals, patients, policy makers, and society at large. TRANSCAN-2 results will be disseminated on the TRANSCAN-2 website, through publications in peer-reviewed international journals, by supporting the operation of NETWATCH, through linking to the ERAWATCH project, CORDIS WIRE and social networks.

The proposed work plan will also allow the monitoring and evaluation of TRANSCAN-2 performance. The partners, by consensus, will define indicators and implement a review process allowing a continuous evaluation

of the TRANSCAN-2 performance with respect to partners' expectations (WP6). Furthermore, in order to increase the overall efficiency and the satisfaction of the participating funding organisations with the performance of TRANSCAN-2, the consortium will define the degree and precision of decision-making (WP4).

Figure 1: Pert diagram of TRANSCAN-2 activities





Figure 2: Gantt chart of TRANSCAN-2 activities



3.2. Management structure and procedures

The following three main governing bodies will be responsible for the TRANSCAN-2 management organisation (Fig.1): the Network Steering Committee (NSC) as the strategic decision-making body; the Network Coordination Unit (NCU) as the body responsible for the day-to-day management and the external TRANSCAN-2 consortium representation; the Scientific Advisory Board (SAB) as a continuous source of input on and feedback about the work of TRANSCAN-2.




Figure 3: Governance structure and management organisation of TRANSCAN-2

Dark blue (light blue) boxes and arrows = internal (external) structures and communication paths

3.2.1. Network Steering Committee (NSC)

The NSC will be composed by one representative from each TRANSCAN-2 partner organisation and will be responsible for strategic decisions. The coordinator will chair the first NSC meeting, at which a chairperson and a vice-chairperson will then be elected by the NSC members for a 1 year-period.

The NSC will represent the ultimate decision-making body of TRANSCAN-2 with respect to the following issues: approval of the Consortium Agreement; election of the NSC chair and vice-chair persons; monitoring of the work plan and approval of results delivered; agreement on modification of tasks and decision on corrective actions if needed; appointment and dismissal of the TRANSCAN-2 coordinator; authorisation of the timing and scope of TRANSCAN-2 (internal and external) project meetings; approval of TRANSCAN-2 dissemination activities and internal and external (for the EU Commission, for specific stakeholders, for the general public) reports; approval of high-level experts for the Scientific Advisory Board (SAB); decision on modifications of the budget distribution (if needed); approval of new partners joining the TRANSCAN-2 consortium.

The NSC will meet at least twice a year, with intermediate teleconferences in-between at occasions of busy workload. The physical meetings will be organised in rotating order by the respective NSC members, with support from the NCU.

In general, the NSC will aim at reaching consensus decisions, agreed upon unanimously by all NSC members. In exceptional cases, a decision can be taken by voting according to the simple majority principle (i.e. >50%), with all NSC partners having equal votes. There will be just one vote per country on scientific issues, independently of the number of partners belonging to the same country. However, partners from the same country but with independent research budgets can each vote on financial issues, when appropriate. If two

partners act as an "institutional couple", i.e. if they come from the same country and manage the same research budget, they will have one vote only.

Work package leaders (WPL1 to WPL9) are also members of the NSC and responsible for organising the work with other TRANSCAN-2 partners contributing to their work package. The WPL continuously report the progress of work or any problems to the coordinator who, in turn, informs the NSC.

For matters regarding joint transnational calls, decisions will be taken by the members of the Call Steering Committee (CSC), made up of those NSC members taking part in the joint call ("variable geometry" principle) and, in exceptional cases, additional partners outside the consortium which may be invited to join the call.

3.2.2. Network Coordination Unit (NCU)

The NCU will be composed of the TRANSCAN-2 coordinator, Dr. Giovanni Leonardi; the deputy coordinator and scientific coordinator, Dr. Gaetano Guglielmi; the project manager, Dr. Maria Ferrantini, and the project assistants, Dr. Silvia Paradisi and Ms. Maria Romero. The NCU will be responsible for ensuring that the objectives of TRANSCAN-2 are achieved, that the timetable is maintained and milestones met, and for proposing to the NSC corrective actions if necessary. The NCU will have also the responsibilities of informing and reporting to the NSC, the SAB, and the EC. The NCU will organise or co-organise, together with the hosting partners, the NSC meetings as well as the joint meetings of the NSC and the SAB.

The TRANSCAN-2 coordinator, Dr. Giovanni Leonardi, Director General of DG Health Research and Innovation, Italian Ministry of Health, is the contractor with the European Commission on behalf of the TRANSCAN-2 partners and thus responsible for all financial, legal and ethical issues.

The scientific coordinator and the project manager will be responsible for the overall timely management of the TRANSCAN-2 project comprising the content of the work plan, and will ensure that all relevant information is provided to the NSC in a timely fashion.

In case of problems (e.g. delays in and/or low quality of deliveries), the coordinator will describe the situation to the NSC, suggest corrective actions and ask for decisions. Another role of the coordinator is the external representation of the TRANSCAN-2 consortium at cancer research specific meetings.

Additional, more specific functions of the NCU include: preparation of the Consortium Agreement; preparation of NSC and SAB meetings (including reports); timely delivery of regular reports (both on work progress and finances) to the European Commission; communication with the European Commission, the NSC, the SAB and other stakeholders; further development of the communication infrastructure (website); contacts with non-TRANSCAN-2 countries, which consider joining the network at a later time.

3.2.3. Scientific Advisory Board (SAB)

TRANSCAN-2 members are aware of the importance of continuous feedback on recent developments and new challenges in translational cancer research from scientific experts and other stakeholders (e.g. from patients' organisations and pharmaceutical industry).

The SAB will be constituted of at least 10 and up to 15 recognised experts, including representatives of patients' organisations, not belonging to the TRANSCAN-2 consortium, and will serve the main function of providing independent information as well as assessment and advice on the TRANSCAN-2 activities. SAB members will be proposed by the TRANSCAN-2 coordinator and by the other partners and appointed on a personal basis through a consensus decision by the NSC at the start of the project, for the project lifespan.

The SAB will provide advice on strategic issues, on needs and priorities concerning the type of research projects to be funded by the joint transnational calls, including training, mobility and capacity building. Moreover, the SAB will advise the NSC on the implementation of the project.

The SAB will meet at least once a year, along with NSC meetings where important strategic decisions will be made, in particular concerning the scientific priorities for the planned joint transnational calls. If necessary, some members of the SAB with specific expertise might also be invited to specific NSC meetings or WP meetings as external advisors.

3.2.4. Call Steering Committee (CSC)

For matters regarding the preparation and/or implementation of joint transnational calls (incl. the EC co-funded call), decisions will be taken by the members of the Call Steering Committee (CSC) made up of those NSC members taking part in the joint call ("variable geometry" principle) and additional partners outside the consortium, which may join the call. CSC agreements shall usually be reached by consensus and, if not

possible, voting outcomes will follow the simple majority principle. A Joint Call Secretariat (JCS) will be set up for each joint transnational call and be responsible for all operational tasks regarding call implementation. The JCS will be the central contact point for the applicants and is responsible for organising the scientific evaluation by setting up a Scientific Evaluation Committee (SEC) and organising the SEC meeting(s).

3.3. Consortium as a whole

The consortium is made up of 32 Participants from 15 Member States, 3 Associated Countries, and a third-country. The TRANSCAN-2 consortium includes 2 countries from Northern Europe (Latvia and Norway), 4 from Southern Europe (Greece, Italy, Portugal and Spain), 5 from Western Europe (Austria, Belgium, France, Germany and the Netherlands), and 4 from Eastern Europe (Hungary, Poland, Slovakia and Slovenia) plus Israel, Turkey, and a third country (Taiwan). The countries involved provide geographical coverage throughout the European Union (EU) to the largest extent possible including new Member States and Associated Countries (Israel, Norway and Turkey), and beyond (Taiwan). Many of the participating organisations represent policy makers and dedicated funding bodies, experienced in implementing joint calls. Other countries are represented by research institutions that have in addition a funding role in cancer research, mandated by a Research and/or Health Ministry. The heterogeneity of the consortium will allow a productive sharing of ideas and experiences. All the participating organisations have committed to fulfil the TRANSCAN-2 objectives and most of them have declared their intention to try to devote part of their financial resources to support the launch of the joint transnational calls. The participation of the Ministry of Science and Technology of Taiwan in the co-funded JTC 2014 as well as in the additional TRANSCAN-2 activities will contribute to promote fruitful interactions between research groups in the EU and in Taiwan.

3.4 Resources to be committed

Table 3.3: Summary of national/regional call contributions

Participant number	Participant short name	Country short name	(a) Initial national call contribution [€]	(b) indicative possible additional national call contribution [€]	(c) Requested EU Contribution [€]	Minimum total call budget [€] (a + c)	Maximum total call budget [€] (a + b + c)
1	MoH	IT	2,010,000	990,000	990,000	3,000,000	3,990,000
2	FWF	AT	670,000	330,000	330,000	1,000,000	1,330,000
3	ISS	IT	0	0	0	0	0
4	LAS	LT	0	0	0	0	0
5	INCa	FR	1,005,000	495,000	495,000	1,500,000	1,995,000
6	BMBF	DE	2,010,000	990,000	990,000	3,000,000	3,990,000
7	DLR	DE	0	0	0	0	0
8	ARC	FR	335,000	165,000	165,000	500,000	665,000
9	GSRT	GR	500,000	0	0	500,000	500,000
10	CSO-MOH	IL	160,800	79,200	79,200	240,000	319,200
11	ACC	IT	167,500	82,500	82,500	250,000	332,500
12	ZonMw	NL	201,000	99,000	99,000	300,000	399,000
13	DCS	NL	670,000	330,000	330,000	1,000,000	1,330,000
14	RCN	NO	335,000	165,000	165,000	500,000	665,000
15	FCT	PT	217,750	107,250	107,250	325,000	432,250
16	SAS	SK	140,700	69,300	69,300	210,000	279,300
17	MIZS	SL	301,500	148,500	148,500	450,000	598,500
18	ISCIII	ES	335,000	165,000	165,000	500,000	665,000
19	TUBITAK	TR	536,000	264,000	264,000	800,000	1,064,000
20	NCBR	PL	335,000	165,000	165,000	500,000	665,000
21	FWO	BE	134,000	66,000	66,000	200,000	266,000
22	OOI	HU	0	0	0	0	0
23	NCS	NO	335,000	165,000	165,000	500,000	665,000
24	FNRS	BE	134,000	66,000	66,000	200,000	266,000
24	MIUR	IT	335,000	165,000	165,000	500,000	665,000
26	ETAg	EE	67,000	33,000	33,000	100,000	133,000
27	FICYT	ES	201,000	99,000	99,000	300,000	399,000
28	MoST	TW	-	-	-	1,000,000	1,000,000
29	VIAA	LT	201,000	99,000	99,000	300,000	399,000
30	TuscReg	IT	0	0	0	0	0
TP	TLS	IT	0	0	0	0	0
31	FRRB	IT	0	0	0	0	0
32	FCAECC	ES	0	0	0	0	0

	Total	11,337,250	5,337,750	5,337,750	17,675,000	23,012,750
--	--------------	-------------------	------------------	------------------	-------------------	-------------------

Table 3.4: Summary of Work package participation and number of years with coordination costs

Partici pant number	Short name	Participation in Work Packages									Number of years for declaring coordination costs (as unit costs)	
		A. Co-funded call and mgt	B. Additional activities									
		WP2	WP1	WP3	WP4	WP 5	WP 6	WP7	WP 8	WP9		
1	MoH	Y	Y	Y	Y	Y	Y	Y	Y	Y	5	
2	FWF	Y	N	Y	N	N	N	Y	Y	Y	5	
3	ISS	Y	Y	Y	Y	Y	Y	Y	Y	Y	5	
4	LAS	N	N	N	N	N	N	N	N	N	0	
5	INCa	Y	N	Y	Y	Y	N	Y	Y	Y	5	
6	BMBF	Y	N	Y	Y	N	N	Y	Y	Y	5	
7	DLR	Y	N	Y	Y	N	N	Y	Y	Y	5	
8	ARC	Y	N	Y	N	N	N	Y	Y	Y	5	
9	GSRT	Y	N	N	Y	N	N	N	N	N	5	
10	CSO-MOH	Y	N	Y	N	Y	N	Y	Y	Y	5	
11	ACC	Y	Y	Y	Y	Y	Y	N	N	Y	5	
12	ZonMw	Y	N	Y	Y	N	N	N	N	N	5	
13	DCS	Y	N	Y	Y	N	N	Y	Y	Y	5	
14	RCN	Y	N	Y	Y	N	N	Y	Y	Y	5	
15	FCT	Y	N	Y	Y	N	Y	Y	Y	Y	5	
16	SAS	Y	N	Y	N	N	N	Y	Y	Y	5	
17	MIZS	Y	N	Y	Y	Y	N	Y	Y	Y	5	
18	ISCH	Y	N	Y	Y	Y	N	Y	Y	Y	5	
19	TUBITAK	Y	N	Y	Y	Y	Y	N	Y	Y	5	
20	NCBR	Y	N	Y	N	N	N	N	N	N	5	
21	FWO	Y	N	Y	N	N	N	Y	Y	Y	5	
22	OOI	N	N	N	Y	N	N	N	N	N	3	
23	NCS	Y	N	Y	N	N	N	Y	Y	Y	3	
24	FNRS	Y	N	Y	N	N	N	Y	Y	Y	5	
25	MIUR	Y	N	Y	N	N	Y	Y	Y	Y	5	
26	ETAg	Y	N	Y	N	N	N	N	N	Y	5	
27	FICYT	Y	N	Y	Y	Y	N	Y	Y	Y	5	
28	MoST	Y	N	Y	N	N	N	N	N	N	0	
29	VIAA	Y	N	Y	Y	Y	N	Y	Y	Y	5	
30	TuscReg	N	N	N	Y	Y	N	N	N	N	1	
TP	TLS	N	N	N	Y	Y	N	N	N	N	1	
31	FRRB	N	N	Y	Y	Y	N	N	Y	Y	1	
32	FCAECC	N	N	Y	Y	Y	N	N	Y	Y	1	

4. Members of the Consortium

4.1. Participants

Name of organisation	<i>Ministero della Salute (coordinator)</i>		
Short name	MoH	Country	ITALY
Brief description of the legal entity			
<p>The Ministry of Health(MoH) represents the central level of the Italian National Health Service and is responsible for overall planning and control and to establish the Italian NHS targets and most important measures to be implemented.</p> <p>The Ministry is the leading body of the national information system on health, which includes data on hospital admission and health interventions; the Ministry is also responsible for the overall coordination of Prevention Programmes, including those for elderly and disabled people, in particular correct life-style promotion, surveillance of chronic diseases and c.d. risk factors, promotion and surveillance of secondary prevention. The Ministry is entitled of the resource management of operational Health research, and it is also the Governing body for the legislation on Medical Devices and Health Professionals. The participating Directorate General for Research and Innovation in Health performs, among others, the following functions:</p> <ul style="list-style-type: none"> • promotion, development, monitoring and evaluation of results of scientific and technological research in the health field and of experimental processes for innovation; • financing and public-private co-financing of research in health; • promotion of and support to the creation of highly specialized and technologically advanced networks of excellence for research and assistance; • promotion and coordination of health research activities of high quality and impact in the European context; • participation in the activities of international and supranational organisations in the field of health research, with support to the establishment of research infrastructures of European dimension in adherence to the programs of the European Union. <p>Website: http://www.salute.gov.it/</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			Y
Programme Manager			Y
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>The Ministry of Health is the main public body funding biomedical research and biomedical innovation in Italy. As a strategic health policy instrument, the Italian the Ministry of Health runs two types of funding programmes in the fields of biomedicine: one on current research and another on targeted research. Current research funding is available to Scientific Institutes of Research, Hospitalisation and Healthcare, whereas the targeted research funding is open to all researchers of the National Health System. Both programmes constitute priority initiatives for the improvement of the population's health through the rapid translation of research results into new or improved preventive, diagnostic, and treatment products and processes, and incorporation into health policies and practice.</p>			

In the period 2011-2012, in line with what was implemented in previous years, efforts were made to ensure transparency and competitive research with a call for proposals for "Targeted Research and Young Researchers 2011-2012". Within the framework of such programme, the Italian Ministry of Health allocated a total funding of about 135 Mio. €.

By means of the Ministry of Health research funding vital synergies between public research and private research, including national research and research within and outside Europe are strengthened.

The Ministry of Health is involved in multiple European projects in support of research. In particular, it is involved in a series of ERA-NETs (TRANSCAN, NEURON, E-RARE, PerMed). It is also committed to supporting EU projects on the development of the European Strategy Forum on Research Infrastructures (ESFRI) in the health research sector (ECRIN, ETRIS, BBMRI). It is engaged in the CSA PerMed and Joint Programming initiatives (JPND and JPMYBL).

Main tasks attributed the proposed action and the previous experience relevant to those tasks

MoH, together with ISS, will be leader of WP1 (Management and coordination), of WP2 (Preparation and implementation of the co-funded call), and of WP7 (Preparation and implementation of a second joint transnational call). In addition, MoH will participate in all the other work packages.

Short profile of staff member(s) who will be undertaking the work

Dr. Giovanni Leonardi is the Director General of DG for Health Research and Innovation of the Italian Ministry of Health (coordinator).

Dr. Gaetano Guglielmi is the Head of the Office of Health Research, DG for Health Research and Innovation. He represents the Italian Ministry of Health in all EU initiatives in which the DG for Health Research and Innovation is involved.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules

Contribution to the TRANSCAN-2 co-funded call: 3M€.

Information on the funding rules applied by MoH can be found on the website page dedicated to the yearly national calls (*Bando ricerca finalizzata e giovani ricercatori*).

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Austrian Science Fund</i>		
Short name	FWF	Country	AUSTRIA
Brief description of the legal entity			
<p>The Austrian Science Fund (FWF) is Austria's central funding organisation for basic research. The FWF supports the ongoing development of Austrian science and basic research at a high international level. In this way, the FWF makes a significant contribution to cultural development, to the advancement of our knowledge-based society, and thus to the creation of value and wealth in Austria. FWF's objective is to strengthen Austria's international performance and capabilities in science and research as well as the country's attractiveness as a location for high-level scientific activities, primarily by funding top-quality research projects for individuals and teams and by enhancing the competitiveness of Austria's innovation system and its research facilities. The FWF develops Austria's human resources for science and research in both qualitative and quantitative terms based on the principle of research-driven education. The FWF emphasizes and enhances the interactive effects of science and research with all other areas of culture, the economy and society, and in particular to increase the acceptance of science and research through concerted public relations activities. FWF's annual funding budget in 2013 was 202.6 Mio EUR.</p> <p>Website: https://www.fwf.ac.at/en/</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			N
Programme Manager			N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>One of the key objectives guiding the FWF's activities at the international level is to enhance Austria's international visibility as a research location. The FWF's international programs include a variety of funding instruments which are essentially designed to support bilateral and multilateral research projects as well as international networking.</p> <p>Since 2003 the FWF participated in more than 100 international bilateral and multilateral calls, among those around 40 ERA-Net Calls. The funding volume for international programs in 2013 amounted to 15.8 Mio EUR.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>Based on the previous experience FWF will actively contribute to the activities related to the joint calls. The FWF's Department of Biology and Medicine actively participate(d) in the following ERA-NETS: E-Rare, E-Rare-2, TRANSCAN, EUROPOLAR, ERA-CAPS, Pathogenomics, Infect-ERA, NEURON I and II, BIODIVERSA 1 and 2, ERASynBio and New Indigo.</p>			
Short profile of staff member(s) who will be undertaking the work			
<p>Stephanie Resch: diploma and PhD in Microbiology and Genetics. Co-founder and R&D manager in a biotech company focusing on the development of vaccine (Germany, USA). Head of the Department of Biology and Medicine at the FWF since 2005. Participating in different ERA-Nets (E-RARE, TRANSCAN, NEURON).</p> <p>Iris Fortmann: diploma in Biology. Program manager at the FWF, employed since 2006. Participating in</p>			

different ERA-Nets (E-RARE, TRANSCAN, NEURON, BiodivERsA, ERASynBio).	
Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.	
Contribution to the TRANSCAN-2 co-funded call: 1M€.	
Information on the funding rules applied by FWF can be found at http://www.fwf.ac.at/en/research-funding/application/international-programmes/joint-projects-era-nets/	
Does the participant envisage that part of its work is performed by a linked third parties.	N
<i>If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party</i>	
Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
<i>If yes, describe the third party and their contributions</i>	

Name of organisation	<i>Istituto Superiore di Sanità</i>		
Short name	ISS	Country	ITALY
Brief description of the legal entity			
<p>The Istituto Superiore di Sanità (ISS) is the leading technical and scientific body of the Italian National Health Service. Its activities include research, clinical trials, control, and training. It also serves as a major national clearing house for technical and scientific information on public health-related issues. The ISS is the national competent authority for the authorisation of Phase I clinical trials. The ISS, where required by the Italian Ministry of Health and for specific purposes, acts as a funding agency to support scientific programs of national relevance and to promote the Italian participation in international activities. The ISS promotes scientific research in a wide variety of fields of special relevance for public health, and in particular, basic, translational and clinical research in major disease areas, including cancer, and neurological, infectious and rare diseases. Research priorities are based on those set forth in the National Health Plan. In the year 2006, the ISS was appointed by the Italian Ministry of Health as coordinator of the National Program for the funding of major research projects, including translational research, in the context of Alliance against Cancer (ACC), the Italian Scientific Institutes for Research and Care (IRCCS) network in the oncology field. The ISS is also involved in Phase I-III clinical trials, which are frequently conducted in cooperation with the IRCCS and Hospitals. The ISS has been a partner in the Eurocan+Plus, and participates in the ERA-NETs E-RARE (for research programs on rare diseases) and PRIOMEDCHILD (Coordination of research on priority medicines for children Medicines). The ISS participates also in the article 169 EDCTP. The ISS is currently involved in the ESFRI BMS research infrastructures EATRIS, BBMRI, and ECRIN-PPI.</p> <p>Website: http://www.iss.it/</p>			
Identification of the role:			
Programme Owner and Manager			N
Programme Owner			N
Programme Manager			Y
In case you are a Programme Manager, please name the respective Programme Owner			
The respective Programme Owner is the Italian Ministry of Health.			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>The ISS is the main body of the Italian National Health Service for the research support, control and scientific-technical advice in public health. In this context, the ISS acts, upon mandate of the Italian Ministry of Health (MoH), as promoter of networking activities of the National Health Service (NHS) in translational oncology. Said networking activities aim at improving the efficiency and quality of the research in translational oncology at national level as well as at harmonising procedures related to the provision of services by research infrastructures of the NHS.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>ISS will be responsible together with the MoH for the coordination and management of the TRANSCAN-2 consortium and activities (WP1), for WP2 (Preparation and implementation of the co-funded call), and for WP7 (Preparation and implementation of a second joint call). In addition, the ISS will participate in the implementation of all the other work packages activities.</p>			
Short profile of staff member(s) who will be undertaking the work			
<p>Dr. Maria Ferrantini Biologist, former Head of the Section of Experimental Immunotherapy of the Dept. of Cell Biology and Neurosciences of the ISS, and presently Senior Investigator in the Department of Haematology, Oncology and Molecular Medicine of the ISS, has an extensive research experience in the field of cancer immunology and immunotherapy. Since 2007, Dr.Ferrantini has been actively involved in the preparatory phase</p>			

of the ESFRI BMS research infrastructures ECRIN and EATRIS. Dr. Ferrantini is at present the Chair of the Board of Governors of the EATRIS ERIC, where she represents the Italian governmental partner. Since 1 January 2011, Dr. Ferrantini serves as Project Manager of the ERA-NET on Translational Cancer Research TRANSCAN, funded by the European Commission under the 7th Framework Programme and coordinated by the Italian Ministry of Health.

Dr. Silvia Paradisi Biologist, is a researcher with over 25 years of experience on the fields of cell biology and neurosciences. In June 2011, she joined Network Coordination Unit of the ERA-NET on Translational Cancer Research TRANSCAN.

Maria Romero, has a bachelor's degree and postgraduate courses in business administration. She has extensive professional experience in working with international projects. She has served as Project Manager Assistance of the ERA-NET on Translational Cancer Research TRANSCAN, funded by the European Commission under the 7th Framework Programme and coordinated by the Italian Ministry of Health.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Not applicable as the ISS will not contribute financially in the TRANSCAN-2 co-funded call.

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Latvijas Zinatnu Akademija - Latvian Academy of Sciences (Terminated)</i>		
Short name	LAS	Country	LATVIA
Brief description of the legal entity			
<p>The Latvian Academy of Sciences (LAS) is the institution under the authority of the Ministry of Education and Science (MoES). The main tasks of the LAS are the favouring research in the basic and applied sciences, especially the interdisciplinary research; promoting studies in Latvian history, culture and the development of the Latvian language; active participation in the establishing Latvian science policy and consultation of the Government on scientific issues; care about publishing of scientific literature, organisation of congresses, conferences, discussions, and competitions, popularization of scientific achievements and history of Latvian sciences; maintenance of international contacts of Latvian scientists; protection, maintenance, and perfection of research ethics, discussion principles, and traditions.</p> <p>As regards organisation of science, the LAS is involved in the designing of Latvian science strategy as well as in the evaluation and monitoring of the Latvian national research programmes and projects. Under the supervision of the MoES the LAS is involved in the management of certain national research programmes related to the research priorities which have been approved by the Government. MoES has delegated LAS (Agreement from 01.02.2008) to implement the ERA-NET/ERA-NET+ projects of FP7 in Latvia.</p> <p>Website: http://www.lza.lv/index.php?mylang=english</p>			
Identification of the role:			
Programme Owner and Manager			N
Programme Owner			N
Programme Manager			Y
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>Latvian Ministry of Education and Science. Programme covers international scientific collaboration of Latvian Scientific institutions and companies. http://likumi.lv/doc.php?id=249571.</p> <p>LAS has been involved in the implementation of 23 FP7 projects. Currently LAS participates in the following ongoing ERA-NET projects: Ruragri, ICT-Agri, CHIST-ERA, ERACAPS, Wood-WidomNet+, EuroNanoMed2, Transcan, NEURON II, ERASynBio, ERASysAPP, Matera+, M-ERA.NET and BiophotonicsPlus. Besides, LAS represents national government also in European Joint Initiatives (ARTEMIS, IMI), in COST, EUREKA, Eurostars and BONUS (Baltic Sea Research) programmes. Associated partner – E-RARE II.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>LAS will participate in the implementation of the co-funded call (WP2) and also of the additional TRANSCAN-2 joint calls. In addition, LAS will contribute to WP3, WP5 and WP4, in which will co-lead with FCT the Task 4.2 (Strategy on improving partners' success in JTCs) and will participate in Task 4.3 (Strategy on improving the decision-making) and Task 4.5 (Strategy on identifying scientific priority topics).</p>			
Short profile of staff member(s) who will be undertaking the work			
<p>Dr Maija Bundule is the Director of European Programmes Centre, the managing entity for ERA instruments in Latvia, including all ERA-NETs. Maija has a PhD in biology.</p>			

Dr Uldis Berkis, Expert, LAS. Participates in management of Latvian participations since 2007. Managed of Latvian involvement in PRIOMEDCHILD, TRANSCAN, NEURON-II. Has been working at the Riga Stradins University for 24 years, in teaching and administrative positions. He has a PhD in Health Economics/Health Informatics. he is also NCP and PC member for H2020 SC1.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

EU Regulation 800/2008. Meaning public bodies – scientific institutions have 100% support, companies – 75%. Contribution to the TRANSCAN-2 co-funded call: 0.3M€.

Information on the funding rules applied by LAS can be found at <http://www.lza.lv/images/stories/ESdok/Nosac%20Eranet%20Konk.pdf>

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Institut National du Cancer</i>		
Short name	INCa	Country	FRANCE
Brief description of the legal entity			
<p>INCa, France' National Cancer Institute, is the pre-eminent health and science agency dedicated to cancer control. INCa has been created under the Public Health Act of 9 August 2004 and empowered with a national coordination mandate. INCa supports the full spectrum of activities that have value in a comprehensive cancer control strategy and ensures the timely implementation of the national cancer control plans. INCa is attached to both the Ministries of Health and of Research. As per its mandate, INCa activities cover all areas of cancer control: public health, care & patient's life, research, information to people and professionals.</p> <p>INCa conducts studies and surveys, develops recommendations and guidelines, implements national coordinated programs and supports research projects following open and competitive calls for proposals.</p> <p>Website: http://www.e-cancer.fr/en</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			Y
Programme Manager			Y
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>INCa supports national research projects following open and competitive calls for proposals in 4 main research areas: cancer biology (15M€ in 2013), clinical research (20M€ in 2013), translational research (10M€ in 2013), and human, social & economic sciences (5M€ in 2013), including public health, epidemiology and prevention. INCa is also instrumental in the development of shared biological resources and databases, and sponsors large clinical trials such as the PHARE or the SIGNAL trials. INCa's annual budget dedicated to cancer research amounts to about 50 M €. Since 2007, INCa has specific and recurrent funding programs devoted to translational research, including training & educational grants.</p> <p>INCa is involved in international consortia. As way of example, INCa is a founding member of the International Cancer Genome Consortium (ICGC) and the French representative in its executive committee. INCa contributes to the ICGC global effort and funds 4 research projects.</p> <p>INCa has participated / is participating in a number of European Consortia. INCa was the coordinator of CoCanCPG (Coordination of Cancer Clinical Practice Guidelines in Europe) a coordinated action funded under the 6th Framework Programme. INCa has also been involved in the EC funded Eurocan+ project, in BBMRI (Biobanking and Biomolecular Research Infrastructure) a European wide project which aims at constructing a pan-European Infrastructure of biological & bio-molecular resources, in the collaborative project Basis (Breast cancer somatic genetics study), in the joint action EPAAC (the European partnership for actions against cancer) as co-leader for the research WP. INCa is currently involved in the Eranet TRANSCAN (as leader of the Training WP), the new joint action CANCON (aiming at the development of European guidelines for quality improvement in cancer control (as WP8 leader on survivorship & rehabilitation), in the CSA PerMed (a concerted and support action in personalized medicine).</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>INCa will be contributing to the Co-fund call for research proposals with 1.5M€ and is expected to contribute to the following TRANSCAN 2 Joint Calls with an equal level of funding.</p>			

INCa will be co-leader with MoH-ISS of WP2 task 2.2 (preparation and launch of a joint transnational call with EC co-funding) and leader of task 2.1.1 (topic selection of the co-funded call), and of subtask 2.3.3 (appointment of an observer for the two-step evaluation). In addition, INCa will be leader of WP4 and of task 4.4 (strategy on interactions with different projects and stakeholders) and task 4.5 (strategy on identifying scientific priority topics), and will contribute to most work packages.

Short profile of staff member(s) who will be undertaking the work

Frédérique Nowak is currently Head of the Department of Biology, Transfer and Innovations at the Institut National du Cancer (INCa), France

After a master in bioengineering from the EcoleCentrale of Paris, France (1992), Frédérique Nowak started her career at the Institut Gustave Roussy, a pre-eminent comprehensive cancer center in Villejuif, France, where she got a PhD in Molecular Pharmacology in 1996. After her PhD, she joined Genset, a biotechnology company, where she has been project manager for innovative projects in high-throughput molecular cytogenetics. Between 2002 and 2006, she was responsible for a R&D team at the Serono Genetics Institute of the Serono pharmaceutical company in Evry, France.

Christine Berling is currently Head of Department – International Affairs, at the National Cancer Institute (INCa), France.

M.Sc. in Physics, PhD in Biophysics, C. Berling has over 15 years' experience of working in public-private partnership and technology licensing, initially with the French National Institute of Health and Medical Research and subsequently at the European Commission, DG RTD Health Directorate, during the setting up of the Innovative Medicine Initiative Joint Undertaking, a partnership between the European Commission and the European Federation of the Pharmaceutical Industry Associations. C. Berling has also some experience of working in the area of development research with low and medium income countries.

Estelle Gerbaud is currently responsible for the program in translational cancer research at the Institut National du Cancer (INCa), France.

After a diploma in Pharmacy (2004) from the University of Nantes including a 8-month training period in Pierre Fabre research labs, Estelle Gerbaud started her career at the Nantes University Hospital where she was project manager for translational research projects in biotherapy (cellular and gene therapy and transplantation) between 2005 and 2008. Then she joined TcLand Expression, a small biotechnology company in Nantes, developing blood tests based on gene expression biomarkers for transplantation and auto-immune diseases. She was in charge of setting up and implementing European studies for the validation of the biomarkers.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Expected contribution to TRANSCAN-2 per call for research proposals: 1.5M€.

Information on the funding rules applied by INCa can be found at <http://www.e-cancer.fr/linstitut-national-du-cancer/subventions/attribution-apres-le-1er-janvier-2014>

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Federal Ministry of Education and Research</i>		
Short name	BMBF	Country	GERMANY
Brief description of the legal entity			
<p>Education and research are priorities of the German Government. By means of special research funding programmes, which are executed by public competitive calls and peer-review evaluations, the Federal Ministry of Education and Research is supporting innovative research projects in various sectors; e.g. in basic sciences, sustainable development, information and communications technologies, life sciences, chemistry and materials science, transport or space research.</p> <p>Website: http://www.bmbf.de/en/</p>			
Identification of the role:			
Programme Owner and Manager			N
Programme Owner			Y
Programme Manager			N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>The Federal Ministry of Education and Research deals with all central research areas in the life sciences. Health research is dedicated to the molecular basics of health and illness. It aims to develop effective preventative strategies and efficient treatments. Focuses include nutrition research, the individualization of medicine, questions regarding the care of people who are ill or need long-term medical support, and the innovative capacity of the health industry.</p> <p>Within health research, research on cancer is a main focus (with approximately 160 Mio. € per year). In Germany, one important pillar of cancer research is represented by the “German Cancer Research Centre” in Heidelberg, which receives most of its institutional funding from the BMBF. In addition, one of the new German Centres for Health Research, the “German Centre for Translational Cancer Research”, is dealing with the same issues as TRANSCAN. Other research centres are also funded by BMBF and provide major contributions to clarifying the causes of cancer and developing new therapies.</p> <p>The “Health Research Framework Programme of the Federal Government” defines the strategic targeting of health research funding in the coming years. The new German Centres for Health Research are to more closely link competencies, disciplines and institutions, so that research findings will reach patients more quickly in the future.</p> <p>The development of innovative concepts is at the heart of bioeconomy: concepts for securing food supply and for the use of renewable resources and biotechnological processes which respect the environment, climate and resources. With the National Research Strategy BioEconomy 2030, the BMBF is striving for a natural cycle oriented bio-based economy. The new approaches in life sciences - their benefits and risks - are being discussed by the general public. In order to be able to base decision-making on comprehensible facts and rational arguments, the BMBF supports scientific research projects on the ethical, legal and economic aspects of health and bioscientific research.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
BMBF will make available the financial contribution to the TRANSCAN calls for proposals (including the EC co-			

funded call). BMBF and PT-DLR will function as an "institutional couple" in TRANSCAN (see description of partner DLR).

Short profile of staff member(s) who will be undertaking the work

Joachim Klein: PhD in Biology. Officer at the Division 'Health Research' at the Federal Ministry of Education and Research. Among other duties, responsible for developing, implementing and monitoring strategies for cancer research in Germany.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Not applicable (i.e. there is no maximum amount of financial support to a third party). In ERA-NETs, as a rule of thumb, the amount of financial support should not exceed around 250.000 to 300.000 € for a 3-year project (in order to guarantee the funding of about 10-15 research proposals).

Contribution to the TRANSCAN-2 co-funded call: 3M€.

Information on the funding rules applied by BMBF can be found at <http://www.bmbf.de/foerderungen/677.php>

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Project Management Agency in the German Aerospace Centre</i>		
Short name	DLR	Country	GERMANY
Brief description of the legal entity			
<p>The Project Management Agency in the German Aerospace Centre (DLR) is a non-governmental, non-profit research funding organisation for the promotion of the sciences. It is mandated by the Federal Ministry of Education and Research (BMBF), other Federal Ministries and institutions for the implementation of programme-related project funding. In this regard, DLR is responsible for the administration of a funding budget of approximately 1 billion € per year and involved in a variety of research fields – amongst others: information technology, education research, environment and life sciences. Bearing in mind the necessity and the importance of research and development for the science and business location Germany, the DLR is committed to the interests of the community.</p> <p>Within life sciences, the health research department of DLR promotes biomedical, pre-clinical and clinical research, administrating an annual budget of about 222 million € (within the Health Research Framework Programme of the Federal Government).</p> <p>In TRANSCAN, DLR and BMBF will function as an "institutional couple": decisions on political, strategic and budgetary issues are taken by the BMBF, and DLR will speak and act according to these decisions. BMBF will not be a grant receiving partner in TRANSCAN, but will be involved in all decisions and agreements.</p> <p>Website: http://www.dlr.de/pt/en/desktopdefault.aspx/tabid-4270/6848_read-6936/</p>			
Identification of the role:			
Programme Owner and Manager			N
Programme Owner			N
Programme Manager			Y
In case you are a Programme Manager, please name the respective Programme Owner			
BMBF			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>Cancer research is one focus of PT-DLR project funding on behalf of BMBF, and about 30 million € per year are dedicated to various specific funding measures that usually comprise nation-wide interdisciplinary research networks. These national activities are flanked by a growing number of international measures such as the "International Cancer Genome Consortium" (ICGC), in which three German funding consortia funded by BMBF and the German Cancer Aid will analyse genomic changes in pediatric brain tumours, early-onset prostate cancer and lymphoma. Another example was the Eurocan+Plus project, an EC-funded (FP7) feasibility study on improving the coordination of cancer research in Europe consisting of both researchers and funders in which BMBF/PT-DLR were leading a group of funding organisations (see below).</p> <p>The health research department of PT-DLR is currently acting as coordinator of the ERA-NET NEURON, and has participated / is participating in a number of other health research related ERA-NETs (e.g. TRANSCAN, E-Rare, ERA-AGE, ERA-SAGE) and Joint Programming Initiatives (JPND, HDHL). Other departments of PT-DLR are coordinating / participating in many other ERA-NETs (e.g. international bureau of the BMBF, ICT), and there are regular meetings dedicated to discuss experiences with the various ERA-NETs. PT-DLR, on behalf of BMBF, has been involved in the EC-funded Eurocan+Plus project, leading a WP that examined possible ways of improving cooperation between European cancer research funding organisations (one result of this group of funding organisations was the establishment of TRANSCAN in 2011).</p>			

PT-DLR manages a large and growing number of transnational calls, both within and outside of ERA-NETs and JPIs, on behalf of the BMBF, and is serving as call secretariat for many of them. Relevant know-how is pooled and shared, and very experienced personnel is available.

Main tasks attributed the proposed action and the previous experience relevant to those tasks

PT-DLR and BMBF will participate in the implementation of the co-funded call(WP2)as well as of the TRANSCAN-2 additional joint calls.. Furthermore, PT-DLR and BMBF will contribute to WP3 (Follow-up and monitoring of projects resulting from the co-funded JTC 2014 and the TRANSCAN-2 JTCs)andWP4 (Strategy: network and scientific priorities).

Short profile of staff member(s) who will be undertaking the work

Hubert Misslisch: diploma and PhD in Biology, habilitation in Neurobiology. Research in neurophysiology: visual-vestibular interactions and cortical electrophysiology. Scientific officer at the PT-DLR since 2001. Coordinator of health research related ERA-NET activities since 2003. Responsible for the administration of national cancer research networks. Participant in the ERA-NET for research programmes on rare diseases, E-Rare. Within Eurocan+Plus, responsible for the WP on improving the coordination between EU cancer research funding organisations. In the first phase of TRANSCAN, leader of the PT-DLR team and elected (four times) chair of the Network Steering Committee.

FalkoDrews:biologist, obtained his PhD in Biochemistry and conducted post-doctoral research in signalling pathways. Scientific officer at the PT-DLR since 2009. Responsible for the administration of national cancer research and health economic networks. He also supports since several years the German Health Ministry by the further development and implementation of the National Cancer Plan. In the first phase of TRANSCAN, manager of the first joint call secretariat and advisor for the following call secretariats.

Akin Akkoyun: received the PhD degree in Biotechnology and has worked for several years in the field of Biosensors and Analytical Chemistry. He is scientific officer at PT-DLR since 2007. Up to June 2013 he was in charge for promotion of scientific cooperation between German and Turkish institutions and for the BSERA.NET, a project aiming to develop, coordinate and strengthen scientific cooperation in and with the Black Sea region. Next to his duties in TRANSCAN, he is now focusing on global health issues such as neglected and poverty related diseases, German-African Health network and Product Development Partnerships.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Not applicable.

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Fondation ARC pour la recherche sur le cancer</i>		
Short name	Fondation ARC	Country	FRANCE
Brief description of the legal entity			
<p>The ARC Foundation for cancer research is a key player in oncology research in France. With excellence and innovation at the heart of its scientific policy, it contributes to obtaining decisive results that lead to better understanding, prevention and curing of this illness. Part of this mission is the dissemination of cancer-related knowledge, which is an indispensable lever in the fight against cancer.</p> <p>Since its creation as an association in 1962, the ARC (French acronym for: Cancer Research Association) has been a forerunner in the operation and financing of oncology research. In 2012, in order to meet the new research challenges, the ARC decided to become a foundation, namely the ARC Foundation for Cancer Research.</p> <p>Its recognition as a public interest foundation allows it to mobilize significant resources in response to the changing needs of research, and to identify, select, finance and implement programs that are both innovative and experimental, while strengthening the partnerships established with associations and institutions working in the field.</p> <p>Through its actions, the ARC Foundation is increasing its national and international influence and strengthening its support for research.</p> <p>Each year, the ARC Foundation devotes nearly €30 million to cancer research. In the last 10 years, it has contributed to the funding of more than 6400 projects, for a total of €273 million. Without the benefit of public subsidies, its actions rely on the generosity of its donors and testators.</p> <p>Thanks to the innovative nature of its calls for projects and its involvement with establishments at the cutting edge of research, the ARC Foundation has far-reaching influence and is decisively contributing to the direction of French cancer research. In particular, it encourages promising projects by supporting strategic investments.</p> <p>Moreover, as part of its desire to pool oncology research efforts, the ARC Foundation is developing international partnerships. The support for translational research results in the ARC Foundation's participation in the European TRANSCAN network.</p> <p>Website: http://www.recherche-cancer.net/</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			N
Programme Manager			N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
ARC has funded JTCs in the framework of the ERA-NET on Translational Cancer Research TRANSCAN.			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
Fondation ARC will participate in the implementation of the co-funded call (WP2) as well as of the TRANSCAN-2 additional joint calls. In WP2, ARC will co-lead together with MoH-ISS the subtask 2.3.6 (Evaluation of full proposals and ranking list of proposals recommended by the SEC). In addition, ARC will			

contribute to WP3 (Follow-up and monitoring of projects resulting from the co-funded JTC 2014 and the TRANSCAN-2 JTCs) and to WP9, in which it will be co-leader of subtask 9.1.2 (Preparation of the JTC 2017) together with ACC.

Short profile of staff member(s) who will be undertaking the work

Franck Dufour: Ph D in Neurochemistry, 10 years in academic scientific research in France, Poland, and the US working on Epilepsy, Alzheimer disease, and cerebral plasticity. 10 years in science management and policy at UNESCO, then as scientific director in a patient organisation: funding management, coordination of national and international scientific networks, communication. Currently, acting as scientific director of the ARC Foundation.

Nancy Abou-Zeid: PhD in Biology, training in clinical research. Focus on cancer cell migration processes and oncology clinical trials management. Head of Translational research and innovation at the French ARC Foundation for cancer research since 2011. Responsible for national calls in cancer research and project funding partnerships. In charge of the TRANSCAN network for the ARC Foundation.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Contribution to the TRANSCAN-2 co-funded call: 0.5M€.

Information on the funding rules applied by ARC can be found at <http://www.recherche-cancer.net/financements/notif>. The specific funding rules for TRANSCAN projects fit in the “Programmes labellisés” category, and are included in the contracts signed with the researchers

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>General Secretariat for Research and Technology</i>		
Short name	GSRT	Country	GREECE
Brief description of the legal entity			
<p>The General Secretariat for Research and Technology (G.S.R.T.) is the main policy maker and programme owner concerning the RDI system in Greece. G.S.R.T.'s policy is implemented through operational programmes. The new programme covering the period 2014-2020 is currently under finalization. Through its programmes, it supports the research activities of both the country's scientific research institutes and those of its productive industry, focussing on areas that are important for the national economy and for the improvement of the quality of life; it contributes to the reinforcement of the country's research manpower; it represents Greece in relevant institutions of the European Union, thus bringing the country's research and technology activities into line with the requirements of the international community; it promotes bilateral and multilateral cooperation with other countries and international organisations on research and technology issues; it supervises and provides support for 11 of the country's best-known research and technological centres; it encourages activities aimed at raising awareness of the general public about research and technology issues. G.S.R.T employs about 150 well qualified staff, among them a lot of scientists. Furthermore, it is supported by external collaborators, the members of the National Advisory Council for Research and Technology and other experts from Greece and abroad. G.S.R.T. has been involved in 40 EU programmes (ERANETS, ERANET PLUS, INCO-NET, OMC-NET type of projects) in the context of FPs and has a considerable experience being a full partner in geographic and thematic ERA-NETs either as co-ordinator and/or work package leader. In this context, it has contributed in the design and implementation of Joint Calls and has funded 43 joint projects in the frame of 17 joint calls of the abovementioned programmes with an approximate amount of 7M€.</p> <p>Website: http://www.gsrt.gr/central.aspx?sId=119I428I1089I323I488743&JScript=1</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			Y/N
Programme Manager			Y/N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
Not applicable.			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>The GSRT will contribute to the implementation of the co-funded call (WP2) and will also actively participate in WP4 (Strategy: network and scientific research priorities) in all tasks. It currently participates in the ongoing TRANSCAN ERANET and at national level, within the period 2004-2009, it has funded health research projects with a total budget of 20M€.</p>			
Short profile of staff member(s) who will be undertaking the work			
<p>Paraskevi AFENTAKI's main studies are on European Civilization in the Hellenic Open University of Greece. She was employed by the GSRT in 1992, in the European Union Division / International Scientific & Technological Cooperation Directorate, for the diffusion of the 3rd, 4th and 5th Framework Programmes for RTD to the scientific and research community. She was the National Contact Point for TMR, IHP, HRM programmes and the national representative for programme "PEOPLE". Since 2004 she has been nominated in a number of</p>			

ERANET, INCONET and OMC-NET projects. Since 2011, she is responsible for the project management of the Joint Calls in the Bilateral Relations Division, in the frame of ERANET and ERA-NET PLUS programmes and she supports the Joint Calls as a contact person.

Danai's FARMAKI main studies are on Business Administration and owns a master degree in Public Policy and Administration from Athens University of Economics and Business. She was employed by the GSRT in 2010 in the Evaluation and Monitoring Programs Division/ Supervision of Research Institutions Directorate and was responsible for Inclusion of new projects of the European Territorial Cooperation, Digital Convergence and Administrative Reform. She was in the management of their performance, funding process, total of 16 projects. As well participated at the management of the at Unit-CORALLIA of R.C. Athena Indirect finance, credit monitoring and enforcement actions required for 5 projects integrated in NSRF.

From October of 2013 she works at the European Union Division / International Scientific & Technological Cooperation Directorate Monitoring of 3rd Tender joint initiatives JUs (Joint Undertaking) "ARTEMIS" (Embedded Systems) & "ENIAC" (Nano): management of national notices for funding the participation of Greek beneficiaries in the works of the above "JUs"; Editors relevant Resolutions finance & Contracts between Beneficiaries and GSRT/ Monitoring and overseeing the development of a total of 17 projects and Participating in the organisation of events of the GSRT under the Greek Presidency.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Not applicable.

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Chief Scientists Office, Ministry of Health</i>		
Short name	CSO-MOH	Country	ISRAEL
Brief description of the legal entity			
<p>The Chief Scientist Office (CSO) of Israeli Ministry of Health (MOH) through its Medical Research Administration is a pivotal organisation in Israel for managing and funding of bio-medical and medical research.</p> <p>Our strategic approach is to support investigator-initiated, health-related research projects performed in hospitals, universities and research institutes.</p> <p>Grant proposals sent in response to public Calls for Applications issued by the Research Fund, are peer reviewed in various research-disciplines review committees (Study Sections). Funding of feasibility studies and fellowships to Physicians-Researchers is also available. CSO-MOH is also mandated to regulate animal experimentation, genetic human experimentation and homeland security aspects of biomedical research in Israel.</p> <p>Websites. CSO: http://www.health.gov.il/English/MinistryUnits/PH/Scientist/Pages/default.aspx MOH: http://www.health.gov.il/english/Pages/HomePage.aspx</p>			
Identification of the role:			
Programme Owner and Manager			N
Programme Owner			Y
Programme Manager			N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
CSO-MOH has funded JTCs in the framework of the ERA-NET on Translational Cancer Research TRANSCAN.			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>CSO-MOH is a partner in several active ERA-NETs and JPIs besides E-RARE: EuroNanoMed2, Infect-ERA, TRANSCAN, SIINN, ERA-NET NEURON II and JPIAMR and JPIND. As leading the issue of communication/dissemination and on Science to Society in the previous ERA-PathoGenoMics and ERA-Neuron and the current EuroNanoMed, Neuron II and Infect-ERA and as task leaders of social media in the JPIAMR, we maintained an interactive teaching tool, produced short explanatory video clips, flyers, newsletters, brochures and press releases in addition to constructing and maintaining Facebook and LinkedIn pages. Dissemination was carried out nationally and internationally, by active presentations in meetings, stakeholders mailing lists and electronic portals (e.g. business wire).</p>			
Short profile of staff member(s) who will be undertaking the work			
<p>Prof. Avi Israeli, MD, is the Chief Scientist at the Ministry of health. He is a specialist in internal medicine and the current head of the Department of Health Policy, Health Care Management and Health Economics at the Hebrew University– Hadassah Faculty of Medicine. Prior to this he was the Director General of the Israel Ministry of Health (2003-2009) and the Director – General of Hadassah Medical Organisation (1998 -2001). Prof. Israeli is an NSC member in several ERA-Nets, CSAs and JPIs.</p> <p>Dr. Ahmi Ben-Yehudah is the Director of Research Administration at the Ministry of Health. He received his PhD in 2003 from the Hebrew University. Prior to his work at the Ministry of Health, he held the position of</p>			

Director of Bio-Medical Research at the Ministry of Science and Technology (2011-2013). Dr. Ben-Yehudah is an NSC member in several ERA-Nets, CSAs and JPIs.

Dr. Irit Allon, DMD, is the national coordinator of several ERA-Nets and JPIs in the CSO-MOH. She is a specialist in Oral pathology and since 2005 has gained experience in managing ERA-Nets and leading the Science to Society and Communication & Dissemination activities. She is the former national coordinator of ERA-NET PathoGenoMics, ERA-Age1 and 2, FUTURAGE and the current liaison of E-RARE, Infect-ERA, EuroNanoMed2, and JPIAMR at the CSO-MOH.

Mrs. Leah Geula is the- ICT officer in CSO-MOH, supporting the technical and financial aspects of ERA-NET activities.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Contribution to the TRANSCAN-2 co-funded call: 0.24M€.

Information on the funding rules applied by CSO-MOH can be found at
<http://www.health.gov.il/Subjects/research/Pages/Research-Foundation.aspx>

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Alliance Against Cancer - Alleanza Contro il Cancro</i>		
Short name	ACC	Country	ITALY
Brief description of the legal entity			
<p>Alliance Against Cancer (Alleanza Contro il Cancro, ACC) is a non- profit association that acts as an “excellence network” by promoting and facilitating the exchange of information, knowledge, data, scientific results, and personnel at the National and International level. ACC was founded in 2002 by the Ministry of Health. Among the tasks covered, the following are noteworthy: coordination and implementation of National activities aimed at informing patients’ decisions, creating and sustaining cancer networks, supporting scientific activities with a translational focus in Cancer research. A focal point has been recently established with the task of interacting with similar bodies to promote the Italian participation in European or other International Programmes. Prof. Ruggero De Maria, who has been recently appointed as new chair of ACC, will oversee ACC participation in this ERA-NET project.</p> <p>Website: http://www.alleanzacontroilcancro.it/</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			Y
Programme Manager			Y
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
ACC has participated in the preparation and implementation of JTCs under the framework of the ERA-NET on Translational Cancer Research TRANSCAN.			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
ACC will participate in the management and coordination of TRANSCAN 2 (WP1, subtask 1.2: Installing the TRANSCAN-2 Scientific Advisory Board); Preparation and implementation of the co-funded call (WP2); Development and implementation of the network and scientific research agenda (WP4, subtask 4.5: Strategy for identifying scientific priority topics; Implementation of capacity building & training activities (WP5, subtask 5.1: Set up and implementation of the communication strategy; and subtask 5.4: Scientific Symposia focused on targeted network activities). In addition, ACC will be leader of WP9 (Preparation and implementation of a fourth joint call).			
Short profile of staff member(s) who will be undertaking the work			
<p>Ruggero De Maria graduated in Medicine and Surgery at the University of Catania in 1989 where he later specialized in Endocrinology and Metabolic Diseases at the University of Palermo in 1994. From 2004 onwards he coordinated a series of studies dedicated to stem cells and solid tumours where the results were published in the most prestigious international scientific journals. De Maria was appointed Director of the Department of Hematology, Oncology and Molecular Medicine at the Istituto Superiore di Sanità from 2008 to 2011. He was later appointed Scientific Director of the National Cancer Institute Regina Elena as well as Chair of the Italian Association of Alliance Against Cancer where he still stands to this day. Prof. De Maria holds positions such as Affiliate Full Professor at the George Mason University in Fairfax, Virginia since 2006; Adjunct Professor at the University of Naples Federico II at the Universities of Palermo, Bari and Catania since 2006. In addition, he lectures several doctoral courses in renowned national and international institutions.</p>			

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.	
Contribution to the TRANSCAN-2 co-funded call: 0.25M€.	
Does the participant envisage that part of its work is performed by a linked third parties.	N
<i>If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party</i>	
Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
<i>If yes, describe the third party and their contributions</i>	

Name of organisation	<i>The Netherlands Organisation for Health Research and Development</i>		
Short name	ZONMW	Country	THE NETHERLANDS
Brief description of the legal entity			
<p>ZONMW originates from the integration of the Dutch Health Research and Development Council (ZONMW) with the Council for Medical and Health Research (MW), which was part of The Netherlands Organisation for Scientific Research (NWO). ZONMW receives its national total budget, about € 70 million per year, mainly from the National Ministry of Health, Welfare and Sport and from NWO. NWO has commissioned its responsibilities for administrating national research programs in the field of medical and health research to ZON.</p> <p>ZONMW has a broad experience in research management, on a national as well as an international level. It is a member of the European Medical Research Council (EMRC) and has been involved in many international activities amongst which a number of ERA-nets and JPI's. Dr. Edvard Beem, co-director of ZONMW, has been a Dutch delegate in the programme committees for Life Sciences since FP5. He has also been involved in the successful application for the European Developing Countries Clinical Trials (EDCTP) initiative and represents ZonMw in the EMRC and in various ESFRI projects.</p> <p>Website: http://www.zonmw.nl/en/</p>			
Identification of the role:			
Programme Owner and Manager			N
Programme Owner			N
Programme Manager			Y
In case you are a Programme Manager, please name the respective Programme Owner			
National Ministry of Health, Welfare and Sport (VWS) and The Netherlands Organisation for Scientific Research (NWO)			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>ZONMW manages national research programmes in the areas of genomics, gene therapy, pharmaceutical research and development, vaccines and tissue engineering and translational research towards a personalised medicine. It subsidises a range of projects in the area of health, prevention and care, from basic scientific research to innovation projects in practice. Moreover, the Innovational Research Incentives Scheme of ZONMW offers maximum opportunities for individual creative research talent. All mentioned programmes are accommodated by the team 'Science and Innovation' of ZONMW.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>ZONMW, Erica Hackenitz participated in ERA-net TRANSCAN from the start. ZONMW was co-leader of WP2, Survey and analysis of national cancer research funding of translational cancer research and contributed to work packages 1,3,5 and 6.</p> <p>In this ERA-net ZONMW will contribute to work packages:</p> <p>WP1: Contribution to the development, alignment and implementation of national and international plans with other TRANSCAN-2 partners.</p> <p>WP3: Contribution to the preparation of a template for monitoring.</p> <p>WP4: Co-leadership together with MoH-ISS of Task 4.1 (Strategy on enlarging the network of funding organisations).</p> <p>WP5: Contribution to the dissemination of information.</p>			

WP6: Contribution to the monitoring of partners' satisfaction with TRANSCAN-2 procedures and results.

Short profile of staff member(s) who will be undertaking the work

Edvard Beem obtained his Ph D in Medical Chemistry in 1988 at the Free University of Amsterdam. In 1989, he joined the Council for Medical and Health Research (MW) of the Netherlands Organisation for Scientific Research (NWO), where he has occupied the functions of senior program officer (1989-1994), deputy director (1994-2000) and acting director (2000-2001). Since 2001, he is co-director of the Netherlands Organisation of Health Research and Development (ZON). Dr. Beem is a member of numerous scientific committees, notably, the EC Steering Committee for the establishment of the European and Developing Countries Clinical Trial Partnership (EDCTP), the European Medical Research Council (EMRC) of the European Science Foundation (ESF) (Dutch delegate and acting member of its Executive Group), and the Dutch Delegation of the EC FP6 / FP7 Committees (expert).

Erica Hackenitz obtained an MSc in Biology (environment, tropical health and nutrition) holds a BSc in social sciences. She worked for Preventicon, the first breastcancer screening project in the Netherlands, followed by 9 years freelance research consulting in various EC, multi- and bilateral projects on environmental health, health ecology and poverty, both as coordinator and researcher. She then joined the Royal Tropical Institute in the Netherlands (KIT) as research coordinator. Since 2003 she is programme officer at ZonMw particularly involved in international projects. Recently she has been the executive officer of a work package in the EC Eurocan+Plus project, ERA-net E-Rare, ERA-net TRANSCAN and CSA PerMed. She is based in ZonMw's team Science and Innovation.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Cofund contribution 0.3M€. This is the call contribution of ZonMw, as no other maximum amount of financial support is defined under national funding rules. Financial support will be provided according to the general funding rules of ZonMw, which can be provided and assessed here:
<http://www.zonmw.nl/nl/over-zonmw/werkwijze/>

Additional specific financing criteria differ per programme and can differ per call topic within programmes.

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Stichting Koningin Wilhelmina Fonds voor de Nederlandse Kankerbestrijding</i>		
Short name	DCS	Country	THE NETHERLANDS
Brief description of the legal entity			
<p>The Dutch Cancer Society(DCS) is a nation-wide organisation for cancer related work in the Netherlands, founded in 1949 at the instigation of Queen Wilhelmina. The mission of the DCS is that <i>we want to cut cancer rates as soon as possible, and get it under control. We are here to help people living with cancer and those who share their lives.</i> In our vision scientific research is the basis for combating cancer and actually improving survival and patients' quality of life. We can only reduce cancer rates by understanding the disease better, which is why we invest in basic research, among other things. We also ensure that the knowledge gained is transferred to 'the bed', to patients. We also invest in scientific research to increase our knowledge of psychosocial problems. Translational research was one of our priority areas from 2011-2014. We will continue our support for (translational) research from 2015-2018. The DCS spends its disposable budget for objectives to finance cancer research, education and training, public awareness and information, prevention and patient support programmes. Our overall budget in 2013 was nearly 150 million euro. The DCS professional staff amounts to 170 persons and over 100.000 volunteers support the DCS. Over 1 million donors contribute to our annual income.</p> <p>Website: http://www.kwf.nl/english/pages/default.aspx</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			N
Programme Manager			N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>As cancer research funding organisation DCS has experience with executing cancer research calls and the process of project assessment, monitoring and evaluation. In addition, the DCS has a large scientific community linked to our organisation.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>The DCS will contribute to WP2 (Tasks 2.2, 2.3), WP3 (task 3.1), WP 4 (tasks 4.1, 4.2, 4.3, 4.4, 4.5), WP7 and WP9. The DCS will lead WP8.</p> <p>The DCS was previously involved in TRANSCAN (FP7), including participation in joint transnational calls.</p>			
Short profile of staff member(s) who will be undertaking the work			
<p>Michel T. Rudolphie, Msc, MBA, president and CEO Dutch Cancer Society. After several senior positions at pharmaceutical and medical devices companies Michel Rudolphie joined the Dutch Cancer Society in 2011.</p> <p>Sandra Kloezen, Msc, director of Research, Prevention and Patient Support. Recently Sandra Kloezen joined the Dutch Cancer Society after a professional career in oncological care and cancer patient support.</p> <p>Merel Hoozemans, PhD, senior program coordinator translational research. In 2007 Merel joined the Dutch Cancer Society as policy advisor and coordinator of translational and applied research projects. At present, Merel is senior program coordinator of an initiative of the DCS on Translational Research, aiming to innovate</p>			

expenditure and activities in order to ensure that patients benefit as quickly as possible from the results of scientific research.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Amount for co-funded call contribution: 1 M€.

Information on the funding rules can be found in the general grant conditions of DCS at <http://www.kwf.nl/SiteCollectionDocuments/Algemene%20Subsidievoorwaarden%202014.pdf>

Does the participant envisage that part of its work is performed by a linked third parties?	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>The Research Council of Norway</i>		
Short name	RCN	Country	NORWAY
Brief description of the legal entity			
<p>The Research Council of Norway is a national strategic and funding agency for research activities, and a chief source of advice and input into research policy for the Norwegian Government, the central government administration and the overall research community. An important objective is to ensure that Norway adequately invests in research and development activity, to identify Norway's research needs and to recommend national priorities. Using targeted funding schemes, the Council helps to translate national research policy goals into action. Using "bottom up" schemes the Council fosters research of the best scientific quality.</p> <p>The Research Council works to promote high-calibre research and win greater acknowledgment of research as a cultural, value-creating force that fuels social development. A knowledge-based society is dependent on a research establishment that is on the cutting edge internationally. The Research Council seeks to strengthen the international position of Norwegian research together with other players in the research system.</p> <p>Four key challenges</p> <ul style="list-style-type: none"> • To enhance the capacity and quality of Norwegian research. • To strengthen research in areas of particular importance for research, trade and industry, and society at large. • To promote constructive cooperation, distribution of responsibility and structures in the research system. • To translate research results into action. <p>Norway has one single research council, hence the RCN covers all subjects fields and discipline and all kinds of R&D carried out in the higher education sector, institute sector, public sector (hospitals) and industrial sector. The value of the 2013 project portfolio in health and medicine amounts to nearly 1,2 M€.</p> <p>Website: http://www.forskningsradet.no/en/Home_page/1177315753906</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			Y/N
Programme Manager			Y/N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>Norwegian participation in European collaboration on research and innovation through Horizon2020 and ERA, is a high priority target for the Norwegian government. The RCN is at present participating in 29 ERA-Net's and all the 10 JPIs.</p> <p>RCN administers one research program dedicated specifically to cancer research. The Programme for Publicly-initiated Clinical Cancer Studies aims to provide support to research projects that will increase understanding and thereby enhance the basis for effective decision-making within cancer treatment and care. The research programme is funded by the Norwegian Ministry of Health and Care Services. The Ministry has provided earmarked money for Norwegian participation in TRANSCAN, approx. 0,5M€ annually. The programme board is responsible for monitoring the Norwegian part of the TRANSCAN-projects funded.</p>			

Main tasks attributed the proposed action and the previous experience relevant to those tasks	
RCN will participate in the preparation and implementation of the co-funded call (WP2), in the other three joint calls (WP7, WP8 and WP9), and in WP3 and WP4.	
Short profile of staff member(s) who will be undertaking the work	
<p>Karianne Solaas, Ph.D., is scientific coordinator for two national research programmes, one in cancer and one in generic biobanking and registry research. In addition, she is the Norwegian delegate in the BBMRI-ERIC Assembly of Members and the IARC Governing Council. She was the Norwegian representative in the first JPND Call Steering Committee. After receiving her biomedical Ph.D. degree in 2002 she was a researcher for eight years before she joined the Research Council of Norway.</p> <p>Henrietta Blankson, Ph.D. in cell biology 1999. At present special adviser in The Research Council of Norway with responsibility for The Clinical Research Programme and The Research-based Evaluation of the Norwegian Mammography Programme. Norwegian delegate in IARC Governing Council (2006 – 2013). Experience in clinical research from work in a Norwegian Contract Research Organisation (1999 – 2004).</p>	
Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.	
No maximum amount of financial support is defined under RCNs national funding rules. The amount RCN plans to allocate to each of the co-fund/joint transnational calls is 0,5 M€. Information on the funding rules applied by RCN can be found at http://www.forskningsradet.no/en/Apply_for_funding/1138785830985	
Does the participant envisage that part of its work is performed by a linked third parties.	N
<i>If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party</i>	
Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
<i>If yes, describe the third party and their contributions</i>	

Name of organisation	<i>Foundation for Science and Technology</i>		
Short name	FCT	Country	PORTUGAL
Brief description of the legal entity			
<p><i>Fundação para a Ciência e a Tecnologia</i> (FCT) is the national funding agency for science, technology and innovation, in all scientific domains. Under responsibility of the Ministry for Education and Science, FCT started its activity in August 1997, succeeding the <i>Junta Nacional de Investigação Científica e Tecnológica</i> (JNICT). Since March 2012 FCT coordinates public policies for the Information and Knowledge Society in Portugal, after the integration of the UMIC – Knowledge Society Agency. In October 2013, FCT took over the attributions and competences of the <i>Fundação para a Computação Científica Nacional</i> (FCCN), [Foundation for National Scientific Computation].</p> <p>FCT's vision is:</p> <ul style="list-style-type: none"> • To establish Portugal as global reference in science, technology and innovation • Ensure that knowledge generated by scientific research is used fully, for economic growth and the well-being of all citizens. <p>FCT's mission is to continuously promote the advancement of knowledge in science and technology in Portugal, attain the highest international standards in quality and competitiveness, in all scientific and technological domains, and encourage its dissemination and active role in society and in economic growth.</p> <p>FCT pursues its mission by funding fellowships, studentships and research contracts for scientists, research projects, internationally competitive research centres and state-of-the-art infrastructures, via competitive calls with international peer-review. FCT ensures Portugal's participation in international scientific organisations, fosters the participation of the scientific community in international projects, and promotes knowledge transfer between R&D centres and industry. Working closely with international organisations, FCT coordinates public policy for the Information and Knowledge Society in Portugal and ensures the development of national scientific computing resources. FCT also provides the institutional framework for the Research Councils.</p> <p>FCT's budget encompasses funds from the Portuguese state budget and European structural funds. For 2014, FCT has a budget of circa €436 million for direct investment in science (this figure does not yet include structural funds from the current European programme, which are under negotiation with the European Commission). Funding is structured around the following schemes: Graduate Education and Career Development (studentships, fellowships and contracts), R&D Projects (in all scientific domains), R&D Centres (Associate Laboratories, R&D Units), International cooperation (bilateral cooperation, membership of international organisations and international partnerships) and Others (includes <i>Rede Ciência, Tecnologia e Sociedade</i>, Information Society, B-on, Support for Scientific Community Fund and Public Understanding of Science).</p> <p>Website: http://www.fct.pt/index.phtml.en</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			N
Programme Manager			N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>The R&D National Projects Program aims to promote the growth, reinforcement and consolidation of the National Scientific and Technological System in order to make it more competitive at national and international levels and encourage the transfer of scientific knowledge and technological innovation to the productive field. Within this program open calls in all scientific domains are launched every year.</p>			

Occasionally FCT launches small thematic programs to stimulate the development of targeted areas (e.g., History of Science, Long Term Ecosystem Research and Monitoring, obtainment and characterization of Cork Oak ESTs, Clinical Research). FCT also participates in regular or occasional thematic programs under cooperation protocols with other organisations, like the European Laboratory for Particle Physics (CERN), the National Coordination for the Infection HIV, the National Institute for Rehabilitation, I.P., the Commission for Citizenship and Gender Equality, the Ministry of Education or the Department of Studies, Statistics and Planning of the Ministry of Social Security and Labour

Given the ongoing development of a National Strategy for Smart Specialization, it is foreseen in the upcoming years the creation and implementation of thematic programs in strategic scientific and technological areas.

Main tasks attributed the proposed action and the previous experience relevant to those tasks

FCT will participate in the implementation of the co-funded call (WP2) as well as of the TRANSCAN-2 additional joint calls. In addition, FCT will contribute to WP3, WP4 and WP9, in which it will be leader of Task 4.2 (Strategy on improving partner's success in JTCs), together with LAS, and of Task 4.3 (Strategy on improving the decision making), together with ISCIII, and co-leader of Task 9.1 (Preparation and launch of the joint transnational call JTC 2017) together with ACC. FCT will lead WP6 (Assessment and monitoring of TRANSCAN-2 performance).

FCT has wide experience in Monitoring and Assessment of the network activities. We lead WPs related to monitoring and assessment in the following ERA-NETS: E-Rare-2, TRANSCAN, EuroNanoMed, Infect-ERA, and ERA-IB.

Short profile of staff member(s) who will be undertaking the work

Marta Abrantes, PhD. Marta Abrantes has a 5-year degree in Biochemistry from the Faculty of Sciences of the University of Lisbon (UL), holds a Masters degree in Pharmaceutical Chemistry from the Faculty of Pharmacy of UL and a PhD in Microbial Biology, from the Institute of Biological and Chemical Technology – New University of Lisbon. From January 2013 to October 2013 she was a Senior Scientist at the biotech company Bioalvo, working on FP7 projects. In November 2013 she joined FCT as a scientific officer at the Department of International Relations, to work in the management of ERA-NET projects.

Rui Durão was trained as a Science Teacher at Faculty of Sciences- University of Lisbon, and is currently developing his PhD work in Sociology at ISCTE - University Institute of Lisbon, after completing his MSc in Social Studies of Science there, and after attending an MPhil in Cultural and Political History at FCSH – New University of Lisbon. He worked for several years as a project officer at Ciência Viva – National Agency for Scientific and Technological Culture, where he gained experience in science outreach and public understanding of science, and developed a keen interest on the structure of scientific systems, science policy, and the connections between academia and society. Rui is currently Project Officer at the Department of International Relations of FCT, involved in the management of ERA-NETs and JTIs.

Ana Paula Castro has a degree in Economics, a Master in International Cooperation and Development and experience in the financial Management of International/FP7 Projects. She will be the financial officer at FCT for this ERA-NET.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Contribution to the TRANSCAN-2 co-funded call: 0.325M€. Information on the funding rules applied by FCT can be found at <http://www.fct.pt/apoios/projectos/regulamento.phtml.en>

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
<i>If yes, describe the third party and their contributions</i>	

Name of organisation	<i>Slovak Academy of Sciences</i>		
Short name	SAS	Country	SLOVAKIA
Brief description of the legal entity			
<p>The Slovak Academy of Sciences (SAS), a governmental research organisation, is the recognized leading research and scientific institution in Slovakia. The self-governing scientific institution of the Slovak Republic activities of which are in accordance with the Act No.133/2002 on the Slovak Academy of Sciences (SAS) focused on the development of science, education, culture, economy and carried out by scientists and specialized and service organisations. By its research, the SAS is developing efforts to advance knowledge in international context considering the social needs of Slovakia.</p> <p>Website: http://www.sav.sk/?lang=en</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			Y
Programme Manager			Y
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>“Research in the field of biological, medical and farmaceutical sciences” (including cancer research).</p> <p>The SAS participates also in two FP7 ERA-Net projects concerning the field of medicine i.e. TRANSCAN – ERA-NET on Translational Cancer Research and NEURON II- Network of European Funding for Neuroscience Research.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>SAS will be leader of WP3 (Follow-up and monitoring of projects resulting from the co-funded JTC 2014 and the TRANSCAN-2 JTCs) and will actively participate in the project as committed partner in several tasks resulting from participation and experience in many ERA-NETs including the field of medicine.</p>			
Short profile of staff member(s) who will be undertaking the work			
<p>Jan Barancik, PhD., Coordinating person responsible for the overall timely management of the project, comprising the content of the work plan, the finances and the administration. He is the head of International Cooperation Dpt. at SAS. He has a teoretical and working experience as a coordinator and project manager of many European networks (ERA.NETs) and international projects for SAS e.g. TRANSCAN, NEURON II, M-ERA.NET, INCOMERA, ANIHOWA, CONCERT Japan, ERA.NET RUS Plus etc.</p> <p>Richard Imrich, MD, PhD., Senior scientist, currently a vice-president of the Slovak Academy of Sciences. He is the head of the Laboratory of Human Endocrinology with more than 14 years of experience in clinical research focused on neuroendocrine-immune interactions. During his research carrier, he published more than 70 with around 500 SCI citations, f index 14. He has been involved in several research project including NIH clinical protocols and FP7-funeded clinical trials.</p> <p>Martin Novak, PhD., Project Manager responsible for the day-to-day operational management of administrative and organisational aspects in this project. He is engaged in severaleuropean and international projects at SAS.</p>			

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.	
<p>Amount for co-funded call contribution is 0.21M€.</p> <p>Information on the funding rules applied by SAS can be found at http://www.sav.sk/index.php?lang=sk&charset=&doc=services-news&source_no=25&news_no=5570</p>	
Does the participant envisage that part of its work is performed by a linked third parties.	N
<i>If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party</i>	
Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
<i>If yes, describe the third party and their contributions</i>	

Name of organisation	<i>Ministry of Education, Science and Sport</i>		
Short name	MIZS	Country	SLOVENIA
Brief description of the legal entity			
<p>The Ministry of Education, Science and Sport (Ministrstvo za izobraževanje, znanost in šport - MIZS) was established in 2013 and is responsible for regulating all levels of education (from pre-school to higher education), as well as fields of science and sport. The Science Division as part of the Science Directorate defines the expert bases for the adoption of political documents in the field of research policy. It drafts laws and implements regulations on research activities. It establishes and enhances the system of comprehensive analyses and monitoring of the developments in research, develops new tools for attaining research policy goals, and plans the required financial resources for research.</p> <p>When it comes to international activity, MIZS hosts the National Contact Points (NCP) network for EU framework programmes on research and innovation, offering advice and raising awareness concerning cooperation from Slovenian research community. Its representatives sit in the EC Programming Committees. Following the orientation set in main policy and strategic document, the Research and Innovation strategy 2011-2020, the ministry actively cooperates in the formation of European Research Area with international coordination of national research programs through ERA-NET projects, such as ERA-MBT, ARIMNET-II, TRANSCAN, WoodWisdom-Net, ERASynBio, M-ERA.NET, etc. It also cooperates in the preparation of Joint Transnational Calls within Joint Program Initiatives (JPIs), such as JPI Climate.</p> <p>Website: http://www.mizs.gov.si/en.</p>			
Identification of the role:			
Programme Owner and Manager			N
Programme Owner			Y
Programme Manager			N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>The International Scientific Cooperation Program is the main program for funding MIZS's participation in ERA-NET calls. The total annual budget of the program varies and reached 1.7 million EUR in 2013. The objective of the program is to facilitate and increase the participation of Slovenian researchers in transnational projects in line with strategic objectives of the Research and Innovation strategy 2011-2020. The Ministry has participated in several ERA-NET calls, including 2 TRANSCAN calls (JTC 2010 and JTC 2013), with the size of funding of Slovenian partners in a project recommended for funding reaching up to 70.000 EUR per year (140.000 EUR if the Slovenian partner is the coordinator of the transnational project).</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>MIZS will lead Work Package 5 (Communication, Dissemination and Networking) and will also be an active partner in other Work Packages in line with the Description of Action.</p> <p>The ministry representatives have substantial experience with preparing and managing various Work Packages, most often those dealing with Communication, Dissemination and Networking, as well as Education and Training Work Packages, and have actively contributed to the implementation of numerous tasks within different projects.</p>			
Short profile of staff member(s) who will be undertaking the work			

Kim Turk is a graduate of Political Science – International Relations. She received her degree from the University of Ljubljana where she is currently in the final steps of receiving her Master of Science in International Economics. Kim has substantial international experience, working first in the academic sphere as a young researcher and later in the private sector as a consultant and Slovenian representative of an international company. Ms. Turk is currently in charge of managing and coordinating 7 different ERA-NET projects, namely ERA-MBT, SUMFOREST, ARIMNET-II, SUSFOOD, ERASynBio, TRANSCAN, and WoodWisdom-Net +. She is the work package leader in ERASynBio on training and education and work package leader in WoodWisdom-Net + on dissemination and networking, task leader in ERASynBio's and ERA-MBT's communication work package, actively participating in the communication work package of ARIMNET-II.

Luka Živić has a Master's Degree in European Studies from the University of Ljubljana, Faculty of Social Science. He is a Programme Committee member and NCP for Societal Challenge 5 ("Climate Action, Environment, Raw materials and Resource efficiency") under Horizon 2020. He is also part of the Project Coordinators' Committee of the JPI Climate, as well as NCP for the Joint Transnational Call. He has substantial experience with preparing and managing Calls for proposals under EU Structural Funds as well, mainly for research institutions and SMEs. In 2013 he worked as a Blue Book Trainee at the European Commission (DG Employment, Social Affairs and Inclusion), supporting Slovenian and Croatian team in the European Semester process.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Amount for TRANSCAN-2 co-funded call contribution: 0.45M€.

Information on funding rules applied by MIZS can be found at
http://www.mizs.gov.si/si/javne_objave_in_razpisi/okroznice/arhiv_okroznice/okroznice_razpisi_in_javna_narocila/javni_razpisi/

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Instituto de Salud Carlos III</i>		
Short name	ISCIII	Country	SPAIN
Brief description of the legal entity			
<p>The National Institute of Health Carlos III (ISCIII) is the main public research body in Spain, providing funding, management services and conducting research in the fields of biomedicine and health sciences. For over 25 years, its mission focuses on basic, translational and applied research as well as health technologies. In addition to this, ISCIII performs intramural activities and has a regulatory role as far as biobanking and accreditation of research centres is concerned. It is also responsible for managing Spain's Strategic Action for Health Research and developing the short-to-long term scheme within the National R+D+I Plan framework.</p> <p>The Institute reports directly to the Ministry of Economy and Competitiveness (Royal Decree 345/2012) and the Ministry of Health, Social Services and Equality (Royal Decree 200/2012). It also has a pivotal role in the creation of scientific knowledge in the realm of health sciences, disease prevention, care and medical treatment.</p> <p>Moreover, under the Europe Horizon 2020 umbrella, the Institute is actively involved in the promotion of Spanish research excellence via its participation in key European transnational initiatives such as: ERA-Nets (E-RARE, NEURON, EuroNanoMed, TRANSCAN, Infect-ERA, ERASysApp), ERICs (ECRIN, EATRIS), ESFRI project preparatory phases (e.g. BBMRI, ELIXIR, ERINHA), Art. 185 TFEU initiatives (EDCTP and AAL), and Joint Programming Initiatives (e.g. JPND, JP HDHL, JP AMR, and JP MYBL) JPIs to Work and EULAC Health. The Institute also participates in other international research consortia (e.g. IRDiRC, ICGC and the Personalized Medicine Coalition).</p> <p>In terms of budget, the Institute is publicly funded (280 M€ in fiscal year 2013 –approved by Spanish Parliament in its annual National Budget Act) and allocates approximately 225 M€ to extramural research funding, including competitive annual calls. Since its inception, through a rigorous selection process based on peer review evaluation, ISCIII has awarded grants for research projects, networks, equipment, fellowships, technical manpower and research contracts.</p> <p>ISCIII's participation in this action will be carried out by the Research and Innovation Activities Assistance Office (OAIN) and which is part of the Deputy Director's Office for International Research Programmes and Institutional Relations (SGPIIRI). The Foundation for International Cooperation, Health and Social Affairs (FCSAI) will be involved as a third party. FCSAI has authorisation to administer the activities carried by OAIN. Due to the skills necessary by the nature of the activities to be carried out, it may be required to hire the persons dedicated to this ERA-Net at market price and not according to the listed waves for the Statutory Public Service.</p> <p>In a rapidly changing world and with biomedical and health research excellence at the core of its operational strategy, ISCIII's action is intended towards the successful adaptation of the Spanish National Health System in the competitive global learning economy.</p> <p>Website: http://www.eng.isciii.es/ISCIII/es/general/index.shtml</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			Y/N
Programme Manager			Y/N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>ISCIII is committed to the funding, management and follow-up of transnational calls in the field of biomedicine and health sciences. It collaborates with European research infrastructures in the development of the ESFRI roadmap (e.g. ECRIN, EATRIS, ELIXIR and ERINHA) and it is also involved in the reinforcement of cross-border cooperation of research programmes through Joint Programme Initiatives: JPND, JP HDHL, JPAMR, JP MYBL; Article 185 TFEU (AAL and EDCTP); ERA-Nets (E-RARE, NEURON, TRANSCAN, EuroNanoMed,</p>			

Infect-ERA and ERASysAPP), JPIs to Co-Work and EULAC Health. Within the context of these initiatives, the Institute has adopted a number of roles: Coordinator, National Contract Point and Joint Call Secretariat.

ERA-Net ERASysAPP aims to promote multidimensional and complimentary research projects, programmes and initiatives in Europe. As Call Secretariat, ISCIII will execute and monitor a total of 3 transnational calls in Systems Biology with a focus on translational. To this end, it is in charge of designing the transnational calls, drafting the documents, setting-up the evaluation system and aspects related to the governance.

ERA-Net Neuron II seeks to coordinate national and regional research programmes in neuroscience. The Institute has been responsible for Neuron II's Work Package 7, which dealt with the development of a long-term collaboration framework. Additionally, ISCIII participates in the execution of Work Package 2, which deals with the creation of the strategic agenda; Work Package 5, intended to provide support to young researchers; and the monitorization of the consortia's communication activities.

ERA-Net EuroNanoMed II (ENM II) seeks to foster the competitiveness of European research centres engaged in Nanomedicine. ISCIII is responsible of the Work Package that deals with the development of the Research Strategic Agenda, the drafting of joint call documents and the design of the long-term collaboration framework.

ERA-Net E-Rare In two occasions (2012 and 2014) ISCIII has been in charge of running the Joint Call Secretariat. The tasks executed during both Calls include: drafting of call documents, design and coordination of the assessment process, management of the IT platform, selection of reviewers and the organization of the evaluation panels –among other things.

EU Joint Programme – Neurodegenerative Disease Research (JPND) ISCIII participates in kind in the JUMPAHEAD project that supports the implementation of JPI to combat neurodegenerative diseases. It is a three year project funded by an FP7 2 million euro grant GA no. 260774, in which ISCIII has actively contributed with the execution of organizational tasks.

ERA-Net Infect-ERA is an initiative in which ISCIII has contributed to the development of Work Package 7. The latter dealt with the design of a long-term collaboration framework, the set-up of the external scientific committee and the generation of a network with similar initiatives.

J-AGE is a Coordination Action for the implementation of the JPI "More Years, Better Lives - the Challenges and Opportunities of Demographic Change". ISCIII has participated in the drafting of a non-comprehensive list of possible instruments that could be used for the implementation of the Strategic Research Agenda (SRA) and the compilation of results of a Workshop held in Madrid on 22/03/2013.

Main tasks attributed the proposed action and the previous experience relevant to those tasks

ERA-Net TRANSCAN project is intended to foster national and regional translational research collaborations aimed at integrating basic, clinical and epidemiological cancer research. ISCIII will contribute to the implementation of the co-funded call (WP2) and to WP3 and WP4, in which it will co-lead the Task 4.3 (Strategy on improving the decision-making) together with FCT. ISCIII will also participate in WP9 (Preparation and implementation of a fourth joint transnational call), with a role of co-leader of the Subtask 9.2.1 together with ACC.

Short profile of staff member(s) who will be undertaking the work

Dr Rafael de Andrés Medina is Chief of the International Research Programmes and Institutional Relations Office at ISCIII. His previous professional experience includes: Deputy Director and Head of the Technical Studies Department at ISCIII and Secretary General of the National AIDS Plan at the Ministry of Health and Consumers Welfare (1987-1990). Dr Rafael de Andrés is the Spanish representative for a wide range of programmes: EU Joint Programming Initiatives (JP ND, JP HDHL, JP AMR, JP MYBL), ESFRI Health and Food Strategic Working Group, projects in the ESFRI roadmap (ERINHA, BBMRI, Euro-BioImaging) ERIC (ECRIN –where holds the position of Chair of the Assembly of Members since 2014- and EATRIS) and EDCTP. Furthermore, he was elected Chair of the AAL Association Executive Board (Article 185, TFEU initiative) by its General Assembly of countries (November 2013-ongoing) and has served as Treasurer in 2007, 2009 and 2011. Also, he has been linked to the Restraint Committee on the Impact of the AIDS Epidemics on Health Services and their Planning (Council of Europe, 1989-1991), International Committee on Ethics and AIDS (1989), EC Research Working Party on AIDS (1987-1991) and is committed to the development of the Spanish participation in European and transnational initiatives (e.g. E-RARE, NEURON, TRANSCAN, EuroNanoMed, ERASysAPP,

INFECT-ERA, EULAC Health and IRDiRC) to foster the competitiveness of Spanish biomedical research world-wide.

Ms Elsa Moreda Sánchez works as a Project Officer at the Deputy Director's Office for International Research Programmes and Institutional Relations (SGPIRI) at the National Institute of Health Carlos III. Ms Moreda is actively involved in the coordination, management and follow-up of European transnational collaborations such as: ERASysAPP, TRANSCAN, NEURON, and INFECT-ERA. Besides her occasional participation in training and promotional biomedical activities, Ms Moreda plays an instrumental role in the management and coordination of ERASysAPP's Joint Call Secretariat's administrative and financial activities –a total of 16 funding agencies cooperate within the novel ERA-Net for Applied Systems Biology. Previously, during 2010-2011, she worked at the Spanish Ministry of Health, Social Services and Equality as a Communication Officer. During her time at the Ministry she contributed to the planning, development and implementation of the National AIDS Plan's communication strategy and the composition of editorial content for "Zum: Otraperspectiva del VIH en España" magazine.

Ms Ana Tardón works as a Project Officer at the Research and Innovation Activities Assistance Office (OAIN) which is part of the Deputy Director's Office for International Research Programmes and Institutional Relations (SGPIRI). Ms Tardón has a long experience working with EU Framework Programmes and other R&D international programmes in different relevant places as in the European Projects office at University Carlos III of Madrid, in the European Projects office at Research Center for Energy, Environment and Technology (CIEMAT), and in the Research Department of the Regional Health Ministry of Madrid giving support to Madrid Public Health System in the planning and implementation of research European projects.

Mr Ignacio Baanante Balastegui works as a Project Officer managing and coordinating European transnational research collaborations at SGPIRI. During 2010 and 2012 he worked at the European Office of the Spanish Ministry of Science and Innovation, based in Brussels. Throughout his time there, he not only participated in the evaluation and the monitorization of scientific policies at national, European and International level, but also contributed to the drafting of analytical documents (i.e. Impact Assessment). During 2008-2009, in addition to his role as Work Package leader in ERA-Net PRIOMEDCHILD and NEURON, he also provided support in other initiatives such as Art. 185 TFEU; AAL, EDCTP, European infrastructures; ECRIN, EATRIS and BBMR. Furthermore, Mr Baanante has been involved in training activities in the biomedical field and is also engaged in multilateral European and international collaborations; for instance, EuroNanoMed, TRANSCAN, INFECT-ERA and JPI More Years Better Life. In the course of 2012 and 2014 he undertook the Joint Call Secretariat for Research Programmes on Rare Diseases (ERA-Net E-Rare), part of the Institute's agenda to tackle the Health and Wellbeing Societal challenge, identified in Horizon 2020.

Ms Carme de Andrés Sanchis is currently undergoing a 4-year training programme at the National Institute of Health Carlos III where she provides managerial support in the development of national and European transnational calls e.g. TRANSCAN, ERASysAPP, NEURON and AAL. Her professional background includes project management for the European External Action Service (2010-2011) and the Embassy of the Republic of Argentina in Beijing (2008-2010), where she contributed to the coordination and organisation of the Group on Earth Observations Summit, the EU-China High Level Economic and Trade Dialogue (HED), the launch of the European Union SME Centre in China and the High-Level Strategic Dialogue, among others. Between 2006 and 2008 she worked as an Editor at the China Central Television where she assisted in the preparation of news content.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

No maximum amount of financial support is defined under ISCIII's national funding regulations. Amount for co-funded call: 0.5M€.

Information on funding rules applied by ISCIII can be found at <http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-financiacion/fd-convocatorias-ayudas-accion-estrategica-salud/convocatoria-aes-2014.shtml>

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

Does the participant envisage the use of in-kind contribution provided by third parties (Articles	N
---	---

11 and 12 of the Model Grant Agreement)	

Name of organisation	<i>Türkiye Bilimsel ve Teknolojik Araştırma Kurumu</i>		
Short name	TUBITAK	Country	TURKEY
Brief description of the legal entity			
<p>Founded in 1963, TUBITAK is the leading agency in charge of management, funding and coordinating scientific and technological research in Turkey. TUBITAK functions under the fold of the Ministry of Science, Industry and Technology with adequate administrative and financial autonomy. TUBITAK is also the national coordinating body for the EU Framework Programme Horizon 2020 in Turkey.</p> <p>TUBITAK's main tasks are to determine Turkey's science and technology policies; to support, encourage and coordinate scientific research; to establish and operate special institutes to conduct research and development activities geared towards the priorities set by the Science Board. It provides scholarships and support to researchers and organizing contests to discover and train future scientists; develops support programs for R&D activities and innovations in public and private sectors; promotes university- industry collaborations; publishes scientific journals, popular science magazines and books that make science accessible to the public and supports researchers with awards. TUBITAK is the executing agency in deployment of international scientific and technological agreements.</p> <p>Website: http://www.tubitak.gov.tr/</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			N
Programme Manager			N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>TUBITAK, the programme owner and manager of Technology and Innovation Programmes in Turkey, coordinates EU Framework Programmes via its department, EU Framework Programmes National Coordination Office (NCO). TUBITAK NCO organises info-days, conferences, workshops and brokerage events to raise the awareness about EU Framework Programmes. It also supports researchers during the development and coordination of projects with support funds and awards. TUBITAK NCO participated in 6 ERA-NET projects in FP6 and 11 ERA-NET projects in FP7 in which 7 of the ERA-NET projects are still ongoing. TUBITAK has been a full partner in TRANSCAN and participated in all Joint Transnational Calls it has launched.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>TUBITAK will participate in the implementation of the co-funded call (WP2) as well as of the TRANSCAN-2 additional third and fourth joint calls. In addition, TUBITAK will contribute to WP3, WP4, WP5 and WP6. TUBITAK has participated in TRANSCAN WP1 (leader of subtask 1.2.3) in WP3 (task 3.1) and WP6 (task 6.1).</p>			
Short profile of staff member(s) who will be undertaking the work			
<p>Ms Ayse Ozge Gozay got her BSc degree in Molecular Biology and Genetics from Middle East Technical University in 2009 (Ankara, Turkey) and attended the Molecular and Cellular Biology master programme in Rupprechts Karls University Heidelberg (Heidelberg, Germany). She joined TUBITAK in October 2013 where she acts as a project officer in life sciences projects and scientific programmes assistant expert. Currently, she is the National Contact Point for Horizon 2020 Health, Demographic Change and Wellbeing and TUBITAK</p>			

representative for E-Rare-2 and TRANSCAN ERA-NET projects as well as JPND and JPIAMR.	
Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.	
<p>TUBITAK funds ERA-NET projects according to the rules of 1001- The Support Program for Scientific and Technological Research Projects, the maximum amount is subject to change.</p> <p>Contribution to the TRANSCAN-2 co-funded call: 0.8M€.</p> <p>Concerning the funding rules applied by TUBITAK, the applicants from academia are supported through 1001 programme http://www.tubitak.gov.tr/en/funds/academy/national-support-programmes/content-1001-the-support-program-for-scientific-and-technological-research-projects, and applicants from SMEs and industry are funded through 1509 programme http://www.tubitak.gov.tr/en/funds/industry/international-support-programmes/content-1509-tubitak-international-industrial-rd</p>	
Does the participant envisage that part of its work is performed by a linked third parties.	N
<i>If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party</i>	
Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
<i>If yes, describe the third party and their contributions</i>	

Name of organisation	<i>National Centre for Research and Development</i>		
Short name	NCBR	Country	POLAND
Brief description of the legal entity			
<p>The National Centre for Research and Development (NCBR) is the implementing agency of the Minister of Science and Higher Education. It was appointed in the summer 2007 as an entity in charge of the performance of the tasks within the area of national science, science and technology and innovation policies. When it was founded, it was the first entity of this type, created as the platform of an effective dialogue between the scientific and business communities.</p> <p>Currently, it operates under the Act on National Centre for Research and Development dated 30 April 2010 (Journal of Laws from 2010, No. 96 item 616). The science reform adopted in the autumn 2010 gave the Centre more freedom to manage its financial assets, within the scope of a strategic research programme.</p> <p>In addition, the National Centre for Research and Development extended its activity with new initiatives and possibilities on 1 September 2011. Assigned by the Ministry of Science and Higher Education the function of the Mediation Institution in three operational programmes: Human Capital, Innovative Economy and Infrastructure and Environment, the Centre became one of the greatest innovation centres in Poland.</p> <p>The activity of the Centre is funded by the national treasury and the European Union.</p> <p>Website: http://www.ncbr.gov.pl/en/</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			N
Programme Manager			N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
NCBR is currently involved in a variety of European initiatives. NCBR has funded transnational join calls in the context of TRANSCAN.			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
NCBR will participate in the implementation of the co-funded call (WP2) and in other workpackages activities.			
Short profile of staff member(s) who will be undertaking the work			
<p>Dr. Izabela Rzepczynska, born in 1979, studied Biotechnology, Specialization: Genetic diagnostics at Poznan' University of Life Sciences. With the Socrates Erasmus scholarship she was involved in Research Project: "Identification of experimental design hormonal interactions in vitro in Arabidopsis", at University of Ghent, Belgium. During studies she started cooperation with the Division of Infertility and Reproductive Endocrinology at the Poznan University of Medical Sciences. She finished studies with master thesis "Evaluation of hormonal activity of human granulosa cells cultured in vitro condition". She got her PhD from the Karol Marcinkowski Poznan University of Medical Sciences on the thesis: "Evaluation of oxidative stress influence on ovarian theca-interstitial cells." During her PhD studies she got the position of Research Scholar, Postgraduate Associate at Yale University, New Haven, CT, USA. Since the 2007 she has been working in National Centre for Research</p>			

and Development. Mrs. I. Rzepczynska is the Deputy Head of Programmes Management Department in NCBR.

Dr Marcin Chmielewski – studied Biology at the University of Warsaw, specialisation - Parasitology. He got his PhD from the Warsaw Medical University on the thesis “Apoptosis during the course of infection with hepatitis C virus (HCV) and human immunodeficiency virus (HIV).” Former lecturer at Warsaw Medical University. Since summer 2011 employed in National Centre for Research and Development (NCBR) as a Scientific officer. Currently responsible for coordination of national and international programs in the field of medicine. Main task is to take care of the projects during the whole funding period. It includes administrative and formal issues, but also scientific reviews.

Robert Lesiuk, born in 1973 studied Public Health at the Marii Skłodowskiej - Curie University of Warsaw. He has been working in the NCBR since September 2013. Currently responsible for coordination of national and international programs in the field of medicine. He participate in coordination strategic program in the frame Prevention and Treatment of Civilization Diseases.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Contribution to the TRANSCAN-2 co-funded call: 0.5M€.

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Research Foundation – Flanders</i>		
Short name	FWO	Country	BELGIUM
Brief description of the legal entity			
<p>Street: Egmontstraat 5 Town: Brussels Postcode: 1000 Country: Belgium Webpage: www.fwo.be</p> <p>FWO is an independent agency founded in 1928 that supports ground-breaking fundamental research in all scientific domains at the universities of the Flemish Community. Fundamental research seldom leads to short-term economic or social valorization. It is, however, essential for ensuring our welfare and well-being in the long term. The FWO embraces the “bottom-up” principle; this means that the focus of research proposals is determined by the researchers. The decision of the FWO to participate in BiodivERsA3 is based on the advice that we have received from both researchers and research coordination offices of the universities.</p> <p>The FWO is a Public Utility Foundation which was granted legal personality by the Royal Decree of 20 January 2006.</p> <p>The Decree of 30 April 2009 on the organisation and financing of the scientific and innovation policy (BOG (Belgian Official Gazette) 6/7/2009) recognizes the FWO as an External Independent Agency operating under private law.</p> <p>The enterprise number of the FWO is 0880.212.840</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			N
Programme Manager			N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>The research programme with which the FWO participates is Research Project. The objective of the FWO's Research projects is to advance fundamental scientific research through the bottom-up principle (Research projects are initiated by the researchers). Except for some specific provisions within the context of ERA-NET (e.g. project duration), Flemish researchers are subject to the rules for regular research projects. http://www.fwo.be/en/fellowships-funding/research-projects/research-project/.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
Handling of communication, eligibility check and monitoring peer review as far as Flanders is concerned.			
Short profile of staff member(s) who will be undertaking the work			
<p>Dr. Olivier Boehme, Science Policy Advisor, PhD, Research Foundation Flanders, +32-(0)2-550 15 45, olivier.boehme@fwo.be</p>			

Geertrui Poelaert, Advisor Research Affairs, Master, Research Foundation Flanders, +32-(0)2-550 15 55, eranet@fwo.be

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

An indicative budget of co-funded call 0.2M€ [1 project / 3 years]:

- Under the eligibility conditions as stated in our regulations on Research Projects (<http://www.fwo.be/en/fellowships-funding/research-projects/research-project/regulations-for-research-projects/>)
- Through the virtual common pot principle

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Országos Onkológiai Intézet</i>		
Short name	OOI	Country	HUNGARY
Brief description of the legal entity			
<p>The predecessor of the National Institute of Oncology has been founded under the name of Loránd Eötvös Radium Institute in 1936 as a comprehensive cancer center. After the WWII the Institute was relocated its current place and has been nominated as the National Institute of Oncology. The institute now is a large comprehensive cancer center with about 12000 new registered patients per year, comprising of 15 clinical/diagnostic and 7 research departments. Its clinical activities extend to prevention, screening, early detection, diagnostics, treatment and rehabilitation / palliation of cancer patients. Its research center is active in nearly all field of translational cancer research.</p> <p>According to its founding document the institute is the professional background Institution of the Ministry of Health and responsible for the postgraduate education of oncology and radiotherapy, developments and implementation of the National Cancer Control Plan, development of the national guidelines on oncology, running the National Cancer Registry.</p> <p>As the expert institute of the Ministry of Health, the National Institute of Oncology participates in the distribution of budgets allocated by the Ministry of Health in all areas of oncology. In the project of ERANET on translational cancer research the National Institute of Oncology have a special entitlement from the Ministry of Health of Hungary to organize the distribution of the allocated budget.</p> <p>Website: http://www.oncol.hu/site/en/index.html</p>			
Identification of the role:			
Programme Owner and Manager			N
Programme Owner			N
Programme Manager			Y
In case you are a Programme Manager, please name the respective Programme Owner			
Ministry of Human Resources of Hungary			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>The institute participated and takes part in several projects in European oncology development and network formations like EUROCANPLUS+, CoCanCPG, OECI project on accreditation and designation of cancer centers. NIO also organizes and participates in regional networks like the Central and Eastern European Cancer Genetics Network, educational network between central-European countries etc. NIO is a participant of the largest oncology research consortium, a network of excellence funded by the EU the acronym EUROCNAPLATFOM. NIO is an active participant of the TRANSCAN ERA-NET.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>NIO will participate in the strategic development of the consortium (WP4).</p> <p>Previous experience. NIO has been active in the TRANSCAN ERA-NET from the beginning. A staff of OOI (Jozsef Lovey) has been served as the vice chair of the consortium's network steering committee.</p>			

Short profile of staff member(s) who will be undertaking the work	
<p>Jozsef Lovey, M.D. 1993, specialization in radiation oncology in 1997, in medical oncology in 2000, Ph.D. in radiation oncology and tumour biology in 2006, employed in various positions at the National Institute of Oncology since 1993, currently deputy department head in Radiation Oncology former director of international relations and currently medical director.</p> <p>Peter Nagy, Ph.D. Head of department of Molecular Immunology and Toxicology with primary research focus on basic cancer research (more specifically: proteomics, biomarker discovery, redox mediated cellular signaling and oxidative stress). Currently Director of International Relations at the National Institute of Oncology.</p> <p>Erzsebet Podmaniczky, M.D. Ph.D. Specialist of surgical pathology. Former department head of International Affairs at the Ministry of Health of Hungary. Currently head of International Department of the National Institute of Oncology Budapest.</p>	
Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.	
Not applicable.	
Does the participant envisage that part of its work is performed by a linked third parties.	N
<i>If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party</i>	
Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
<i>If yes, describe the third party and their contributions</i>	

Name of organisation	<i>Kreftforeningen - Norwegian Cancer Society</i>		
Short name	NCS	Country	NORWAY
Brief description of the legal entity			
<p>The Norwegian Cancer Society is a national cancer charity addressing the challenges of cancer on multiple levels. The Society supports cancer research, helps cancer patients and their families, launches and supports initiatives that provide improvements in cancer care, engages in political advocacy, and puts problems with health policy on the agenda. Priority areas are research, international work, cancer care, advocacy and public relations, information/health education and cancer prevention. The head office of the Norwegian Cancer Society is located in Oslo and it also has regional offices in Tromsø, Trondheim, Bergen, Kristiansand, Hamar, Tønsberg, Stavanger and Oslo.</p> <p>The Norwegian Cancer Society receives very little governmental funding and the work is funded primarily through fundraising, bequests and support from Norsk Tipping (Norwegian National Lottery). In 2013 the Society allocated NOK 448, 9 million (€ 56,1 million) to its core activities. This represents 86 per cent of total allocated funds. Of this, 51 per cent was allocated to research.</p> <p>The Norwegian Cancer Society is a significant source of funding for cancer research in Norway and allocated a total of NOK 221,4 million (€ 27,7 million) to cancer research projects at Norwegian universities, hospitals and other research institutions in 2013 mainly through open national calls. The Society also offers investment funds for early stage capital funding for start-up companies within the oncology field.</p> <p>Website: https://kreftforeningen.no/en/about-us/</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			N
Programme Manager			N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
NCS has funded JTCs in the framework of the ERA-NET on Translational Cancer Research TRANSCAN.			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
NCS will participate in the preparation and implementation of the co-funded call (WP2) and in other work packages activities.			
Short profile of staff member(s) who will be undertaking the work			
<p>Nina Ånensen, PhD in cell biology, University of Bergen 2006. Previous experience as cancer researcher, and as clinical assessor for the national competent authority on medicines. Is at present a special adviser with the Norwegian Cancer Society.</p>			
Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.			
No maximum amount of financial support to a third party is set by NCS. The amount for the co-funded call contribution will be 0.5 M€.			

Information on the funding rules applied by NCS can be found at: <https://kreftforeningen.no/forskning/slik-tildeler-vi-forskningsmidler/> and in the [Guidelines for research grant applications and allocations](#)

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Fonds National de la Recherche Scientifique</i>		
Short name	FNRS	Country	BELGIUM (French speaking community)
Brief description of the legal entity			
<p>The Fund for Scientific Research (F.R.S.-Fnrs) is a research funding agency that promotes and supports basic scientific research in the French-speaking community of Belgium. Founded in 1928, it mainly receives public subsidies, currently from the French-speaking Community of Belgium, the Walloon Region and the Federal Government of Belgium. The Fund supports individual researchers on the basis of the criterion of excellence by offering temporary or permanent positions; funding to research teams; grants and credits for international collaboration and scientific prizes. F.R.S.-Fnrs fosters research in all scientific fields, following a bottom-up approach of investigator-driven research. Further, the Fund supports researchers in an evergrowing context of internationalisation through facilitating their mobility, allowing for collaborative transnational projects and supporting a high level international working environment. Since October 2008, Dr. Ir. Véronique Halloin is the Secretary-General of F.R.S.-Fnrs.</p> <p>Website: http://www.fnrs.be/</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			
Programme Manager			
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>The FNRS is currently involved in a variety of European initiatives and bilateral agreements at the international level. The FNRS is full partner in CHIST-ERA (ICT), FLAGERA (ICT), ERA-CAPS (plant sciences), E-RARE-2 (rare disease), GENDER-NET (gender policies and research), Pasteur4O (open access) and HERA (ERA-Net+ in humanities). In addition, the FNRS participates in the transnational join calls of JPND, TRANSCAN, JPI-AMR, ERA-CAPS, INFECT-ERA, NEURON, JPI Urban Europe and JPI HDHL.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>FNRS will contribute to the implementation of the co-funded call (WP2) as well as of the TRANSCAN-2 additional joint calls. In addition, FNRS will participate in WP3.</p>			
Short profile of staff member(s) who will be undertaking the work			
<p>Arnaud Goolaerts, PhD in biomedical and pharmaceutical sciences is a scientific officer at the Unit of International and European Affairs in charge of transnational cooperation. He represents the Fund at several national and European networks.</p> <p>Freia Van Hee, M.A. in international and European law, is a policy officer at the Unit of International and European Affairs in charge of transnational cooperation. She has gained experience in advocacy work towards policymakers, the development of transnational policies as well as the implementation thereof. She represents the Fund at several national and European networks and monitors European research policies. She was a member of the Iglo (Informal Group of RTD Liaison Offices in Brussels) WG on Joint programming and is currently a member of the national consultation group supporting the Belgian representation at the High Level Group on Joint Programming (ERAC-GPC).</p>			
Please specify the maximum amount of financial support to a third party and the criteria for			

determining the exact amount under national funding rules.	
No maximum amount of financial support is defined nor constrained by FNRS funding rules. The amount for the Co-fund call contribution will be 0.2 M€.	
Information on the funding rules applied by FNRS can be found at: http://www.ncp.frs-fnrs.be/index.php/17-appels/131-fnrs-eligibility-criteria-transcan-2014	
Does the participant envisage that part of its work is performed by a linked third parties.	N
<i>If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party</i>	
Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
<i>If yes, describe the third party and their contributions</i>	

Name of organisation	<i>Ministero dell'Istruzione, dell'Università e della Ricerca</i>		
Short name	MIUR	Country	ITALY
Brief description of the legal entity			
<p>The Italian Ministry for Education, University and Research (MIUR) is the key RTD policy actor and funding agency in Italy at state level.</p> <p>MIUR is in charge to prepare and to submit the National Research Programme (PNR – Piano Nazionale della Ricerca) proposal to the Government and to directly manage it. In preparation of the new PNR, MIUR adopted, on March 2013, a new strategic document called “Horizon 2020 Italy” aimed at defining a reference framework coherent with the European one.</p> <p>Besides, the Ministry, in charge of definition of strategic priorities in Research and higher education, has the following responsibilities: coordination, assessment and evaluation of the national university system and advanced training schools; supporting and fostering basic research in university and research institutions, programming intervention in public research institutions; coordination, regulation and funding of national research institutions; coordination of the research activities promoted by other Ministries; monitoring and supporting the integration between the research system and industries; integration between public research and applied research; promoting and supporting research in the industry system; funding research programmes for southern regions; promoting initiatives such as the Funds for the diffusion of scientific culture (PUS); enforcement of EU and international rules on university education and research. The Ministry also has key responsibilities for international co-operation. It concludes bi- and multilateral agreements on research and technology collaboration and is in charge of co-ordinating Italy's participation in the European Union's Framework Programme.</p> <p>Website: http://www.istruzione.it/</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			N
Programme Manager			N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>MIUR runs a special programme named FIRST (Fondo per gli investimenti nell'area scientifica e tecnologica – Fund for Investments on scientific and technological research).</p> <p>This programme, set at the beginning of year 2007 and completely renewed in mid-2013 with new, simplified and very flexible procedures, replaces all the programmes previously managed by the ministry. FIRST is a sort of framework programme dedicated to fund basic research, industrial research and experimental development activities. Thematic orientations and implementing procedures will be defined in each call text.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>MIUR will participate in the activities related to preparation and implementation of the co-funded call (WP2) as well as of the TRANSCAN additional joint calls. In addition, MIUR will contribute to WP3 and WP6.</p> <p>Previous experience relevant to those tasks:</p> <p>MIUR has participated in seven FP6 ERANETs, in eleven FP7 ERANET and in three FP7 ERANET+,</p>			

MATERA+, FACCE+ and HERITAGE+.

Short profile of staff member(s) who will be undertaking the work

Dr. Maria Uccellatore is in charge as Head of EU programmes Office within MIUR. She is also the Italian representative in several EU initiatives (ERAC, COST, GPC, EU-LAC ...) and she is the person in charge of the administrative, legal and financial aspects in all the ERANET and ERANET+ projects participated by MIUR.

Dr. Aldo Covello is a senior scientific advisor for MIUR and represents the ministry in several European initiatives and committees: JTIs ENIAC and ARTEMIS, JPIs, ERANETs and ERANET+.

Dr. Silvia Nardelli is in charge as Head of the Office for the management of the national funding procedures for international collaborative projects.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Maximum contribution to the co-funded call is 0.5M€.

Information on the funding rules applied by MIUR can be found at <http://www.ricercainternazionale.miur.it/>

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contribution

Name of organisation	<i>Estonian Research Council - Eesti Teadusagentuur</i>		
Short name	ETAg	Country	ESTONIA
Brief description of the legal entity			
<p>The Estonian Research Council (ETAg, website: http://www.etag.ee) is a private body fulfilling public functions, responsible to the Ministry of Education and Research. Its main goal is to support the most promising research initiatives in all fields of basic and applied research including humanities and social sciences.</p> <p>The ETAg includes several national programmes for research: Health R&D programme, Environmental Conservation and Environmental Technology R&D Programme and Estonian Research Infrastructures Roadmap activities.</p> <p>The ETAg acts as National Contact Point for the Horizon 2020, coordinates participation in the COST network and consults mobile researchers through the EURAXESS network and manages the Estonian R&D Liaison Office in Brussels.</p> <p>Estonian Research Council is also responsible for coordination of several international, bi- and multinational cooperation programmes (BONUS, ERA-NETs, EUROCORES and other).</p> <p>The ETAg is the authorized processor of the Estonian Research Information system, the information channel for submitting and processing grant applications, as well as submitting and confirming project reports.</p> <p>The ETAg runs a wide variety of science communication activities, and leads a national programme for science popularization.</p>			
Identification of the role:			
Programme Owner and Manager			<u>Y</u> /N
Programme Owner			Y/N
Programme Manager			Y/N
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>ERA-NET Cofund calls will be financed from ETAg budget line aimed to support the Estonian participation in the international scientific co-operation initiatives.</p> <p>Activities are additionally supported by Health promotion research programme TerVE The programme is designed to raise health consciousness among Estonians and to sustainably improve the nation's health indicators on the basis of the best science-based knowledge. The important objectives of the programme include making the evaluation of the impacts of environmental risk factors to health more effective, developing opportunities to collect and use health information and evaluating health technologies. Following projects are supported: Cancer Screening Registry, Estonian Cancer Registry Quality Analysis.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>ETAg will participate in the implementation of the co-funded call (WP2) as well as of the TRANSCAN-2 additional fourth joint call (WP9). In addition, ETAg will actively contribute to the WP4 Task 4.5 (Strategy on identifying scientific priority topics).</p> <p>ETAg has been partner in more than 20 ERA-NETs, and has fulfilled a variety of functions (manager of proposal submission environment, organizer of several type of events, etc.)</p>			
Short profile of staff member(s) who will be undertaking the work			

Argo Soon, NCP as well as Programme Committee member for Health and BioEconomy since begin of FP7, has been involved in FP projects since FP5.

Aare Ignat, project manager. He has long term experience working in ETag international scientific co-operation initiatives (ERA-NETs, bi-lateral cooperation initiatives).

Margit Suuroja, chief specialist of the environmental and life sciences. She has good experience with project management of the ERA-Net projects (BONUS, AMPERA, BiodivERsA).

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Contribution to the TRANSCAN-2 co-funded call: 0.1M€.

Information on the funding rules applied by ETag can be found at <http://www.etag.ee/en/research-funding/>

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

If yes, describe the third party and their contributions

Name of organisation	<i>Fundación para el fomento en Asturias de la Investigación Científica Aplicada y la Tecnología</i>		
Short name	FICYT	Country	SPAIN
Brief description of the legal entity			
<p>Private non-profit Foundation that manages the Regional Technology & Science Funding Programme (PCTI), carrying out tasks of elaborating the strategic agenda of the PCTI and the calls, evaluating projects and managing the projects funded. The Government of the Principality of Asturias is the Program Owner. FICYT has a mandate of the Government of the Principality of Asturias to manage the Regional R&D Funding Programme, but FICYT is an independent entity, FICYT is a private non-profit entity and does not currently belong to the Government.</p> <p>The regional calls are published in the Regional Official Journal (BOPA) in the name of the Government of the Principality of Asturias, but the budget of the Regional calls is given to FICYT and FICYT distributes it through the beneficiaries (companies and research organisations). Other activities and departments of FICYT:</p> <ul style="list-style-type: none"> – Management of the Regional Health Research Office, by mandate of the Regional Health Ministry, to foster the participation of Asturian Health System researchers in National and European Health related projects, carry out the management of National and European funded projects and develop the Health Observatory in Asturias. – Coordination of the consortium Galactea+ that covers four regions in the northwest of Spain, in the framework of the Enterprise Europe Network (EEN). The EEN foster the participation of European entities in H2020 and transnational technology transfer activities. – Scientific and Culture Innovation Unit (UCC+i): disseminate, at regional and national level, research results of relevant R&D projects carried out by Asturian companies and research centers. The channels used are press media, press conferences, National Agencies for dissemination of research results, social networks,... – Mobility Programs: FICYT manages Leonardo Program in Asturias and a National Program of Mobility for university students to carry out internships in international companies. FICYT also coordinates an FP7 Mobility Project, “Clarín2013” (2013-2017), funded under COFUND-PEOPLE program that co-funds Postdoctoral incoming and outgoing grants. – “Support Services to foster the participation of Asturian companies in H2020” project (2014-2016). Project funded by the Spanish Ministry of Economy and Competitiveness. <p>Website: http://www.ficyt.es/</p>			
Identification of the role:			
Programme Owner and Manager			N
Programme Owner			N
Programme Manager			Y
In case you are a Programme Manager, please name the respective Programme Owner			
Regional Employment and Economy Ministry			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>The Regional Technology and Science Funding Programme contains different kind of calls to fund: university students, doctorates, R&D projects to be developed by companies or research organisations, support technology transfer activities and participation in European projects, protection of R&D projects results,... For the participation in TRANSCAN-2, it will be launched a new Regional R&D funding call in Cancer research to fund Regional companies that develop a research project in collaboration with at least a research organisation of other TRANSCAN-2 partner country. The main aim of the new call will be to step up funding of transnational collaborative research projects in the area of translational cancer research. Cancer research in Asturias region is strategic since there are several research groups and companies relevant at</p>			

national and international level. Several research groups at the University of Oviedo, the Asturias Central University Hospital and the Asturian University Institute of Oncology.

There are at least 6 companies, 5 SMEs and 1 private Institute of Molecular and Oncological Medicine of Asturias, that are carrying out research projects in Cancer and that have shown their interest in applying for a project in a Regional call under TRANSCAN-2.

Main tasks attributed the proposed action and the previous experience relevant to those tasks

FICYT will contribute to the achievement of the following objectives:

- Development and alignment of national and regional plans with other TRANSCAN-2 partners;
- Establishment and/or implementation of a common strategic research agenda;
- Elaboration of a Regional R&D funding call in Cancer field in coordination with other partners from different countries: definition of requirements of the call, evaluation criteria, budget and dates. Identification of common research priorities and research needs, also taking into account developments on the international level where relevant;
- Sharing of data and knowledge with other TRANSCAN-2 partners and networking of infrastructures and databases;
- Dissemination of TRANSCAN-2 aim and activities and the Regional R&D call.

In particular, FICYT will participate in the implementation of the co-funded call (WP2) as well as of the TRANSCAN-2 additional joint calls. In WP9 (Preparation and implementation of a fourth joint call), FICYT will be co-leader in subtasks 9.1.1 (with FCT), 9.1.3 (with ACC), and in Task 9.2 (Implementation of the JTC 2017) together with ACC. FICYT will also contribute to WP4, in which it will co-lead the subtask 4.5 (Strategy on identifying scientific priority topics) together with INCa.

FICYT does not have previous experience in ERANET actions but has wide experience in collaborating and exchanging knowledge with national and international funding agencies, apart from its experience in elaborating research agendas and Regional R&D funding calls.

Short profile of staff member(s) who will be undertaking the work

Inés Rey Hidalgo: Biology degree. Female. Innovation Management Technician of FICYT since 2002. Wide experience in elaboration and management of Regional funding calls and evaluation of Regional R&D projects. Other tasks: management of European projects and support of companies and research organisations to take part in European projects, mainly European Health Programme and FP7/H2020, and management of the European Projects department of the Asturian Health Research Office.

Guadalupe Fernández Tresguerres: Economy degree. Female. Manager of the Financial Department of FICYT since 2000. Wide experience in financial management of Regional R&D Calls and payment to beneficiaries, financial management of European projects and audits.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.

Contribution to the TRANSCAN-2 co-funded call: 0.3M€

Information on regional funding rules applied by FICYT can be found at

http://www.ficyt.es/pri/docs/Bases_Investigacion_Empresas2013.pdf

Does the participant envisage that part of its work is performed by a linked third parties.	N
---	---

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
---	---

Name of organisation	<i>Ministry of Science and Technology</i>		
Short name	MoST	Country	TAIWAN, R.O.C
Brief description of the legal entity			
<p>The predecessor to the Ministry of Science and Technology (MoST) is the National Science Council (NSC), traces its history back to February 1, 1959. As the government's dedicated scientific and technological development agency, the NSC was charged with three main missions of promoting the nation's overall S&T development, supporting academic research, and developing the science parks. In today's knowledge-based economy, S&T innovation has become a key driver of economic growth and national progress. As such, the NSC was reorganized and became MoST on March 3, 2014 with a new organisational structure aiming to facilitate stronger links between academic research and industrial development. MoST will carry on the NSC's tradition of innovative measures and programs and bring academic research another step closer to industrial needs. By fostering an innovative and entrepreneurial spirit and encouraging creativity in science and technology, MoST will boost Taiwan's academic and industrial competitiveness at the international level.</p> <p>MoST currently oversees 16 S&T divisions around the world; these offices broaden partnerships with host nations, maintain contact with scientists in those nations, and have been actively recruiting overseas S&T professionals to meet growing demands at home. In the effort to promote bilateral and multilateral S&T exchange with other countries, MoST has signed 110 cooperation agreements with 43 nations, cooperation takes the form of building exchanges among researchers, organizing joint symposia, conducting collaborative research projects, promoting high-level official visits, and conferring international. All of these efforts help develop practical partnerships with other countries while promoting diplomacy and supporting the government's foreign policies.</p> <p>Website: http://www.most.gov.tw/most_ebook/2014/en/#2</p>			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			N/A
Programme Manager			N/A
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>The MoST funds and operates National Contact Pointes and it is a unique funding agency for Research and Development in Taiwan. Taiwan is classified as a high-income third country by the Commission, which means not eligible to receive direct financial contribution from the Commission. During Framework Program 7, the MoST provided research grants to Taiwan researchers participated in over 30 FP7 projects. In addition, the MoST actively engages in dialogue meeting with the Commission via EU-Taiwan Annual Consultation Platform (usually involves DG RTD and DG CONNECT (former DG InFSO), during the past years, we were also invited to have meeting with ISTAG (Information Society and Technology Advisory Group) to presenting our priorities, the ISTAG made a recommendation to the Commission to support cooperation with Taiwan in some mutual prioritised areas.</p> <p>The MoST operates and funds several National Science and Technology Programs in Taiwan, covering the following themes: Networked Communications, Biopharmaceuticals, Intelligent Electronics, Energy, Genomic Medicine, E-learning and Digital archives, Nano-technology and also Hazards mitigation. Among which the National Program for Nano Technology (NPNT) operates as a program manager to the M-ERA.NET consortium, the MoST has launched a couple transnational calls under M-ERA.NET, and provides research grants to average 2 successful M-ERA.NET projects per year. A separate funding policy has been announced to encourage and support Taiwan researcher participating in the Horizon 2020 program (mainly target for industrial leadership and societal challenges pillars).</p>			

Main tasks attributed the proposed action and the previous experience relevant to those tasks	
MoST will participate in the implementation of the co-funded call (WP2) as well as in WP3 (Follow-up and monitoring of projects resulting from the co-funded JTC 2014 and the TRANSCAN-2 JTCs).	
Short profile of staff member(s) who will be undertaking the work	
Dr. Louis (Yu-Ming) Chen is the Program Director, Department of International Cooperation and Science Education, Ministry of Science and Technology. He is also the Horizon 2020 contact point of Taiwan.	
Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules	
<p>Contribution to the TRANSCAN-2 co-funded call: € 1M (100% by the MoST, 0% from the Commission).</p> <p>The MoST will provide research funding to support Taiwan researchers with successful project. Normally the research grant is up to New Taiwan Dollar (NTD) 3M/year, but it can vary case by case, depends on the size and scale of each project, the exact amount is usually determined after technical reviews conducted by the academic departments of the MoST.</p> <p>The MoST usually publishes national funding rule of a specific program together with Calls for Proposals. The following link is MoST's announcement page; the national funding rule for the TRANSCAN-2 will appear in this site (most likely in Chinese). http://www.most.gov.tw/wlp.aspx?CtNode=42&CtUnit=31&BaseDSD=7&mp=1 (to appear)</p>	
Does the participant envisage that part of its work is performed by a linked third parties.	N
Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
<i>If yes, describe the third party and their contributions</i>	

Name of organisation	<i>Valsts izglītības attīstības aģentūra</i>		
Short name	VIAA	Country	LATVIA
Brief description of the legal entity			
<p>The State Education Development Agency (VIAA) is a governmental institution under the direct auspices of the Ministry of Education and Science (MoES). The main tasks of the Agency are Implementation of European Union programmes, structural and financial instruments in the area of education and science. According to the Decision of The Cabinet of Ministers, Republic of Latvia (Provisions Nr 572, 23.09.2014: Changes in the provisions No 934, 18.12.2012 “Regulations of State Education Development Agency”), official publication 31.10.2014, the Latvian National coordination functions for European Union Research and Innovation programme Horizon2020 as well as functions related to European Research area (ERA) instruments, in particular – ERA-NET, ERA-NET COFUND, Article 185/187 initiatives, EJP have been transferred to the Agency. As of January 2015, the Agency is the owner and manager of the National programme. Participation in International Co-operation Programmes in the Fields of Research and Technologies” comprising the Latvian national funding instrument for participation in all ERA-NET and ERA-NET COFUND scheme projects. VIAA is the signatory for ERA-NET Cofunds HERA, COBITE, EURONANOMED-III, ERA-CVD, NEURON-Cofund, SuSAN, JPI-EC-AMR for Latvia.</p>			
Identification of the role:			
Programme Owner and Manager			N
Programme Owner			Y
Programme Manager			Y
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>State Education Development Agency is the owner and manager of the National programme. Support to participation in International Co-operation Programmes in the fields of research and technologies”, according to provisions of the Cabinet of Ministers No 259, 26.05.2015.</p>			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<p>VIAA will participate in the implementation of the co-funded call (WP2) and also of the additional TRANSCAN-2 joint calls. In addition, LAS will contribute to WP3, WP5 and WP4, in which will co-lead with FCT the Task 4.2 (Strategy on improving partners’ success in JTCs) and will participate in Task 4.3 (Strategy on improving the decision-making) and Task 4.5 (Strategy on identifying scientific priority topics).</p>			
Short profile of staff member(s) who will be undertaking the work			
<p>Dr Maija Bundule (female), Head of the Department of International Research programmes, VIAA. Maija has more than 20 years of experience in scientific collaboration activity management on international scale. Maija has a broad experience in managing Latvian participation in ERA-NETs across all areas.</p> <p>Dr Uldis Berkis (male), Senior Expert, VIAA. Participates in management of Latvian participations in ERA since 2007. Has a broad experience in managing Latvian participation in ERA-NETs in Health and KBBE areas. NCP/PC Health and Research Infrastructures.</p>			
Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules.			
<p>Support rate correspondingly to EU Regulation 651/2014. Research organisations registered as scientific institutions in Latvia have 100% support. Companies depending on research category, for fundamental research 100%, as this is the research type supported in TRANSCAN-2.</p>			

Contribution to the TRANSCAN-2 co-funded call: 0.3M€.

Information on the funding rules applied by VIAA can be found at
http://viaa.gov.lv/lat/zinatnes_inovacijas_progr/era_net_proj/par_era_net/

The maximum contribution is currently 210.000 EUR per participant and proposal, and maximum two participants funded by VIAA are allowed in a proposal.

Does the participant envisage that part of its work is performed by a linked third parties.	N
<i>If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party</i>	
Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
<i>If yes, describe the third party and their contributions</i>	

Name of organisation	<i>Tuscany Region</i>		
Short name	TuscReg	Country	Italy
Brief description of the legal entity			
<p>Regione Toscana (Tuscany Region) is the regional authority and administrative body of Tuscany Territory; it has legislative, administrative, and financial autonomy and is responsible, on a regional level, for issues including education, social issues, healthcare, international cooperation, and the environment.</p> <p>The Tuscan health system includes three Local Health Authorities, four university hospitals, ISPRO and Monasterio Foundation:</p> <ul style="list-style-type: none"> • Central Tuscany: Local Health Authorities (Florence, Prato, Pistoia, Empoli) • Northwest Tuscany: Local Health Authorities (Lucca, Massa e Carrara, Versilia, Pisa and Livorno) • Southeast Tuscany: Local Health Authorities (Siena, Arezzo and Grosseto) • University hospital Careggi (Florence) • University hospital Meyer (Florence) • University hospital of Pisa • University hospital of Siena • ISPRO (Istituto per lo Studio, la Prevenzione e la Rete Oncologica) • Fondazione Toscana Gabriele Monasterio <p>The health system is the sector to which the region commits the largest share of its budget and organizational structure, and constitutes an infrastructure of services and activities that can generate positive effects throughout the region. It is, in spite of and even more so in a period of economic crisis, a driving force of development for the entire regional economy, in which economic development is seen not as an end in itself but also includes, in a context of sustainability, measures tied to the social sector and the environment. Regione Toscana is also actively involved in the promotion of the Tuscan Life Sciences Cluster for large and small companies operating in the sector.</p> <p>Regione Toscana has a long-standing tradition of activities to promote wellness, including healthy diets and physical activity. The latest version of Regione Toscana's multi-year health plan includes a major focus on "health in all policies", i.e. the promotion of healthy lifestyles across all sectors (urban planning, environment, welfare, transportation, commerce, schools, culture, sport, etc.). The project team will include colleagues in other relevant sectors of the regional government as well as the region's associated health agencies for specific expertise on obesity; expertise in the management of European projects will also be present.</p> <p>Tuscany Region promotes health research and innovation policies to structure an integrated and synergistic research and innovation system in a coordinated context among Tuscan university hospitals and other institutions of the Regional Health Service.</p> <p>Main activities in this field:</p> <ul style="list-style-type: none"> • Calls for funding (using regional, national and structural funds); • Creation of UVaR - office for exploitation of research results – that is engaged in assessing, monitoring and exploiting the results of research in terms of applicability and transferability. An activity to support the Tuscan university hospitals and other institutions of the Regional Health Service, universities and public research organizations in order to develop and leverage innovative capacity and technology transfer, also through the creation of collaborative channels with companies and other stakeholders in the Life Sciences sector; • Support to Tuscany Life Sciences Cluster, founded in 2011 by an initiative of the Tuscany Region aimed at creating an integrated Life Sciences system. Its mission is to act as the "glue" between the specialist industrial dimension and the institutional and systemic one, promoting dialogue among companies and the network of excellence present in the field of research and technology transfer in the region. <p>The Regional Network on Cancer</p> <p>The regional network on cancer coordinates all the activities for the prevention, diagnosis, treatment and research in the oncological field carried out by regional health organisations, ISPRO is in charge of the operational</p>			

coordination of the network, approves the multiannual strategic program and supports the management, implementation and monitoring of the network itself.

ISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica: The Istituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO) is a body of the Regional Health Service whose purpose is to promote, measure and study primary, secondary and tertiary actions for cancer prevention and to organize and coordinate, in synergy with other bodies of the regional health service, prevention, diagnosis, treatment and research in the field of oncology.

Inside ISPRO, the Core Research Laboratory operates, through different Units located in Florence, Siena and Pisa, with the task of carrying out basic research on cancer and in particular on the molecular mechanisms that are at its origins, creating synergies within the regional oncology network.

Website: <http://www.regione.toscana.it/home>

Identification of the role:	
Programme Owner and Manager	Y
Programme Owner	Y
Programme Manager	Y
In case you are a Programme Manager, please name the respective Programme Owner	
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;	
Tuscany region grants research projects through open calls and uses regional resources, ERDF resources and national resources. The call are not published regularly (i.e. once a year); often, in order to commit more resources to a particular/strategic topic, multiannual resources are allocated on one call	
The latest call (2018) committed 27,5 Million € on 3 strategic topics: <ol style="list-style-type: none"> 1. Personalized Medicine; 2. New organisational Models; Big data analytics for diagnosis and prevention of diseases ; 3. Basic and translational research in oncology with Personalised medicine approaches. 	
Main tasks attributed the proposed action and the previous experience relevant to those tasks	
TUSREG intends to actively participate in WP5 (Communication, dissemination and networking) and to contribute to the advancement of the network goals as well as to the achievement of long-term priorities (under the framework of WP4 - Strategy: network and scientific research priorities). As translational research in oncology is a regional priority, we are fully committed to join forces with the Transcan 2 network and co-create and deliver the sustainability strategy which aims at a successful transition to the next phase of the Transcan network.	
Short profile of staff member(s) who will be undertaking the work	
<p>Mrs Donatella Tanini (f) Donatella has been working for Tuscany Region - Health Direction since 1990 in the dealing mainly health research and health system. She is responsible of the Organisational Office "Health research and cooperation international health".</p> <p>Skills: Organization and coordination of activities related to health research, for the development and funding of research-innovation projects financed by regional, state and community funds. Relations with health research subjects and with regional directorates interested in the research and innovation system. Relations with regional technical structures of the European Union for the promotion and development of the Tuscan health research system. Coordination of administrative activities related to international health cooperation.</p> <p>Mrs. Silvia Sciammacca (f): Silvia has been working for Tuscany Region - Health Direction since 1990. Since 2004 she has been involved in the regional network on cancer, in charge of the aspects related to prevention and cure, as well as for the cancer research activities. Since 2015 she is responsible of the organisational and administrative aspects connected to Clinical risk, relational risk and gender medicine</p>	

Ms Teresa Vieri (f) Master's Degree in Art, Music and Performing Arts Disciplines, University of Bologna, graduated with honours; First Level Master in "Local human development and International Cooperation: theories, methods and best practices".

She has been Deputy Coordinator of the ART Secretariat for Decentralized Cooperation UNOPS/PNUD in Florence; Area Manager in the Nusa Tenggara Timur Province, Indonesia for the ART Programme (Articulating Territorial and Thematic Networks for Human Development) of UNDP (United Nations Development Programme), Public Officer for International Relations and Cooperation in staff of the Mayor of Florence, Municipality of Florence. She is currently Assistant for the Management of National and European Funds, Directorate for Citizenship Rights and Social Cohesion, Tuscany Region.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules:

<http://www.regione.toscana.it/bandi/aperti>

Does the participant envisage that part of its work is performed by a linked third parties.

Y

Toscana Life Sciences Foundation (TLS) is a non-profit organization founded by a group of public and private institutions in Tuscany to support research activities in life sciences, in particular, for sustaining the development of projects from basic research to industrial application. It operates in the sector of technology transfer for incubated companies and all regional stakeholders to provide an integrated support for the exploitation of the research system, with particular attention to the protection of intellectual property, business development, and support for the activation of the process of business creation. TLS also supports the Tuscany Region Government in the development and management of innovative policies for the Regional Healthcare System. **TLS and Tuscany Region jointly coordinate the Regional Office for the Exploitation of Biomedical Research Results (UVaR)** established with an agreement by Tuscany Region, as well as the activities of the Tuscany Life Sciences Cluster (TLSC). TLS gathers together all the Tuscany life sciences stakeholders (6 universities, 3 National Research Council Institutes, 4 university hospitals and about 200 companies,) with the purpose of creating, maintaining and keep growing a productive environment in terms of innovation and business opportunity for all players of regional life sciences sector.

TLS is part of many networks at Italian and European level. Namely, TLS is part of the APSTI (Italian Scientific Park Association). TLS manages the Tuscany Life Science Cluster (TLSC), thus having access to its entire network of about 200 companies and several research centres, and takes active part in the Italian Life Sciences Cluster. TLS takes also part into the In2LifeSciences project as an Observing Region. TLS is an active member of the National Life Science Cluster of Italy (3 national life sciences industrial associations, 4 national research organizations, 12 life sciences organizations representing regional interests in the sector) and it is also a member of the European Council of Bioregions (CEBR).

In addition, TLS is coordinator of the Regions4PerMed project which is a H2020 initiative focused on the coordination of regional policies and innovation programmes on personalised healthcare and personalised medicine.

Staff members involved:

Mr. Gianni D'Errico (m) is the International Project Officer and EU affair at Toscana Life Sciences Foundation (TLS). He obtained his degree cum laude in International Relations At Napoli University Federico II. He obtained his Post Graduate master's degree in Project Management in Rome at SIOI (Società Italiana per l'Organizzazione Internazionale) and a certification in IP Management at University of Bonn (DE). He started his professional career in Brussels managing R&D project within FP7. In 2013, he moved in Slovenia where he gained an extensive experience on the R&D project in Health Sector for the main international players. In 2015, he moved to Milan as European Funding Officer at Regional Foundation for Biomedical Research (Lombardy Region) and in 2018 he moved to Tuscany Region as International Project Officer and EU affairs responsible at Toscana Life Sciences Foundation (TLS). Gianni is supporting the active participation of Tuscany Region in the main European Consortium of Personalised Medicine: ERA-PerMed and IC-PERMED.

The main Projects he currently manages:

- Regions4PerMed: CSA for the creation of the first interregional coordination of regions on personalised health (Role: Coordinator).
- AI4Diag: Strategic Cluster Partnership for increased competitiveness of European Medical Diagnostics

SMEs thanks to Artificial Intelligence.

- Development of joint interregional project under the s3 platform on Medical technology.

Dr. Andrea Frosini (m): Andrea is the scientific responsible of the Tuscany Region Office for the exploitation of Research Results, and IPR manager at Tuscany Life Science Cluster & Foundation. He received a Pharmaceutical Chemistry and Technology degree in 1999 at the University of Florence, and a Ph.D. in Molecular Medicine at University of Milan, Chemical Sciences, in 2005. Besides the activity of technology transfer and business development strategies for the patent and know-how portfolios, he supports the setup of regional policies and procedures for technology transfer for the three universities (of Florence, U. o Pisa, and Siena, and the four university hospitals in the region. He is also involved in education and dissemination activities to foster the developing of entrepreneurial culture in Tuscany stakeholders. He coordinates activities relevant to technology transfer in the field of Life Sciences with regional and national government bodies and policy-makers. In the past years he has been the reference and the contact person for all European project of TLS Foundation and he was the Work Package Leader for the project EPISODE, funded in FP7. He is author of more than 7 peer-reviewed international publications and 2 patents.

Dr. Cinzia Giordano (f): Cinzia is IPR & Technology Transfer Specialist at Tuscany Life Science Foundation. She received a Biology degree in 2003 and a Ph.D. in Cell Biology and Development in 2007 at Sapienza, University of Rome. At Tuscany Region Office for the Exploitation of Biomedical Research Results (UVaR), she supports researchers from the three universities (Florence, Pisa, and Siena) and the four university hospitals in the region in the analysis of the prior art, freedom to operate and in the assessment of competitive scenario and regulatory framework of innovative ideas and inventions in biomedical and health-related field. She also supports researchers in the drafting of agreements for the exploitation of research results and technology transfer. Moreover, she supports the Healthcare Directorate of the Tuscany Region in the preparation and execution of calls for proposals, with particular reference to the definition of the evaluation process for the projects, identification of candidates for the scientific evaluation committee and in monitoring the technical and scientific issues of the funded projects.

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)

N

If yes, describe the third party and their contributions

Name of organisation	<i>Fondazione Regionale per la Ricerca Biomedica</i>		
Short name	FRRB	Country	Italy
Brief description of the legal entity			
<p>Founded in 2011 by Lombardy Region, Fondazione Regionale per la Ricerca Biomedica (FRRB) represents one of the main strategic platforms for boosting progress, research, development and innovation in hospitals, universities and research centres focused on biomedical research. Its <i>raison d'être</i> is to serve as support for the implementation of the regional health research policy. FRRB aims to invest local and European resources in innovative basic and translational research projects to generate positive impact on the local healthcare eco-system and citizens. Characterised by interdisciplinarity, biomedical research is leading to medical and technological advancements, with major impact on both life expectancy and quality.</p> <p>FRRB provides resources and support to biomedical research in Lombardy through the following activities:</p> <ul style="list-style-type: none"> - Supporting translational research projects through competitive calls for proposals - Attracting European and International research funds to Lombardy by participating in European projects, as those in the EU HORIZON 2020, and in international partnerships. - Liasing with Regional technological clusters in life sciences, thus enabling a better coordination of research agendas in the biomedical area. FRRB is member of the Lombardy Life Sciences Cluster - Promoting the dissemination of scientific knowledge, including Responsible Research and Innovation (RRI) principles and promoting gender equality policies <p>FRRB is supported by a Scientific Committee, composed by highly regarded scientists in the field of life sciences (most recognised scientists, Director and Scientific directors of local R&D Health Organisation).</p> <p>Website: www.frrb.it</p>			
Identification of the role:			
Programme Owner and Manager		Y	
Programme Owner			
Programme Manager			
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>FRRB is dedicated to sponsor research and innovation in Lombardy by assigning regional funds to basic and translational research projects through annual competitive calls for proposals open to all public and private IRCCS (Italian Scientific Institutes for Health Research and healthcare), hospitals and research institutes located in Lombardy.</p> <p>The FRRB annual research programme ("Action Plan") is approved by the Board of directors and formally accepted by the Regional Government. The Action Plan establishes where the regional funding (approximately 25 M Eur per year) will be allocated. The Regional Government approves also the rules and conditions of the competitive calls for proposals launched by FRRB.</p> <p>FRRB participates, both as Funding Agency and Beneficiary, in the other EU-funded initiatives, namely</p> <ul style="list-style-type: none"> - Regions4PerMed, Interregional coordination for a fast and deep uptake of personalised health (GA 825812) - TITTAN, Network for Technology, Innovation and Translation in Ageing (Interreg) - TARGET, TAKing a Reflexive approach to Gender Equality for institutional Transformation (GA 741672) <p>In addition, FRRB is member of the IC PERMED network, being part of the Executive Committee and the Steering Committee and Leader of the Working Group 5.</p>			

Main tasks attributed the proposed action and the previous experience relevant to those tasks	
<p>FRRB has been actively participating as Funding agency in Transcan 2, specifically for the Joint Transnational call-JTC 2016 (budget available 1 M Eur and in JTC 2017 (budget available 1,25 M Eur).</p> <p>As Funding Agency, it has been involved in the following WPs:</p> <p>WP3 - Follow-up and monitoring of projects resulting from the co-funded JTC 2014 and the TRANSCAN-2 JTCs</p> <p>WP4 - Strategy: network and scientific research priorities</p> <p>WP5 - Communication, dissemination and networking</p> <p>WP8 - Preparation and implementation of a third joint transnational call</p> <p>WP9 - Preparation and implementation of a fourth joint transnational call</p> <p>Once Partner, FRRB will continue to work on these WPs, attending meetings and contributing to the implementation of all related actions.</p> <p>Previous experience relevant to the Tasks:</p> <p>FRRB is working both as partner and Funding Agency in other ERANETS:</p> <p>1. ERA-PERMED: FRRB is partner and Work package Leader of Era-PerMed (GA779282). It committed 4M Eur in the JTC 2018, and 1,5M Eur in JTC 2019.</p> <p>2. EJP Rare Diseases: Since 2019 FRRB participates as Funding agency and Partner in the Joint programme or rare diseases (GA 825575). It committed 1,5M Eur in the JTC 2019 and will commit 1 M Eur in the JTC 2020</p>	
Short profile of staff member(s) who will be undertaking the work	
<p>Marina Gerini (f) is General Director at FRRB. Since 1983 she has been working as civil servant. She worked as Manager and Head of Unit for Lombardy Region Government and for Lombardy hospitals.</p> <p>Paola Bello (f) is the European Funding Officer at FRRB, where she is responsible for the implementation and monitoring of EU projects. She has been working on EU projects for several years in Italy and abroad, where she developed her experience in the management of H2020, MSCA and ERC grants.</p> <p>Carmen De Francesco (f) is responsible of the Grant Office. She has more than 10 years of experience in the financial management of EU projects including FP6, FP7, H2020 and ERC projects. Her activities include funding allocation, monitoring of expenditures, drafting of financial reports, supporting the external auditors in the preparation of the Audit certificates, providing all the information and documents required.</p> <p>Paola Larghi (f) Scopus Author ID: 24740841600 ORCID: http://orcid.org/0000-0001-7074-1590</p> <p>Since 2017 Paola is Scientific Officer at Fondazione Regionale per la Ricerca Biomedica. She got her degree in Biologic Sciences a University of Milan in 2005 followed by a PhD in experimental Pathology and Neuropathology. She is responsible for the supervision of all scientific activities funded by FRRB.</p>	
Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules:	
<p>FRRB has been actively participating as Funding agency in Transcan 2, specifically for</p> <ul style="list-style-type: none"> - JTC 2016 (budget available 1 M Eur) - JTC 2017 (budget available 1,25 M Eur). <p>Each project can be funded up to an amount of 500,000 €.</p> <p>Information on FRRB's funding rules can be found at: http://www.frrb.it/it/finanziamenti-alla-ricerca</p>	
Does the participant envisage that part of its work is performed by a linked third parties.	N
<i>If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party</i>	
Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)	N
<i>If yes, describe the third party and their contributions</i>	

Name of organisation	<i>Spanish Scientific Foundation against Cancer</i>		
Short name	FCAECC	Country	Spain
Brief description of the legal entity			
<p>The Spanish Scientific Foundation against Cancer (FCAECC) was established in 1973 and it has long experience in managing and funding research programmes and fellowships, being nowadays the main private entity that devotes its funds to promote and support cancer research in Spain. In the current Strategic Plan (2017-2020), FCAECC states its firm commitment to finance high quality cancer research in Spain, aiming at promoting talent, fostering multidisciplinary collaborations, stabilizing the professional career of researchers and involving society in cancer research, among other goals. Since 2011, FCAECC has granted 334 fellowships and grants to research projects that results in a total of 56 million EUR, of which 17.6 million were granted in 2018. In addition, FCAECC has invested a total of 6,1 million EUR to fund the participation of Spanish research groups in European network with the objective of solving the challenges in cancer by working together. In addition, FCAECC has also a national fellowship programme running since 2002 that aims to support experienced researchers to develop their own research lines and has granted 180 fellowships so far. FCAECC is the first private funding agency of cancer research in Spain.</p>			
Website: https://fundacioncientifica.aecc.es			
Identification of the role:			
Programme Owner and Manager			Y
Programme Owner			Y
Programme Manager			Y
In case you are a Programme Manager, please name the respective Programme Owner			
Identify and describe the research programme(s) with which you participate, the main programme objectives, and any previous experience and participation;			
<p>FCAEE offers different fellowships and grants in order to support cancer research and stabilize scientific career in Spain:</p> <p>1. Fellowships to promote talent:</p> <ul style="list-style-type: none"> - Laboratory Practices Programme AECC: fellowships for undergraduate students that want to have a short-term experience in a research laboratory. - Pre-doctoral AECC: directed to people that would like to obtain a PhD in the cancer field. - Postdoctoral AECC: aimed at helping young researchers to perform a research project after obtaining their PhD. - Investigator AECC: to support scientists that want to consolidate their career in cancer research. - Junior/Senior Physician AECC: to promote research vocation and increase science in the clinical environment. - Master AECC: aimed at physicians to update their molecular oncology knowledge. <p>2. Grants:</p> <ul style="list-style-type: none"> - Proof of Concept AECC: to fund innovative and risky ideas that, in case of success, can result in a change of paradigm in cancer field. - Lab AECC: grants to perform solid projects that are executed by emerging groups. - Projects AECC: grants to finance projects directed by solid principal investigators. - Coordinated Teams AECC: grants for funding cancer research multidisciplinary networks. <p>3. International grants to support multidisciplinary international networks:</p> <ul style="list-style-type: none"> - Accelerator Awards AECC: strategic alliance of FCAECC with Cancer Research UK (CRUK) and Associazione Italiana per la Ricerca sul Cancro since 2017. - Transcan-2: FCAECC has been collaborating with TRANSCAN-2 consortium since October 2016 when the Memorandum of Understanding to fund JTC 2016 was signed. - Permed: since 2019 FCAECC is participating in this ERA-NET. - Worldwide Cancer Research: in collaboration with CRUK since 2019. 			
Main tasks attributed the proposed action and the previous experience relevant to those tasks			
<ul style="list-style-type: none"> - WP3 - Follow-up and monitoring of projects resulting from the co-funded JTC 2014 and the TRANSCAN-2 JTCs 			

- WP4 - Strategy: network and scientific research priorities
- WP5 - Communication, dissemination and networking
- WP8 - Preparation and implementation of a third joint transnational call
- WP9 - Preparation and implementation of a fourth joint transnational call

Short profile of staff member(s) who will be undertaking the work

Marta Puyol, PhD

Marta Puyol, PhD graduated in Genetics in Biotechnology from the University of Sussex, UK in 2002 and then she obtained an MSc in Biochemistry from the Universidad Francisco de Vitoria, Spain and in Molecular Oncology. In 2009 she received her PhD in Life Science by Kingston University, UK. Her PhD was performed at the Spanish National Cancer Centre (CNIO) under the guidance of Dr. Mariano Barbacid on the importance of the inhibition of the Cdk's in a Kras activated context. This pioneering project has led to drug development (Cdk4 and Cdk6 inhibitors) and further clinical trials. Following the PhD she moved to Boston, to join Dr. Richard Hynes laboratory at the MIT Koch Institute, to study the importance of angiogenesis in breast cancer. In 2013 she joined the Scientific Foundation of the Spanish Association against Cancer (FC AECC) where she holds the position of Scientific Director. Her work is focused on developing new approaches to allow Spanish-based researchers to accelerate the results in cancer, raising awareness on cancer research and studying the impact of cancer research on the population.

Esther Aguilar, PhD

PhD in Biotechnology at the University of Barcelona in Barcelona (Spain, 2010-2015) and 2 postdoctoral international experiences at the Cochin Institute in Paris (France, 2015-2017) and the McGill University in Montreal (Canada, 2017-2019). Along all these years she has leveraged her skills in cancer research project management, troubleshooting, critical thinking and data interpretation. In 2019 she joined the Scientific Foundation of the Spanish Association against Cancer (FC AECC) as Research Project Manager. She is in charge of managing national and international fellowships during the various steps involved in the application, selection and follow up of cancer research projects.

Patricia Nieto, PhD

PhD graduated in Biotechnology from the Universidad Francisco de Vitoria, Spain in 2009; and she obtained an MSc in Molecular Biomedicine from the Universidad Autónoma de Madrid, Spain in 2010. In 2009, she joined Dr. Mariano Barbacid's Laboratory to study the therapeutic effect of different protein kinase inhibition to treat lung cancer as well as defining the side effects associated to these treatments. During this period she was responsible of experiment planning and execution of these projects coordinating the activity of facilities and programs, managing, integrating and analysing data from distinct disciplines. In 2015, she obtained her PhD. in Biochemistry, Molecular Biology, Biomedicine and Biotechnology from the Universidad Autónoma de Madrid, Spain. Due to her interest in education and scientific popularization, in 2016 she studied the Master of Secondary School Teaching, Vocational Training and Language Teaching Training from the Universidad Internacional de La Rioja. Finally, in 2017 she joined the Scientific Foundation of the Spanish Association against Cancer (FC AECC) where she works as a Responsible of Projects Execution.

Cristina Mellado

Degree in Management and Business Administration from the Carlos III University of Madrid, and specialized in the Third Sector in Foundation Management from the San Pablo CEU University of Madrid. In 2011 she joined FCAECC where she currently serves as Finance Director, guaranteeing the economic sustainability of the Foundation and its grants and fellowships programmes.

Please specify the maximum amount of financial support to a third party and the criteria for determining the exact amount under national funding rules:

There is not a maximum amount of financial support to a third party, it depends on the available annual budget of FCAECC. Specifically, in the context of the last two calls of Transcan-2, the final budget made available from FCAECC was:

445.909 €. for JTC2016 and 618.300 € for JTC2017.

The criteria for determining the exact amount under national funding rules can be found at:

<https://fundacioncientifica.aecc.es>

Does the participant envisage that part of its work is performed by a linked third parties.

N

If yes, describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party

Does the participant envisage the use of in-kind contribution provided by third parties (Articles 11 and 12 of the Model Grant Agreement)

N

4.2. Third parties involved

Fondazione Toscana Life Sciences (TLS) is involved in the TRANSCAN-2 action as a third party affiliated to TuscReg. TuscReg and TLS work as an institutional couple in the TRANSCAN-2 initiative and have joined to the efforts of the consortium in the communication, dissemination & networking activities (WP5). And, above all, they contribute to the definition of the objectives of the network for a future phase, as well as to the definition of long-term priorities (WP4).

TLS is a non-profit organisation founded by a group of public and private institutions in Tuscany to support research activities in life sciences, in particular, for sustaining the development of projects from basic research to industrial application. TLS also supports the Tuscany Region Government in the development and management of innovative policies for the Regional Healthcare System. TLS and TuscReg jointly coordinate the Regional Office for the Exploitation of Biomedical Research Results (UVaR) established with an agreement by Tuscany Region, as well as the activities of the Tuscany Life Sciences Cluster (TLSC). In the context of the UVaR framework, TLS provides supports to TuscReg in the following areas: a) evaluation, monitoring and exploitation of research results in the life sciences sector; b) support for the definition of regional strategies and the consequent actions to attract investments in the territory, in particular in the field of biomedical research; c) development of innovation in health matters, with particular reference to the pharmaceutical sector, also in order to guarantee better access to innovative and safe medicines for citizens; d) support for the definition of new strategies in clinical experimentation; and, e) activities in support of health research strategies, with particular attention to fund raising activities.

It is worth mentioning that TLS plays a central role in the Regions4PerMed project which is a H2020 initiative focused on the coordination of regional policies and innovation programmes on personalised healthcare and personalised medicine. An eventual synergy between TRANSCAN and Regions4PerMed could open a strategic partnership to actively seek common ground on issues of mutual interest, support each other's agendas and take joint actions at regional, national and EU level.

4.3. Financial support to third parties

Not applicable.

5. Ethics and security

5.1. Ethics

The ethical issues listed in the ethical issue table in the administrative proposal forms do not apply to the specific work proposed by the TRANSCAN-2 consortium.

TRANSCAN-2 will address the following ethical issues:

- (i) Equality and transparency in operational procedures. These principles will be guaranteed by the management and decision-making structures, which are based on the principle of consensus, and by the large experience of the involved partner organisations in European cooperation.
- (ii) Ethical issues in funded research projects. TRANSCAN-2 will make sure that the applicants for research funding must correctly address potential ethical issues involved in their planned research projects (e.g. research on humans or animals, privacy of data and biomaterials, informed consent, etc.). The TRANSCAN-2 partners will only fund those projects that completely fulfil the legal and ethical International/EU and National and Institutional standards. The adherence to these standards is usually confirmed by positive votes from the responsible ethical committees.

5.2. Security

Please indicate if your project will involve:

- activities or results raising security issues: NO
- ‘EU-classified information’ as background or results: NO

ESTIMATED BUDGET FOR THE ACTION

	Estimated eligible ¹ costs (per budget category)							EU contribution			Additional information				
	A. Costs related to trans-national projects						B. Direct coordination costs of additional activities		C. Indirect costs ²	Total costs	Reimbursement rate %	Maximum EU contribution ³	Maximum grant amount ⁴	Information for auditors:	Other information:
	A.1 Direct costs of providing financial support to third parties	A.2 Direct costs for the implementation of trans-national projects by the beneficiaries												Declaration of costs under Point A.2.3.4	Estimated costs of beneficiaries/ linked third parties not receiving funding/ international partners
		A.2.1 Direct personnel costs		A.2.2 Direct costs of subcontracting	A.2.3 Other direct costs										
		A.2.1.1. Employees (or equivalent) A.2.1.2. Natural persons under direct contract A.2.1.3. Seconded persons			A.2.3.1 Travel A.2.3.2 Equipment A.2.3.3 Other goods and services [A.2.3.4.Costs of large research infrastructure]	A.2.3.5 Costs of internally invoiced goods and services									
Form of costs ⁵	Actual	Actual	Unit ⁶	Actual	Actual	Unit ⁷	Unit ⁸		Flat-rate ⁹						
							29000 EUR/year		25%						
	a	b	Total c	d	e	Total f	No units	Total h	i=0,25*(g+h)	j=a+g+h+i	k	l	m	Yes/No	
	Total g ¹⁰														
1. MoH	3 000 000.00	0.00					5.00	145 000.00	36 250.00	3 181 250.00	33.00	1 049 812.50	1 007 459.00	No	n/a
2. FWF	1 000 000.00	0.00					5.00	145 000.00	36 250.00	1 181 250.00	33.00	389 812.50	374 086.00	No	n/a
3. ISS	0.00	0.00					5.00	145 000.00	36 250.00	181 250.00	33.00	59 812.50	57 399.00	No	n/a
4. LAS	0.00	0.00					0.00	0.00	0.00	0.00	33.00	0.00	0.00	No	n/a
5. INCa	1 500 000.00	0.00					5.00	145 000.00	36 250.00	1 681 250.00	33.00	554 812.50	532 429.00	No	n/a
6. BMBF	3 000 000.00	0.00					5.00	145 000.00	36 250.00	3 181 250.00	33.00	1 049 812.50	1 007 459.00	No	n/a
7. DLR	0.00	0.00					5.00	145 000.00	36 250.00	181 250.00	33.00	59 812.50	57 399.00	No	n/a
8. ARC	500 000.00	0.00					5.00	145 000.00	36 250.00	681 250.00	33.00	224 812.50	215 743.00	No	n/a
9. GSRT	500 000.00	0.00					5.00	145 000.00	36 250.00	681 250.00	33.00	224 812.50	57 399.00	No	n/a
10. CSO-MOH	240 000.00	0.00					5.00	145 000.00	36 250.00	421 250.00	33.00	139 012.50	133 404.00	No	n/a
11. ACC	250 000.00	0.00					5.00	145 000.00	36 250.00	431 250.00	33.00	142 312.50	136 571.00	No	n/a
12. ZonMw	300 000.00	0.00					5.00	145 000.00	36 250.00	481 250.00	33.00	158 812.50	152 405.00	No	n/a
13. DCS	1 000 000.00	0.00					5.00	145 000.00	36 250.00	1 181 250.00	33.00	389 812.50	374 086.00	No	n/a
14. RCN	500 000.00	0.00					5.00	145 000.00	36 250.00	681 250.00	33.00	224 812.50	215 743.00	No	n/a

ESTIMATED BUDGET FOR THE ACTION

	Estimated eligible ¹ costs (per budget category)							EU contribution			Additional information				
	A. Costs related to trans-national projects						B. Direct coordination costs of additional activities		C. Indirect costs ²	Total costs	Reimbursement rate %	Maximum EU contribution ³	Maximum grant amount ⁴	Information for auditors:	Other information:
	A.1 Direct costs of providing financial support to third parties	A.2 Direct costs for the implementation of trans-national projects by the beneficiaries												Declaration of costs under Point A.2.3.4	Estimated costs of beneficiaries linked third parties not receiving funding/ international partners
		A.2.1 Direct personnel costs		A.2.2 Direct costs of subcontracting	A.2.3 Other direct costs										
		A.2.1.1. Employees (or equivalent) A.2.1.2. Natural persons under direct contract A.2.1.3. Seconded persons			A.2.3.1 Travel A.2.3.2 Equipment A.2.3.3 Other goods and services [A.2.3.4.Costs of large research infrastructure] A.2.3.5 Costs of internally invoiced goods and services										
Form of costs ⁵	Actual	Actual	Unit ⁶	Actual	Actual	Unit ⁷	Unit ⁸		Flat-rate ⁹						
							29000 EUR/year		25%						
	a	b	Total c	d	e	Total f	No units	Total h	i=0,25*(g+h)	j=a+g+h+i	k	l	m	Yes/No	
			Total g ¹⁰												
15. FCT	325 000.00			0.00			5.00	145 000.00	36 250.00	506 250.00	33.00	167 062.50	160 322.00	No	n/a
16. SAS	210 000.00			0.00			5.00	145 000.00	36 250.00	391 250.00	33.00	129 112.50	123 904.00	No	n/a
17. MIZS	450 000.00			0.00			5.00	145 000.00	36 250.00	631 250.00	33.00	208 312.50	199 908.00	No	n/a
18. ISCIII	500 000.00			0.00			5.00	145 000.00	36 250.00	681 250.00	33.00	224 812.50	215 743.00	No	n/a
19. TUBITAK	800 000.00			0.00			5.00	145 000.00	36 250.00	981 250.00	33.00	323 812.50	310 749.00	No	n/a
20. NCBR	500 000.00			0.00			5.00	145 000.00	36 250.00	681 250.00	33.00	224 812.50	215 743.00	No	n/a
21. FWO	200 000.00			0.00			5.00	145 000.00	36 250.00	381 250.00	33.00	125 812.50	120 737.00	No	n/a
22. OOI	0.00			0.00			3.00	87 000.00	21 750.00	108 750.00	33.00	35 887.50	34 436.00	No	n/a
23. NCS	500 000.00			0.00			3.00	87 000.00	21 750.00	608 750.00	33.00	200 887.50	192 783.00	No	n/a
24. FNRS	200 000.00			0.00			5.00	145 000.00	36 250.00	381 250.00	33.00	125 812.50	120 737.00	No	n/a
25. MIUR	500 000.00			0.00			5.00	145 000.00	36 250.00	681 250.00	33.00	224 812.50	215 743.00	No	n/a
26. ETAg	100 000.00			0.00			5.00	145 000.00	36 250.00	281 250.00	33.00	92 812.50	89 068.00	No	n/a
27. FICYT	300 000.00			0.00			5.00	145 000.00	36 250.00	481 250.00	33.00	158 812.50	152 405.00	No	n/a
28. MoST ¹¹	n/a			n/a			n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 000 000.00
29. VIAA	300 000.00			0.00			5.00	145 000.00	36 250.00	481 250.00	33.00	158 812.50	152 405.00	No	n/a

ESTIMATED BUDGET FOR THE ACTION

	Estimated eligible ¹ costs (per budget category)							EU contribution			Additional information				
	A. Costs related to trans-national projects						B. Direct coordination costs of additional activities		C. Indirect costs ²	Total costs	Reimbursement rate %	Maximum EU contribution ³	Maximum grant amount ⁴	Information for auditors:	Other information:
	A.1 Direct costs of providing financial support to third parties	A.2 Direct costs for the implementation of trans-national projects by the beneficiaries												Declaration of costs under Point A.2.3.4	Estimated costs of beneficiaries/ linked third parties not receiving funding/ international partners
		A.2.1 Direct personnel costs		A.2.2 Direct costs of subcontracting	A.2.3 Other direct costs										
		A.2.1.1. Employees (or equivalent) A.2.1.2. Natural persons under direct contract A.2.1.3. Seconded persons			A.2.3.1 Travel A.2.3.2 Equipment A.2.3.3 Other goods and services [A.2.3.4.Costs of large research infrastructure]	A.2.3.5 Costs of internally invoiced goods and services									
Form of costs ⁵	Actual	Actual	Unit ⁶	Actual	Actual	Unit ⁷	Unit ⁸		Flat-rate ⁹						
							29000 EUR/year		25%						
	a	b	Total c	d	e	Total f	No units	Total h	i=0,25*(g+h)	j=a+g+h+i	k	l	m	Yes/No	
		Total g ¹⁰													
30. TuscReg	0.00	0.00					1.00	29 000.00	7 250.00	36 250.00	33.00	11 962.50	11 480.00	No	n/a
- TLS	0.00	0.00					1.00	29 000.00	7 250.00	36 250.00	33.00	11 962.50	11 480.00	No	n/a
Total beneficiary	0.00	0.00					2.00	58 000.00	14 500.00	72 500.00		23 925.00	22 960.00	n/a	0.00
31. FRRB	0.00	0.00					1.00	29 000.00	7 250.00	36 250.00	33.00	11 962.50	11 481.00	No	n/a
32. FCAECC	0.00	0.00					1.00	29 000.00	7 250.00	36 250.00	33.00	11 962.50	11 481.00	No	n/a
Total consortium	16 675 000.00	0.00					135.00	3 915 000.00	978 750.00	21 568 750.00		7 117 687.50	6 672 187.00		1 000 000.00

¹ See Article 6 for the eligibility conditions.² Indirect costs already covered by an operating grant (received under any EU or Euratom funding programme; see Article 6.5.(b)) are ineligible under the GA. Therefore, a beneficiary/linked third party that receives an operating grant during the action's duration cannot declare indirect costs for the year(s)/reporting period(s) covered by the operating grant, unless it can demonstrate that the operating grant does not cover any costs of the action (see Article 6.2.C).³ This is the theoretical amount of EU contribution that the system calculates automatically (by multiplying all the budgeted costs by the reimbursement rate). This theoretical amount is capped by the 'maximum grant amount' (that the Commission/Agency decided to grant for the action) (see Article 5.1).⁴ The 'maximum grant amount' is the maximum grant amount decided by the Commission/Agency. It normally corresponds to the requested grant, but may be lower.⁵ See Article 5 for the forms of costs.⁶ Unit : hours worked on the action; costs per unit (hourly rate) : calculated according to beneficiary's usual accounting practice.⁷ Unit and costs per unit: calculated according to the beneficiary's usual accounting practices.

ESTIMATED BUDGET FOR THE ACTION


⁸ Unit : years in which additional activities were carried out.

⁹ Flat rate : 25% of eligible direct costs, from which are excluded: direct costs of subcontracting for the implementation of trans-national projects by the beneficiaries, costs of in-kind contributions not used on premises and direct costs of financial support to third parties implementing trans-national projects (see Article 6.2.C).

¹⁰ For the estimated budget, the beneficiaries must only indicate the global amount for budget category A.2 (i.e. NOT broken down into personnel costs, subcontracting costs and other direct costs). For the financial statements the costs will have to be broken down.

¹¹ See Article 9 for beneficiaries not receiving funding.

¹² Only for linked third parties that receive funding.



This document is digitally sealed. The digital sealing mechanism uniquely binds the document to the modules of the Funding & Tenders Portal of the European Commission, to the transaction for which it was generated and ensures its integrity and authenticity.

Any attempt to modify the content will lead to a breach of the electronic seal, which can be verified at any time by clicking on the digital seal validation symbol.